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Abstract
In mamals a single receptor protein binds both insulin-like growth factor IT (IGF-
II) and mannose 6-phosphate (Man 6-P) containing ligands, most notably lysosomal
enzymes. However, in chick embryo fibroblasts IGF-II binds predominantly to a type 
IGF receptor, and no IGF-II/an 6-P receptor has been identified in this species. In order
to determine if chickens possess an IGF-IIjMan 6-P receptor, an affinity resin
(pentamannosyI6-phosphate (PMP) Sepharose) was used to purfy receptors from chicken
membrane extracts by their ability to bind mannose 6-phosphate. Then 125I-IGF-II was
used to evaluate their abilty to bind IGF-II. These experiments demonstrate that
nonmammalian Man 6-P receptors lack the ability to bind IGF- , suggesting that the ability
to bind IGF-IT has been gained recently in evolution by the mamalian Man 6-P receptor.
The second area of study involves the serum form of the IGF-II/an 6-P receptor.
This receptor had been detected in the serum of a number of mammalian species, yet its
strcture, function, regulation, and origin were unkown. Initial studies, done with Dr. R.
G. MacDonald, showed that the serum receptor is truncated such that the C- terminal
cytoplasmic domain of the cellular receptor is removed. These studies also demonstrate a
regulation of serum receptor levels with age, similar to that seen for the cellular receptor
and that the serum form of the receptor existed in several forms which appeared intact
under nonreducing conditions, but as multiple proteolytic products upon reduction.
Finally, these studies demonstrated that both the cellular and serum IGF-II/Man 6-
receptors are capable of binding IGF-IT and Man 6-P simultaneously.
In studies on the serum form of the IGF-II/an 6-P receptor that I have conducted
independently, the regulation of the serum IGF-llan 6-P and transferrn receptors by
insulin has been demonstrated. In these studies, insulin injected into rats subcutaneously
resulted in a time and dose dependent increase in serum receptor levels Finally, to
investigate the relationship of the serum IGF-llan 6- P receptor to the cellular form of the
receptor, pulse chase experiments were performed. These experients demonstrate that the
soluble (serum form released into the medium) receptor is a major degradation product of
the cellular receptor. Furermore, the lack of detectable amounts of the lower Mr soluble
receptor intracellularly and the parallel relationship of cell surface and soluble receptor
suggest that the proteolysis is occumng from the cell surface. Finally, a number of
experiments suggest that the degrdation rate depends upon the conformation state of the
receptor: binding of IGF- IT or Man 6-P makes the receptor more susceptible to proteolysis
while the presence of lysosomal enzymes prevents receptor proteolysis.
In summar, the serum form of the IGF- II receptor is a proteolytic product of the
cellular form of the receptor. The rate of release depends upon the number of receptors at
the cell surace and the binding state of the receptor. In circulation, the receptor retains the
abilty to bind both types of ligands, it thus may serve as an IGF binding protein and/or a
lysosomal enzyme binding protein. These results suggest a model whereby the cellular
receptor is proteolytic ally cleaved by a plasma membrane protease to produce a short
membrane anchored fragment and the serum receptor. In vivo this pathway serves as the
major degradative pathway of the IGF-IIan 6-P receptor, with the serum form being
cleared from circulation by furer degrdation and reuptake.
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A. Diabetes
Diabetes melltus translated literally from Greek means siphoning of sugar and
obtains its name from the fact that people with this condition excrete large amounts of a
sugar rich urne. Until the twentieth century, people with diabetes died shortly after the
symptoms appeared. At present, treatment prolongs life, but the life expectancy of a
diabetic is significantly shorter than the population at large (57 for insulin dependent
diabetes melltus, 70 for non-insulin dependent diabetes melltus, as compared to 77 for the
general population (Ekoe, 1988)). Furermore, complications diminish the quality of life
of a diabetic. Among these complications are neuropathy (peripheral numbness present in
12% of diabetics upon diagnosis for diabetes), small vessel disease (such as retinopathy
which can result in blindness; present in 3% upon diagnosis and eventually afflcts 92% of
diabetics (Brownlee, 1985)), and nephropathy (kidney disease is present in 10% of
diabetics upon diagnosis and responsible for up to 50% of deaths caused by diabetes
(Ekoe, 1988)). In addition to these medical complications are less apparent biochemical
changes which may be the underlying cause of the clinical complications. Among the
biochemical alterations are changes in basement membranes (Cahil , 1985) and, in blood,
decreased generation of cytotoxic cells (Fernandes et ai., 1978; Mahmoud et ai. , 1976;
Friedan and Beyer, 1977), a decrease in the afnity of hemoglobin for oxygen , decreased
levels of 2, 3-diphosphoglycerate and increases in the viscosity of serum, the aggregation
of red bloo cells, the rate of fibrinogen consumption, and in the circulating levels of a.2-
macroglobulin, lipoprotein , coagulation factors V and VIII (Marble et ai., 1985) and
lysosomal enzymes (Goi 
l! ai., 
1986 and 1987).
While the name is derived from the Greek, it is likely that diabetes melltus existed
before that era. The mention of polyuria on the Egyptian Ebers papyrus (qated 1550
B.C.,Brothers, 1976) makes it likely that diabetes has always plagued mankind. Further
references to the symptoms of diabetes have been found in the writings of the Indians,
Chinese, Greeks, and Arabs (Brothers, 1976). Diabetes melltus has now been shown to
exist as two types referred to as juvenile (or insulin dependent) and adult onset (or non-
insulin-dependent). Juvenile diabetes is due to the autoimune destrction of the cells of
the islets of Langerhans, thereby destroying the body s source of insulin. People with
certain histocompatability antigens are prone to this disease (Todd et. ai. 1988). Adult
onset diabetes is characterized by insulin resistance, that is the lack of responsiveness of
cells to insulin. In this disease normal or elevated levels of insulin are found in serum, but
glucose levels remain elevated. An understanding of the mechanism of insulin action, and
the possibility of bypassing the necessity for insulin , provides the only hope for a cure to
these diseases.
While its symptoms were described throughout history, the first suggestions of the
cause of the disease weren t obtained until the end of the nineteenth century. Bernard
demonstrated in 1858 (Bernard, 1858; Best, 1952) that a secretion of the pancreas played
an important role in the digestion of carbohydrate, protein, and fat. In 1869, Langerhans
gave strcture to this important organ by publishing his anatomical studies (Langerhans,
1869; Best, 1952). In 1889 Oskar Minkowski and Joseph von Mering showed that
removal of the pancreas from a dog induced diabetes melltus in the animal
(Houssay, 1952). These findings set the stage for the discovery of insulin , the hormone of
the pancreatic islets which is responsible for regulating the metabolism of nutrents, by
Banting and Best in 1922 ( anting and Best, 1922; Bantig, Best, and McLeod, 1922).
B. Insulin
Banting and Best followed up the discovery of Minkowski and von Mering by
using the pancreatectomized dog as a model system. As described above, tHis animal
became diabetic and died shortly thereafter. They collected material from a pancreas 7-
weeks following ligation of the pancratic ducts. Ths treatment caused the degeneration of
the acinar, but not the insular, cells thereby allowing the purfication of insulin in the
absence of the proteolytic enzymes of the acinar cells. Material purified from this extract
was then assayed by injecting it into pancreatectomized dogs and measuring the ability of
the material to decrease glucose in urine and to keep the animals alive. Following their
purficatio of insulin (Banting and Best, 1922; Banting, Best, and McLeod, 1922), this
material was shown to decrease blood glucose levels in diabetic patients. Insulin, 
initialy identied and purfied in 1922, remais the major method of treatment for diabetes.
Following its initial discovery, insulin has become one of the most studied
polypeptides. It was first crstallized in 1926 (Abel, 1926), it was then the first protein
sequenced in 1953 (Sanger and Tuppy 1951a and b; Sanger and Thompson 1953a and b),
and among the first whose strcture was determned using X-ray crystallography (Adams
et ai., 1969; Blundell et aI., 1971; Dodson et ai., 1979). It is a very small protein with a
molecular weight of 5715 Da (bovine). Insulin is synthesized on the rough endoplasmic
reticulum as a larger precursor of Mr=11260 Da referred to as preproinsulin.
Cotranslationally the signal sequence is removed to produce proinsulin (8677 Da).
Proinsulin, which contains the A and B chains of mature insulin connected by the C
peptide, is then packaged in secretory vesicles. Acidification of these secretory vesicles
causes the cleavage of the C peptide by vesicular proteases to produce mature insulin
/OAE" 
(Steiner et al., 1974; Orci 
et. al., 1986). Insulin can then be released by pancreatic 13 islet
cells as necessar to regulate blood glucose.
-,..
c. Insulin- like Growth Factors
Insulin-like growth factors (IGFs) are so named due to their strctural similarty to
insulin. Of the 19 residues which are invarant in the insulins sequenced, 17 are conserved
in the IGFs (Rinderknecht and Humbel, 1978a and b). As shown in Figure 1, IGFs
consist of A and B chains which are homologous with the corresponding chains of insulin
(41-43% identity; Zapf and Froesch , 1986), a longer, unrelated C chain (62% homology
between IGF-I and IGF-II; Zapf and Froesch, 1986), and an additional carboxy-terminal D
chain. Furthermore, IGFs can mimic some of the effects of insulin and, due to the lack of
inhibition of their insulin-like effects by anti-insulin antibodies have been referred to as
non-suppressible insulin- like activity (Froesch et ai. 1963; Rinderknecht and Humbel
1976aand b; Zapf et ai., 1978). The major effects of IGF-I is thought to be as a mediator
of growth hormone action on carilage and bone growth (thus the terms somatomedin
(Daughaday et ai., 1972) and sulfation factor (Salmon and Daughaday, 1957; van Wyk 
ai., 1971)). Direct injection of IGF-I into animals produces a predominantly insulin-
mimetic effect with little or no effect on growth (Skottner et ai., 1987). However, as wil
be discussed in the next section , IGF actions on growth may require that they be
complexed to IGF binding proteins. IGF-II has also been shown to have cell replication
promoting effects for which it has been termed multiplication stimulating activity (MSA)
(Rechler et ai., 1981).
IGFs are found in many vertebrates (Zapf et. ai., 1981; Hey, Brown, and
Thorbur, 1988). IGF-II is the dominant IOF in fetal and neonatal development (Moses
et. ai., 1980, White et ai., 1982; Adams et ai., 1983; DeChiara, Efstratiadis, and
Robertson , 1990) being present at 1.8-4.4 Ilg/ml of serum (20- 100 times the level in
adults), while IGF-I plays a greater role in the maturng animal (Jansen et ai., 1985). IGF-
"",
o',-..r-.
Pro insulin
IGF-
IGF-
Proinsuli
IGF- I
IGF- II
IGF- I
IGF- II
D Chain
Figure 1: Sequences of the Members of the Insulin Family. comparison of
the sequences for proinsulin (Sanger and Tuppy, 1951a and b; Sanger and Thompson
1953a and b; Ullrch et ai., 1977), insulin-like growth factor I (Rinderknecht and Humbel
1978a), and insulin-lie growth factor IT (Riderknecht and Humbel, 1978b). Amno acids
are indicated by single letter codes. Identical amno acids are in bold type and conserved
regions are indicated by shaded boxes.
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I is predominantly secreted by liver and is growth hormone dependent, while IGF- II is
produced by cells thoughout the body and is not regulated by growth hormone (Mesiano
et. at., 1989).
IGF-I and IGF-II are strcturally very homologous (Figures 1 and 2), with
molecular weights of 7649 (Rinderknecht and Humbel, 1978a) and 7471 daltons
(Rinderknecht and Humbel, 1978b), respectively. There are two varations of IGF-II in
mamals: the major "small" form is very similar to IGF- , while the less abundant "big
fonn has the amino acids RLPG inserted in place of S29, CGR in place of S33, and a 21
amno acid C-termal extension referred to as the E-domai (Jansen et at, 1985; Zumstein
Luthi , and Humbel , 1985; Zapf and Froesch, 1986). A "big" form of IGF-II containing
the E-peptide has been measured in circulation to correlate with levels of total IGF- II: 253
ng/ml in neonates as opposed to 5.7 ng/ml in adults (Hylka, Kent, and Straus, 1987). The
big" IGF-II is a minor constituent whose bioactivity has not been demonstrated; therefore
IGF-IT wil refer to only the small form hereafter.
, There is a single 30 kilobase gene for IGF-II on human chromosome 11 , near the
gene for insulin (Dull et at., 1984; Pagter-Holthuizen et at. 1988), which gives rise to a
number of mRNAs in most fetal and neonata tissues through alternate splicing. The most
abundant (4 kb mRA) fails to translate leaving a 1.2 kb message as the major translatable
message. These mRAs produce a 22 kDa prepro-IGF- IT when translated in vitro. No
mRAs encoding IGF-II are detected in adult liver, muscle, or intestine. The prepro-IGF-
n consists of a 24 amino acid presequence (pro-IGF-IT=20kDa), the codng region of 
residues (mature=7500 Da), and an 89 amno acid C-termnal extension referred to as the
peptide (intermediate=8700 Da).
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Figure 2: Structure of the Members of the Insulin Family The predicted strctures of
insulin, proinsulin, insulin-like growth factor I, and insulin-lie growth factor II
(Blundell, Bedarkar, Rinderknecht, and Humbel , 1978; Blundell, Bedarkar, and Humbel
1983).
As will be discussed in later sections, IGFs bind a number of proteins including the
insulin receptor, the IGF-I receptor, the IGF-II/an 6-P receptor, and serum 
carer
protei (Rech1er et ai., 1980). Recent experiments have used the 
available cDNA
sequence of the IGFs to mutate regions in order to ascertain which regions 
of the IGF are
responsibl to binding which proteins (Figure 3). As would be predicted based on the
, abilty of ligands to bind to receptors and binding proteins there is significant overlap
between the binding sites for the insulin and IGF- I receptors, while the binding sites for the
IGF-II/Man 6-P receptor and the IGF binding proteins are distinct. As can been seen
(fi re 3), the insulin receptor binds to one quadrnt of IGF- , with the following residues
being involved: G22, F23, Y24, F25 and Y60 (Cascieri et ai., 1988; Cascieri et ai. , 1989;
DeMeyts et ai., 1990). Similarly, the IGF- I receptor binds to Y24, Y 60, K65, P66, A67,
K68, S69, A 70 in the same region of the IGFs (Cascieri et ai., 1988; Cascieri and Bayne,
1989) and to T4, L5, G30, and Y31 from the another portion of the molecule (Cascieri 
ai., 1988; Cascieri and Bayne, 1989). The IGF-II/an 6-P receptor binds to IGFs in a
number of regions, supoposedly interacting with amino acids which project from the
molecule in three dimensions: T41, V44, D45, C48, F49, R50, 
S51 L54 , R55, R56 and
Y60 (Cascieri and Bayne, 1989; Cascieri et ai., 1989). Finally, the IGF binding proteins
interact with a number of amino acids concentrated in the lower right quadrant: G 1, P2
E3, T4, L5, E9, VII, A13,Q15, F16, D53, L54, R55, and E58 (Szabo et ai., 1988;
Bagley et ai., 1989; Cascieri and Bayne, 1989; Cascieri et ai., 1989; Wallace 
et ai., 1989).
This informtion can explain the affmity differences of varous natual and synthetic ligands
for the receptors and binding proteins and should make possible the synthesis of ligands
with varous desired specificities and biological activities.
--0-
\ \
I) 
IGF -II/Man 6-
Receptor
rigure 3: Binding Sites on Insulin-
like Growth Factor I.
owth factor I indicating the amno acids which have been demonstrated to be involved in
ligand bindig to the insulin, IGF-I, and IGF-IT receptors and serum binding proteins.
(Iormati compiled from Cascieri et ai., 1988; Szabo 
et ai., 1988; Bagley 
et ai., 1989;
Brian et ai., 1989; Casci ri and Bayne, 1989; Cascieri 
et ai., 1989; DeMeyts 
et ai.,
1990)
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D. IGFs in Circulation are Associated with Binding Proteins
IGFs circulate as complexes of much higher molecular weight than would be
expected if the IGFs circulated freely. It has been demonstrated that the increase in
molecular weight is due to the binding of IGFs by specific carer proteins (Zapf
Waldvogel, and Froesch, 1975; Hintz and Liu, 1977) and that, in contrast to free IGFs,
bound IGFs stimulate growth but fail to mimic insulin action (Zapf and Froesch, 1986).
Furhermore, IGFs present in these complexes have a significantly longer half-life than free
10Fs (Moses et aI., 1976). Certain IGF binding proteins may enhance the biological
effects of IGF- l. For instance, in fibroblasts IGF-I alone resulted in only a 38% increase
; O 1' .
fu3H-thymidine incorporation, while addition of amniotic fluid binding protein (which
failed oincrease 3H-thymidine incorporation by itself) resulted in a 4.4 fold increase in
3H-thymidine incorporation (Elgin, Busby, and Clemmons, 1987).
In man, IGFs circulate predominantly as 150 kDa and 40 kDa forms (Van den
Brande et aI., 1986). In circulation, 62% of the IGF-I circulates in the 150 kDa complex
$eremainder in the 40 kDa complex (Yang et aI., 1989). The 150 kDa form has a native
Mr .of 175 kDa and a stokes radius of 4. 8 nm (Rapp et aI., 1988) and a 3-fold higher
affinity for IGF-II than IGF-I (Rapp et aI., 1988). The 40 kDa complex has a 6-fold
preference for IGF-II (Binoux et aI. 1986). The binding proteins can be separated from
the IGFs by gel fItrtion chromatogrphy at acidic pH (Van den Brande et aI. 1986) or by
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE , Binoux et aI.
1986). In either case the free binding proteins are then capable of binding IGFs. In fact,
the use of SDS-PAGE of serum followed by electrotransfer of the proteins from the gel
onto nitrocellulose fiters, then the incubation of the nitrocellulose fiters in a solution of
' .- -
i 125I-
IGF-I or II has proven a valuable tool in the identification of IGF binding proteins
(Hossenlopet 
aI., 1986).
Using these techniques, binding proteins of molecular weights 42, 39, 34, 30, and
24 kDahave been identified which differ in their affmities for IGF-I and IGF-
IT (Binoux 
aI., 1986). When affinity crosslinked to IGFs, the 40 kDa complex referred to earlier is
.' shown to have components of 38, 40, and 46 kDa (Binoux et ai., 1986) or 32 and 43 kDa
, (Yang et aI., 1989), while the large 150 kDa complex is composed of major constituents of
33, 37, and 49 kDa, and less abundant components of 23, 26, 46, 120, and 140 kDa
, (Binoux et ai., 1986). Uncrosslinked components of 30-32, 42, and 45 kDa
; (corresponding to crosslinked components of 37, 46, and 49 kDa) have been isolated from
, the 150 kDa complex and shown to share the same N-terminus (Zapf et ai., 1988) and are
thus likely proteolytic products from the same glycoprotein (Yang 
et ai., 1989). An
additional IGF binding protein has been identifed in humans that has a molecular weight of
32 kDa and was previously identified as pregnancy associated endometral aI-globin (Bell
et aI., 1988). Ths is the major protein synthesized by the decidualized endometrum and is
a predominant protein in the amniotic fluid. This protein inhibits the effects of IGFs, and
its levels in maternal serum are inversely correlated with birweight. In other species, IGF
binding proteins have also been identified. In sheep,for instance, IGF-I is found in a 20-
100 kDa peak in adults and in a 20-50 kDa and a 200 kDa peak in the fetus as determned
by gel fitrtion chromatography (Butler and Gluckman, 1986).
Despite the number of insulin-lie growth factor bindig proteins identifed by their
abilty to bind IGFs, only thee distict forms have been cloned and sequenced thus far
(Drop and Hitz, 1989; Figue 4). Insulin-like growth factor binding protein (IGFBP)- l is
the protein discussed above s a pregnancy associated endometral globulin. IGFBP-3 is
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BP53, referred to above as the 49 kDa component of the 150 kDa complex, and is the acid
stable subunit of the 150 kDa complex (Woo et ai., 1988; Mukku et ai., 1989). Finally,
IGFBP-2, which is discussed below, is the only binding protein which has been cloned
. from a number of species. It is 33% homologous with IGFBP-3 and, like IGFBP-3, is
-ystein6 rich at its termni. In the rat, a IGFBP-2 is a predominant binding protein of 33
kDa in fetal and neonatal serum (White et ai. 1982) which has been shown to be
synthesized by a number of cell lines and fetal cells as a 35 kDa precursor, which
following cleavage of the signal sequence, is released as the mature 33 kDa binding
protein. The cDNA for this binding protein has been cloned and sequenced (Brown 
et ai.
1989) and shown to code for a protein of 32, 886 Da with a 34 residue prepeptide and a
270 amno acid mature protein with molecular weight 29,564 Da. This protein contains 
lined glycosylation sites, but contains a C-termnal RGD sequence which may allow it
to bind to the cell surace via integrn receptor (Margot et ai. 1989). Of the 18 cysteines in
the molecule, 12 are between residues 40- 115 at the N-termnus, and 5 between residues
240-285 and this pattern is conserved in al species from which this protein has been cloned
(rat (Brown et aI., 1989), bovine (Szabo et ai., 1988; Ballard et ai., 1989), and human
(Julkunen et ai., 1986; Brewer et ai., 1988)). The presence of the expected disulfides is
requied for biological and immunological activity (Brinkan et ai., 1989).
Like the IGFs, there is substantial evidence that certain agents regulate the levels of
IGF binding proteins in circulation. Unlike IGF-I which is growth hormone dependent,
levels of IGFBP-2 are increased significantly upon hypphosectomy (Margot et ai, 1989).
By contrast, IGFBP-3 is increased in acromegaly and decreased in hypopituitism (Binoux
et ai., 1986). The effect of growth hormone on IGFBP-3 levels has been demonstrated
directly by hypophosectomy with or without growth hormone treatment (Moses et ai.
1976). In osteoblasts, both growth hormone and estradiol stimulate the release of the 150
kDa carer protein (Schmd 
et al., 1989).
" ':. ,. - ; ",
i''
,:'' :
E. The Insulin and IGF-I Receptors
In addition to binding a number of insulin-like growth factor binding proteins while
in circulation, IGFs bind to several cellular receptors. Specifically, three distict 
receptors
have been identified by crosslinking studies, and a four putative IGF receptor has been
identified by its homology to known IGF receptors (Shier and Watt, 1989). By
crosslinng, the receptors fall into two classes: a monomeric receptor of -250 kDa (the
IGF-IIan 6-P receptor receptor) and heterotetrameric receptors consisting of 2a and 2
subunits ofMr 125- 135 and 90-95 kDa, respectively, referred to as the insulin and IGF-
receptors (Czech, Massague, and Pilch, 1981; Massague and Czech, 1982; Yamaguchi 
al., 1986). While each of these three receptors has the greatest affinity for the homologous
ligand, the ligands are also able to interact with heterologous receptors. As shown in
Figure 5, insulin wil bind to the insulin or IGF-I receptor, while both IGF-I and IGF-
, bind to the insulin, IGF-I, or IGF-IT receptors. While the heterotetrameric strcture of the
insulin and IGF-I receptors allows for binding of two molecules of ligand, there is negative
cooperativity such that the second molecule binds with a much lower affnity than the first
(Pang and Shafer, 1984).
Both the insulin and IGF-I receptors are synthesized as a large precursor (-210
kDa) contaning both the a and subunits (Kasuga et ai., 1982a; Rechler and Nissley,
1986) as determined by crosslinking studies. Studies to follow the biosynthesis and
processing of the insulin receptor have shown that following translation and cleavage of the
., ,; \
signa.l sequence, it has an Mr=170kDa. The molecular weight increases to 190kDa
fono g glycosylation in the ER. This is then proteolytc ally processed upon reaching the
Golgf apparatus into 120kDa and 90kDa subunits, which are furher glycosylated to the
130kDa and 95kDa mature and subunits (Forsayeth , Maddux, and Goldfne, 1986).
; L,
Insulin IGF- IGF-
!. .
t 't
,,"
f".!.A.
5f:;' .
' ,
:1(;
. iirv .
tl\; 
Insulin Receptor IGF -I Receptor IGF-llan 6-Receptor
Figure 5: Ligand-Recepto Interactions in the Insulin Family. Insulin and the
insulin like growth factors show crossreactivity among their specific receptors. This
diagr schematically represents these interactions, with the increased thickness of lines
ifudicating increased afmity.
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The cloning and sequencing of the insulin (Ullrch 
et ai. 1985; Ebina et ai., 1985) and
IGF-I (Ullch et ai., 1986) receptors have further demonstrated their simiarty (Figures 6
and 7).
The similar strctures of the IGF- I and insulin receptors also give rise to similar
inuno10gic and functional propertes (Rechler and Nissley, 1986). Both receptors are
kinases. Upon binding of ligand, the tyrosine kinase is activated by an increase in
for A TP hydrolysis, resulting initially in autophosphorylation of a number of sites in
ytoplasmi domains of the receptors (White et ai., 1988). This autophosphorylation
serves to activate the kinase (Rosen et al., 1983; Yu and Czech, 1984b; Herrera and Rosen
1987) to make its elevated activity ligand independent. Removal of the phosphate by
alaline phosphatase decreases the activity of the tyosine kinase 65% (Yu and Czech
1984b). Furthermore, even in the absence of ligand, tyrosine phosphorylation of these
siteS activate the insulin receptor tyrosine kiase (Yu et ai, 1985). The insulin receptor can
also be regulated by other agents. For instance, cAMP decreases the activity of the kinase
and the affinity of the receptor for insulin (Czech, 1985) and serine phosphorylation in
general can decrease receptor kinase activity (Herrera and Rosen , 1987). Streptozotocin
dia,beticrats had a kinase activity decreased 45% as compared to controls without a change
in receptor number or affinity of receptor for insulin (Gherzi et ai., 1986). This resulted in
an increase in the concentration of insuli required for 1/2 max activation of the kiase from
22 to 55 ng/ml (Gherzi et ai., 1986). Other studies of diabetic rats have confIrmed that the
decrease in kinase activity is proportional to the severity of diabetes even in animals with
inqeased receptor numbers (Okamoto et ai., 1986).
Like the insulin receptor, the IGF-I receptor tyrosine kinase is activated by ligand
(1/4 max at 0.4 nM; Morgan,)arigan, and Roth, 1986). The tyrosine kinase domain of
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the'MO receptors are very closely related as shown by the 
abilty of an antibody to the
ib. Ulln receptor tyrosine kinase domain to inhibit the IGF-
I receptor tyrosine kinase
'(organ, Jarigan, and Roth, 1986). Upon treatment of cells which contain both insulin
ild IGF.:1 receptors with insulin
, both receptor tyes are phosphorylated (Beguinot et ai.,
1988) and downregulated. Similarly, treatment with low levels of IGF-I results in
downregulatio of both receptors although only the IGF-I receptor shows 
increased
phosphorylati and tyosine kinase activity (Heaton, Krett, and Gelehrter, 1986; Beguinot
et ai., 1988). Under certain conditions, insulin receptor heterodimers can combine with
IOF-I receptor heterodimers to produce mixed heterotetramers (Jonas, Newman, and
Harson, 1986; Treadway et ai., 1989; Moxham, Duronio, and Jacobs, 1989).
Despite the similarties between the insulin and IGF- I receptor discussed above,
they are not identical. First, and most obviously, their ligand specificities differ. Second,
, while the insulin receptor binding requires glycosylation , the IGF-I receptor is capable of
binding IGF-I in cell lines with a number of glycosylation defects (Podskalny et ai. , 1986).
There are also differences in the signal produced by the receptor tyrosine kiases (Lamers
et ai., 1989). While both tyrosine kinase domains are equipotent in stimulating glucose
transport, the IGF-I receptor possesses a more active tyrosine kinase (3-fold) and is more
effective at stimulating DNA synthesis (lO-fold; Lammers et ai., 1989).
There are also diferences in insulin receptor isolated from different tissues. While
functionally identical, these receptors show differences in molecular weight, the basis of
which has not been determned in some cases. A comparson of receptors from muscle and
liver r veals that both subunits have a increased Mr in liver (101 vs 98 kDa and 135 vs
131 kDa ex; Burant et ai., 1986). While the difference can be removed from the subunits
by deglycosylation with EnQo H, the ex subunits retain the difference in Mr following this
treatment (Burant 
et ai., 1986). Similarly, comparson of brain and placental insulin and
IGF-I receptors demonstrate that the brain receptors are 10 kDa smaller, but that this
diference can be removed by Endo F treatment (Heidenreich et ai., 1983; Heidenreich 
oJ., 1986). ,
F. The Role of the Insulin Receptor Tyrosine Kinase in Insulin Action
Since the discovery of insulin, diabetes researchers have been tring to unlock the
secrets of how insulin works. Initially this centered upon identifying target tissues,
biological effects, and eventually the receptor for insulin. The main target tissues for
insulin are the liver, muscle, and adipose. The precise effects of insulin differ in each of
these tissues to result in a decrease in blood glucose. For example glycogenesis is
increased in the liver while glucose transport and utilization are increased in adipose and
muscle tissues.
The discovery of the insulin receptor marked a significant advance in the field.
wever, although the fist steps of insulin action on a cell , that is the binding of insulin to
'l't'!fieceptor and the activation of the insulin receptor tyrosine kinase, have been known for
~~~
i-ai years, the steps following have been more difficult to identify. An alternative
n,,;
approach in which a terminal biologic effect is followed back from the observed effect
towards the binding of insulin to its receptor has liewise failed to significantly advance our
understanding of the mechanism of insulin action. Despite, or perhaps due to, this lack of
eVidence, a number of models of insulin action have appeared (Figure 8). In order to
alua:te the validity of these models numerous experiments have been performed. These
\f6d ls have been reviewed in a number of recent articles (Czech, 1981; Berger and
r6htold, 1985; Czech et aI., 1985)
t1"f'
,;y
The preferred model at present involves the insulin receptor tyrosine kinase
1', ()sEhorylating and activating serine/threonine kinases, leading to a cascade of
". 
phosphorylations and dephosphorylations which activate enzymes involved in the ultimate
effects of insulin. In order tQ test the importance of the insulin receptor tyrosine kinase in
: r
:; ,
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J.igure8: Models of Insulin Action. Numerous models have been proposed to
e-xplain the mechanism of insulin action. This diagram depicts a number of landmarks:
binding to the insulin receptor as the fIrst step, kinases and phosphatases stimulated
bY! 1.sulin as intermediate effects, and final effects on gene expression, membrane protein
t(Qution, and enzymatic activities of proteins involved in carbohydrate, protein, and
ljpi,4 'IIWIbolism.
-. .
insulin action, mutations have been created in the ATP binding site (Gly-
Gly- Gly
at 991-996 and Lys 1018; Goldfne, 1987) which destroy 
tyrosine kinase activity. Using
ch, mutations, it has been demonstrated that tyrosine kinase activity is required for
internalzatio of ligand, downregulation, and ligand induced receptor turnover (Russell 
aI., 1987). Using Xenopus oocytes transfected with glucose transporters, the importance
6f1the insulin receptor tyosine kinase in regulation of glucose transport has also been
K/'.
:' 
demonstrated (Vera and Rosen, 1990).
rf) u-
Additionally, the tyrosines in the cytoplasmic domain of the insulin receptor whichGr,
'!(
a1Jtophosphorylated can be mutated or deleted. While 6 tyrosines can be
PH()sphorylated in this region of the insulin receptor (1146, 1150, 1151
, 1316, 1322 and
ypnidentied tyrosine phosphorylated of the remaining 8), deletion of the two most C-
:48wnal tyro sines (1316 and 1322) does not alter kinase activity (Tornqvist 
et ai., 1988;
r\Yte et a/., 
1988). The remaining three identified phosphorylated tyrosines are required
for maximal kinase activity, although only tWo of the three are normally phosphorylated in
vivo (1146 and 1150 or 1151; White 
et al., 1988). Furthermore, tyro sines 1150 and 1151
equired for insulin induced internalization and degradation of the insulin receptor
""tV\
'(eynet et a!., 1990). Yet another mutation has involved the expression of the cytoplasmic
bfuain of the insulin receptor with or without a membrane anchor. In these experiments it
s demonstrated that the membrane anchored form constitutively increased glucose
':;
sport while the constrct lacking a membrane anchor was without effect (Ells et ai.,
1 j ,
. . ,
1987). Taken together these results demonstrate that an intact insulin receptor tyrosine
'' .
'Kha se is plays a critical role in the transduction of the insulin signal across the cell
\t:
memorae.
!'\ ' .
tJ'
G. Insulin Induces the Redistribution of Membrane Proteins
j.11"
1. Glucose Transporters
, "
One of the best characterized and most studied termnal responses to insulin is the
increased uptake of glucose by muscle (park 
et ai., 1959) and adipose tissue (Crofford and
rl8id, 1965; Czech, 1976). Little was known about the mechanism of this increase prior
to ff discovery of the ability of cytochalasin b to inhibit glucose transport (Levine and
Gold t'en, 1955; Carer, 1967; Bloch , 1973; Taverna and Langdon , 1973) by binding to
the 11I2ose transporter (Czech , 1976). By photoaffinity labelling of the glucose transporter
witi\ bytochalasin b, it was demonstrated that insulin induced a redistrbution of glucose
arspdrlers; from an intracellular site to the cell surface (Cushman and Wardzala, 1980;
Suioil nd Kono, 1980; Karieli et ai., 1981; Wardzala and Jenrenaud, 1981; Oka and
Czech, 1984; Karieli et ai., 1986).
The role of the redistrbution of glucose transporters in the insulin induced increase
inglucose transport has not yet been resolved. The increase in glucose transport is larger
W1 the redistrbution
, generally being on the order of 20-fold as opposed to 4-fold, for
istrbution. The change in transporter number at the cell surface has also been
tfsttated to slightly precede the increased transport (Karieli et ai., 1981) Even the
vety of additional glucose transporters in insulin sensitive tissues failed to explain this
$1S hCY (Horuk et ai., 1986; James, Lederman , and Pilch , 1987; Oka et ai., 1988;
f'ii8 kt ai., 1988; Zorzano et ai. 1989; Charron et ai., 1989; James, Strube, and
M\l!:it f, 1989;). In addition , certain agents have been able to mimic the insulin induced
in redistrbution of glucose trnsporters without causing such a change in glucose
: tt_6R(Horner, Munck, and Lienhard, 1987), to alter glucose transport but not glucose
ansporter number (Kuroda 
et ai., 1987; Kahn and Cushman, 1987) or to prevent the
l)psulninduced redstrbution of glucose transporters but not the increase in transport (Baly
hand Horu, 1987). These data demonstrate that glucose transporter number and activity
.i€an independently regulated.
-r'l-""'-
. ..: .
The mechanism by which insulin increases the cell surace number of glucose
(I,
 "
transporters and the rate of glucose transport has not yet been clearly defined. It has been
demonstrated, however, that intracellular calcium (Klip and Ramlal, 1987b), membrae
repotential (Klip, Ramal, and Walker, 1986), protein kinase C (Klip and Ramlal , 1987a;
dRobertsonetai., 1989), and phosphorylation of the glucose transporter (Gibbs, Allard,
trand ,Leinhard, 1986; Allard et ai., 1987) are not involved in these responses to insulin.
Insuli may, however, induce a conformational change in the receptor which could playa
orole in its increased activity (Holmann and Rees, 1987; May, 1988).
:; 
, r:'
:; 
The IGF -II/Man 6-P Receptor
Initially, the effect of insulin on the IGF-llan 6-P receptor was detected as a
g,L, '
change in the apparent affinity of this receptor for IGF-II (Massague, Blinderman, and
Czech, 1982; Oppenheimer et ai., 1983). Later, this effect was demonstrated to be due to
rei.
an increase in the number of IGF-llan 6-P receptors at the plasma membrane and not a
1Pi. '
. change in affmity (Wardzala et ai., 1984; Oka et ai., 1984; Oka, Rozek, and Czech, 1985).
Like the glucose transporter, the increase in IGF-II/an 6-P receptors at the plasma
,",'" 
membrane is accompanied by a decrease in the number of receptors in the low density
microsomes (Wardzala et ai., 1984; Oka et ai., 1984). This change in cell surace receptor
number results from a cha ge in receptor recycling which also accelerates the rate of IGF- 
, ,
degradati (Oka, Rozek, and Czech, 1985). This results in an increase in the rate of
lysosomal enzymes without an interrption of intracellular sortng of newly synthesized
lysosomal enzymes (Braulke 
et ai., 1990). Recent experiments have demonstrated that
anti;;IGF-IIan 6-P receptor antibodies can block this response in a number of cell lines,
whileoverexpressio of the IGF-II/an 6-P receptor increases the effect of insulin
(1(ovacina, Steele-Perkins, and Roth, 1989).
The
While the regulation of the distrbution of IGF-II/an 6-P receptor is similar to the
co,,'
- ,
regulation of glucose transporters by insulin, there may be some differences. First, while
txl\' ; 
there is significant evidence that the activity as well as the distribution of glucose
apc,;r,
trsporters is regulated by insulin , only the subcellular distrbution of the IGF-IT/Man 6-relf,'" 
receptor is altered by insulin. Other differences between these systems include the
observation that the insulin induced redistrbution of IGF-II/Man 6-P receptors is
shloroquine sensitive, while that of glucose transporters is not (Oka 
et ai., 1987) and the
lredistribution of the IGF-II/Man 6- receptor by insulin correlates with its
d$phbsphorylation (Corvera and Czech , 1985; Corvera et ai., 1988a and b). The fold
ohange:in these proteins at the plasma membrane is different as well, with the increase in
, g1Uc.ose transporter (4-fold) being somewhat greater than the increase in IGF-II/an 6-
ptor (-2-fold; Appell , Simpson , and Cushman, 1988). In addition, the distrbution of
IGWeIIan 6-P receptors is altered by a number of agents in addition to insulin: epidermal
wthfactor (Braulke et ai., 1989), IGF-II (Braulke et ai. 1989), mannose 6-phosphate
raulke et ai., 1989), vanadate (Kadota et ai., 1987), and hydrogen peroxide (Kadota 
'II" 1987).
." "',
if""
"'" '
)C' "
fe,
:; 
HX "
3. The Transferrin Receptor
The transfemn receptor is a constitutively cycling receptor with a predominantly
intracellular distrbution. The transferrn-trnsfemn receptor cycle is also very similar to
the movement of the IGF-II/an 6-P receptor (Figure 9). At the cell surface the
trsfemn receptor binds to transfemn which has a high affinity for receptor at neutral pH.
The transferrn-transfemn receptor complex is then internalized and arves at an acidic
comparment, similar to the prelysosomal comparment, where transferrin releases the
bound iron. The iron proceeds to the lysosome, from which it is released into the cell. The
'aP trnSfemn remains bound to the transfemn receptor in the acidic comparment, but is
' '
released at the neutral pH of the cell surface (Klausner et ai., 
1983; Hopkins, 1983).
, This process is regulated by insulin in a manner similar to that observed for the
gluc se transporters and IGF-II/Man 6-P receptor (Davis, Corvera, and Czech, 1986;
Tanner andLeinhard, 1987). The regulation of the distrbution of the transferrn receptor
may De more general and more diverse than that of either of the proteins discussed above.
In addftion to insulin, the distrbution of transfemn receptor can be altered by transferrn
(Klausner, Harord, and van Renswoude, 1984), epidermal growth factor (Wiley and
Kaplan, 1984; Davis and Czech , 1986); platelet derived growth factor (Davis and Czech
1986), IGF-I (Davis and Czech, 1986), and phorbol esters (Klausner, Harord, and van
Renswoude, 1984; May, Jacobs, and Cuatrecasas, 1984).
"lglU'
? :
witntt(' ' ; The kinetic mechanism of the redistrbution of transferrn receptors by insulin, IGF-
t1"s(Cifd. EGF has been studied in some detai. 
The insulin induced redistrbution is due to an
I1ni1 ..."'-
, , -
"'4/
" '
\')pr e in the rate of externalization of receptor (Tanner and Leinhard, 1987) as is the EGF
;;gh .ducedredistrbution (Davis et ai., 1987), while the IGF-I induced translocation is due to
KEY
Iron
Transferr
Transferr
Receptor
Coated Vesic1e
Smooth Vesic1e
t". 
" '
Figure 9: The Transferrin/Transferrin Receptor Cycle. Iron is strongly associated
with transferr at neutral pH to form diferrc transferr. The transferrn receptor binds diferrc
tns 7p: with high affinity at the cell surace. Ligand and receptor are then internalized as a
unit and enter endosomes. There, the acidic pH causes the dissociation of iron from transferrn
,"",hI' "toprootice apotransferr. Despite the loss of iron from transferrn, the apotransferrn remains
tightfy bound to the transfemn receptor at this acidic pH. However, when the transferrn-
ialteratio of both the internalization and externalization rates (Davis 
et aI., 1987).
Similarto theIGF-II/an 6-P receptor discussed above, the transferrn receptor induced
rgClistrbution, in this 
case caused by phorbol esters, correlates with an altered
phb'Sphorylatio of the receptor. Mutagenesis of the sites of phosphorylation, however
has resulted in no change in receptor recycling or in its regulation (Davis and Meisner,
;87.
L/,
v'Th.eCtr Macroglobulin Receptor
Like the proteins described above, the Ct2-macroglobulin receptor is a membrane
prote predomiantly intracellular in distrbution which recycles constitutively. In 3T3-
\.'.;,
VC(;.' L "
. ,
dipocytes, insulin causes a redistribution of this protein to the cell 
surface (Corvera,
, 
:tt :rl
- '
J:i
' "
. Graver, and Smith, 1989). While the redistrbution results in an increase in the rate of
rob:'
i,ternalizati of Ct2-macroglobulin , the internalization rate is significantly less than the
hYr-
,. ' ,
Ei7\ :increase in cell surface receptor number. This suggests that the increase in receptors at the
:htJiuckl"
i;;;cell surface is caused by a decrease in the receptor s internalization rate (Corvera, Graver
\,pho::r
:t', :a,d .Smith, 1989).
(\,:!
.nG
fdemu.. '
Summary and New Avenues of Research
While a number of differences exist in the observed redistributions of receptor
otei!l discussed above, in no case is the data inconsistent with a general mechanism
hich could be responsible for the growth factor induced redistrbution of the proteins
. crbe above, and possibly other proteins not yet characterized. As described above, the
pathways of the IGF-IIan 6-P receptor and the transfemn receptor are very similar.
Both have been shown to be internalized through coated vesicles (Geuze 
et ai., 1984b;
Stoorvogelet al., 
1989) as is the (X2-macroglobulin receptor (Corvera, Graver, and Smith
(\1989) All of these proteins normally exist predomiantly in an intracellular comparment,
ana!d recent evidence suggests that a glucose transporter (Glut 1), the transferrn receptor
re,andthe IGF-IIan 6-P receptor coexist in the same intracellular vesicles (Tanner and
Jbeinhard, 1989). In the case of the IGF-II/Man 6-P receptor, much of the intracellular
Yireceptor has been shown to be in the prelysosomal comparment (Fischer et al. , 1980;
idMar hase, Koro, and Hiler, 1984). Recent evidence demonstrates that clathrin coated
bivesic1eassembly can be regulated by insulin (Corvera, 1990) and mitogens (Corvera 
et at.,
I:Cil989). This could explain the observed redistrbutions. The presence of kiases in coated
tv"vesicles (Bar-Zvi and Branton, 1986; Bar-Zvi, Mosley, and Branton, 1988; Pauloin
thIDhurieau, and Jolles, 1988; Moms, Mann, and Ungewickell, 1990) may explain the
l't0.bserved correlations of phosphorylation and redistrbution , and provides a testable
frh othesis for the mechanism of regulation of clathrin assembly: that growth factors
fciduce a cascade of kinases that result in the activation of coated vesicle kinases,
pposphorylation of specific coated vesicle proteins, and alterations in the rate of assembly
Tiand disassembly of clathrin coats. Recent evidence (Hanson, Schook, and Puszkin, 1990)
hi4 Jlonstrates that changes in the phosphorylation state of clathrn light chain alters the
h0sphorylation and dephosphorylation of the clathn associated protein AP50.
19&j:
ftt:"
v',
: '
(1i;'
\ '
H. The IGF -II Receptor is the MaDnose 6-Phosphate Receptor
The cDNA for the human IGF-II receptor was first cloned and sequenced in 1987
. (Morgan 
et ai., 1987). The sequence revealed 80% sequence identity between this receptor
the available parial sequence from the bovine mannose 6-phosphate (Man 6-
eptor (Lbel et al., 1987). The identity of the sequences was demonstrated when the
ln Man 6-P receptor was cloned and sequenced (Oshima et al., 1988) and shown to be
99.4% identical to the human IGF-II receptor (Morgan et aI. 1987). Despite the sequence
/- "
identity, however, none of these papers demonstrated that a single protein was capable of
, :.- l
binding both ligands. The initial demonstrations that the same protein could bind both
; i'o ,
IGF ll and Man 6-P containing ligands (Roth et al. 1987; MacDonald et aI. 1988) used
two types of evidence: 1. A membrane extract loaded onto a PMP-Sepharose column was
' I'
then eluted with mannose I-phosphate, then glucose 6-phosphate, and finally Man 6-
The only detectable affinity crosslinking to I25I-IGF-II was found in the Man 6-P eluted
fraction. 2. The presence of Man 6-P increased the affinity of receptor for IGF-II two-
fold, and this effect was removed by washing receptor in Man 6-P free buffer. Following
this, a number of repons were published confIrming this finding (Roth et aI. 1987; Tong,
Tollefson , and Kornfeld, 1988; Kiess et al. 1988), demonstrating that both ligands could
bind simultaneously to different sites (Waheed et al., 1988; Braulke et aI., 1988), or that
uptake of IGF-II was increased by Man 6-P in the medium (Polychronakos and Piscina,
1988). The nature of the increased affnity also remains a puzzle, as in some reports the
effect is reversible (MacDonald 
et al., 1988) while in others it is not (Polychronakos,
Guyda, and Posner, 1988)-suggesting that the effect may simply be due to removal of
endogenous lysosomal enzymes by Man 6-P. Physiologically, IGF-II can inhibit
:f-e
lysosoma enzyme binding to the IGF-II/an 6-P receptor and thereby the uptake of these
ligands (Kiess 
et ai. , 1989).
The cloning and sequencing of the IGF-II/an 6-P receptor (Lobel et aI., 1987;
Morgan etaI., J987; Lobel, Dahms, and Kornfeld, 1988; MacDonald et aI., 1988; Oshima
et aI., 1988) revealed a protein structurally very different than the IGF-I or insulin
receptors. The IGF-II/an 6-P receptor is a 2451 amino acid monomer of 270294 Da
which consists of fifteen 150 amno acid repeat regions in the extracellular domain , a single
trsmembrane domain of 23 amo acids, and a short 164 amino acid cytoplasmic domai
(von Figura, Gieselmann, and Hasilik, 1985; Sahagian and Steer, 1985; Morgan et aI.,
1987). The 15 repeat regions have a low homology to each other, but the positions of the
cysteines within each of these regions is well conserved (Figure 10). While this protein
bear nO resemblance to any other protein capable of binding IGFs, it is homologous to the
cation dependent mannose 6-phosphate receptor, which resembles a single repeat unit of
the IGF-IIan 6-P receptor (Figure 10; Dahms et aI., 1987).
..; ':/,
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I. The Role of the IGF-TI/Man 6-P Receptor in the Transport of Lysosomal
Enzymes
The mannose 6-phosphate receptors are responsible for directing the transpon of
BP?t ins possessing a mannose 6-
phosphate recognition marker to the lysosomes. Newly
synthesized lysosomal enzymes (Table 1) bind to the mannose 6-phosphate receptors in the
u-ans-Golgi. These complexes are then localzed into coated pits of the Golgi 
apparatus and
coated vesicles are formed. These vesicles then un coat and enter a comparent, called the
lysosomal comparent (PLC) or comparment of uncoupling of receptor and ligand
(CUR), where the vesicle acidifies and lysosomal enzymes are released. A further sortng
, '
occurs in this compartment such that the lysosomal enzymes are directed to the lysosomes
' ,
d the receptors retur to the Golgi apparatus (von Figua and Hasili, 1986; Geuze et ai.,
g88; Dahms, Lobel, and Kornfeld, 1989). The precise roles of the two mannose 6-
, ph sphate receptors in this process has not been clearly defined as yet. However, only the
IQF-IIan 6-P receptor is capable of binding to mannose 6-phosphate containing proteins
l" t.
::'. 
'l#1 cell surface to direct then to lysosomes (Sly and Fischer, 1982; Kyle et ai., 1988).
, - - - ,
ly, a pathway not involving the mannose 6-phosphate receptors may diect many of
.. tle lysosomal membrane proteins to the lysosomes (Klionsky and Emr, 1990).
(\,: Ths model has developed in the last few decades based on evidence from a number
I; jnvestigators. The initial evidence came from studies by Elizabeth Neufeld of I-cell
,/ .
1,\ disease patients ' fibroblasts. These cells normally secrete lysosomal enzymes into the
'::
'1 
lnedum, but are capable of takng up lysosomal enzymes from other cell lines (Hickman
r1-J 
:, '
;anctNeufeld, 1972). The I-cell lysosomal enzymes, however, cannot be taken up by other
, "
'cel lines (Hickman and Neufeld, 1972). This led to the hypothesis that the enzymes
(! .
t,:cared a recognition marker.- Funher experiments identified the recognition marker to be
Table 1: Lysosomal Enzymes. The IGF-II/Man 6- Receptor serves to sort
lysosomal enzymes from the Golgi apparatus and diect them to lysosomes. The following
is a list of the identified lysosomal enzymes, their function, and pH optima (From Tappel
1969).
Enzyme Substrate(s) pH optimum
a- N -Acety lhexosamnidase Heparan Sulfate
- N -Acetylhexosamiidase glycoproteins and glycolipids
Acid Deoxyrbonuclease DNA
Acid Phosphatases phosphoric monoesters
Acid Pyophosphatase FAD ATP
Acid Ribonuclease RNA
Arlamdae amo acid arlamdes
Arlsulfatae A arl sulfates
Arlsulfatase B arl sulfates
Asparlglucosylame asparylglucosylame link
Amido Hydrolase in glycoproteins
Cathepsin A proteins and pep tides 5.4
Cathepsin B proteins and pep tides 
Cathepsin C peptides
Cathepsin D proteins
Cathepsin E proteins
Collagenase collagen
Esterae fatt acid esters
Fucosidase fucosides
Galactocerebrosidase galactocerebrosides
Galactosidase glycolipids and glycoproteins
Glucocerebrosidase glucocerebrosides
Glucosidase glycogen
Enzyme
Glucosidase
Glucuronidase
Hyaluronidase
Lysozyme
(X- Manosidase
Peptidase
Phosphatidic Acid Phosphatase
Phosphodiesterase
Phospholipase
Phosphoprotein Phosphatase
O-seryl- N -acetyl-galactosamnide
glycosidase
Sialdase
Sphingomyelinase
Triglyceride Lipase
Xylosidase
Substrate(s)
glycoproteins
polysacchardes
hyaluronic acid, chondroitin sulfate
mucopolysacchardes
glycoproteins
peptides
phosphatidic acids
oligonucleotides, phosphodiesters
phospholipids
phosphoproteins
seryl acetylgalactosamnide link
in glycoproteins
gl ycoproteins and gl ycolipids
pH optimum
6.4
4.4
4.4
sphingomyelin 5.
trglycerides 4.
glycoproteins, mucopolysacchardes 5.
sensitive to oxidation (Hckman , Shapiro, and Neufeld, 1974), mannosidase treatment
(Hieber et ai., 
1976), deglycosylation (Ullrch et ai., 1978), and alkaline phosphatase
treatment (Ullrch et ai., 1978). Uptae of lysosomal enzymes was inhibited by a number
of agents, but most strongly by fructose I-phosphate, mannose 6-phosphate, and
phosphomannans (Ullrich et ai., 1978; Sando and Neufeld, 1977; Kaplan , Achord, and
Sly, 1977; Kaplan et ai., 1977). The recognition marker was eventually identified as
mannose 6-phosphate by the ability of proteins containing the marker to inhibit the uptake
of p- galactosidase (Distler et ai., 1979) or by its presence on a- Acetylglucosaminidase
(von Figura and Klein , 1979) or P- glucuronidase (Natowicz et ai., 1979).
The synthesis of the mannose 6-phosphate recognition marker is a two step process
(Figure 11; Lazzarno and Gabel, 1988). Briefly, N-acetylglucosaminyl I-phosphate is
transferred from UDP-N-acetylglucosamine to the C6 hydroxyl of a man nose residue by
UDP-N -acety Igl ucosamine: lysosomal enzyme N -acetylg1ucosaminyl-
phosphotrsferase. The N-acetylglucosame is then removed by N-acetylglucosame 1-
phosphcxester a-N-acetylglucosaminidase to create the mannose 6-phosphate recognition
marker (von Figura and Hasilik, 1986). The transferase prefers oligosacchardes of 6-
residues and shows selectivity for lysosomal enzymes in their native conformation
(Reitman and Kornfeld, 1981). While no concensus sequence for the transferase has been
identified in lysosomal enzymes, the available evidence suggests that several small areas
which are separated in the primary strcture but near each other in the mature, folded
protein may be the recognition signal for this enzyme (Faust and Korneld, 1989). It is this
process that is defective in I-cell fibroblasts due to a defective transferase (Hasilik and
Neufeld , 1980).
Figure 11: Synthesis of the Mannose 6-Phosphate Recognition Marker. The synthesis of
the Man 6-P recogntion marker is a two step process. The first step involves the addition of
N-acetylglucosaminyl I-phosphate to the end of a glycosyl chain on a lysosomal enzyme. The
N-acetylglucosamine is then removed to leave the Man 6-P recognition marker.
The fist receptor identified to playa role in the bindig of lysosomal enzymes was
the IGF-IIan 6-P receptor. This protein was purfied by affinity chromatography on
immobilzed lysosomal enzymes or phosphomannans (Sahagian , Distler, and Jourdian
1981; Steiner and Rome, 1982; Sahagian, Distler, and Jourdian, 1982). Specifically, this
protein recognizes mannose 6-phosphate as a phosphomonoester (Varki and Kornfeld,
1983) and requires two or more of these residues for high affmity binding (Fischer, Creek,
and Sly, 1982). The presence of the cation dependent mannose 6-phosphate receptor
wasn t detected in cell lines possessing the IGF-II/an 6-P receptor. However, the
existence of lysosomes in cells deficient in or lacking this protein (Gabel, Goldberg, and
Kornfeld, 1983) suggested another mechanism existed to direct newly synthesized
nzymes to lysosomes (Hoflack and Kornfeld, 1985b). From P388D1 macrophages, a cell
lacking the IGF-II/an 6-P receptor, the cation dependent mannose 6-phosphate
receptor was identified (Hoflack and Kornfeld, 1985a). This protein is also present in
bovine liver (Hoflack and Kornfeld, 1985a). It has an Mr-46 kDa and appears to bind
ligand as a dimer (Stein et at., 1987 a) trmer (Hoflack and Kornfeld, 1985a), or a tetramer
(Stein et ai., 1987b), and may, in fact, bind ligand independently of cations (Junghans,
Waheed, and von Figura, 1988). The cloning of this protein revealed a homology in the
xtracellular region to a repeat of the IGF-II/an 6-P receptor (Dahms et ai., 1987).
J. The IGF -II/Man 6-P Receptor Binds Some Prohormones and May 
Playa
Role in Their Processing
In addition to lysosomal enzymes, several other proteins have been demonstrated to
possess mannose 6-phosphate and to be capable of bindig to the IGF-IIan 6-P receptor.
In general, the lysosomal enzymes possess two or more mannose 6-phosphate moieties,
thus binding very tightly to the IGF-II/an 6-P receptor, while these other proteins
possess only one or two mannose 6-phosphates and bind with lower affinity (Fischer
Creek, and Sly, 1982; Dong and Sahagian , 1990). This may explain the phenomenon
whereby the vast majority of lysosomal enzymes are sorted directly from the Golgi
apparatus to the lysosome, while the prohormones often escape the cell and are later
fcaptured. Among these prohormones and growth factors are pro-
transformng growth
factor (31 (TGF-(31), proliferin, and thyroglobulin (the precursor to thyroid hormones).
t' Pro-tansforming Growth Factor (31
The presence of two phosphorylated oligosaccharides at Asn 82 and 136 on pro-
(31 has recently been determned (Purchio et ai., 1988) and it has been demonstrated
that this protein binds to the IGF-II/an 6-P receptor in a mannose 6-phosphate inhibitable
thanner (Kovacina et ai., 1989). The presence of a latent, precursor form of TGF(3 has
previously been suggested (Nilsen-Hamilton, et ai., 1980; Wakefield et ai., 1988;
tYyazono 
et ai. 1988) as well as a latent form complexed to a2-macroglobulin (O' Connor-
cCoun and Wakefield, 1987). It is of interest that while there are multiple forms of
(3 (Derynck et ai., 1985; Obberghen- Schillng et ai., 1987; Ikeda, Lioubin , andL -
Marquardt, 1987; Marquardt, Lioubin, and Ikeda, 1987; Dijke, 
et ai., 1988) only the fIrst
.- ,
fonn, TGF l, has been shown to possess the lysosomal enzyme recognition marker
mannose 6-phosphate.
The mature TGF is a homodimer of two 112 amino acid subunits (Marquardt,
Lioubin, and Ikeda, 1987) each subunit of which is synthesized as a much larger precursor
of 391 amno acids (Derynck et ai., 1985). The TGF s bind to several cellular receptors,
one of which (280 kDa) has equal affinities for TGF l and TGF 2, while the other two
receptors (65 and 85 kDa) have higher affinity for TGF l (Cheifetz et ai., 1987). It is the
q5 kDa receptor which appears to mediate the decrease in cellular proliferati induced by
TGF s (Boyd and Massague, 1989).
The precise role of the TGF s is stil being investigated (Roberts et ai., 1987).
They appea to playa role in the production of collagen matrx and its interaction with cells
(Ignotz and Massague, 1987; Montesano and Orci, 1988) and in the control of
proliferation, differentiation, and transformation (Sporn et ai., 1986; Keski-Oja et ai.,
987). The physiological role of the binding of pro-TGF- l to the IGF-II/Man 6-
teptor is also not known at this time, but it may playa role in the processing of this
prohormone.
2. Proliferin
The next growth factor that possesses a mannose 6-phosphate moiety and can bind
to the manose 6-phosphate receptor is proliferi (Le and Nathans, 1988). Proliferin is an
approximately 25 kDa glycoprotein growth factor which is secreted by mouse placental
tissue and a number of growing mouse cell lines (Le and Nathans, 1987). It is related to
the placentallactogens (Le and Nathans, 1987) and shows a 31 % identity with prolactin.
At this tie the only receptor identified for this molecule is the IGF-IT;Man 6-P receptor
which it binds with a high afnity (kd=1-2 nM) which is dependent upon glycosylation and
phosphorylati and can be inhibited by man nose 6-phosphate (kI- lO 11M) or anti-IGF-
II/an 6-P receptor antibodies (Lee and N athans, 1988). The functional role of proliferi
binding to the IGF-II/an 6-P receptor is unkown, as is the ultimate physiologic role of
this molecule.
3. Thyroglobulin
The best studied prohormone possessing mannose 6-phosphate recognition markers
is thyroglobulin (Yamamoto et ai., 1985; Herzog, Neumuller, and Holzmann, 1987).
Thyroglobulin is a large protein which is the precursor to the thyroid hormones T3 and T4.
The process by which this occurs is depicted in Figure 12. Thyroglobulin is secreted into
the thyroid follcle lumen where it is iodinated and concentrated (Herzog, Neumuller, and
Holzmann, 1987). The iodinated thyroglobulin then binds the IGF-II/an 6-P receptor
and is endocytosed. It then arves in a lysosome population which may be distinct from
the cells degradative lysosomes (Selmi and Rousset, 1988). The iodinated thyroglobulin is
then processed into the mature thyroid hormones by sequential cleavage by cysteine
proteinase I, cathepsin B , and other lysosomal proteases (Dunn and Dunn , 1988). The
matue thyroid hormones thus produced can then be released as needed.
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es to produce the matue thyroid hormones, T3 and T4.
K. The Subcellular Location of the IGF -II/Man 6-P Receptor
In order to direct lysosomal enzymes as described in an earlier section , it is
necessar for the IGF-II/Man 6-P receptor to be present in certain intracellular
compartments and absent from others (Nolan and Sly, 1987). Specifically, it must 
present in the Golgi apparatus and the plasma membrane in order to bind ligand. It must
then be sorted by coated pits and appear in the prelysosomal comparent (Griffths et at.,
1988). Finally, it must not arve in the lysosomes in order to be able to diect multiple
lysosomal enzymes to the lysosomes (Figure 13). The mechanism by which IGF-II/an
P receptors are properly sorted has only recently been addessed (Lobel et at., 1989).
The presence of an IGF-II/an 6-P receptor has been demonstrated in essentially
every cell type and tissue studied, although differences in glycosylation may alter its
apparent molecular weight (McElduff, Poronnik, and Baxter, 1987; Taylor, Scott, and
Baxter, 1987). The cell cell types in which the presence of an IGF-IT/Man 6-P receptor has
been demonstrated include rat hepatocytes (Scott and Baxter, 1987) and liver (Valentino 
at., 1988), human fetal fibroblasts (Conover, Rosenfeld, and Hintz, 1987), rat kidney
(Haskell, Pilion, and Meezan, 1988; Valentino et at., 1988), mouse and rat neural tissue
(Valentino et at., 1988; Ocrant et at., 1988) and rat lung, heart, fat, ovary, testes, and
;t! 1
adrenals (Taylor, Scott, and Baxter, 1987). The IGF-II/Man 6-P receptor is normally
trw"
" ,
found in a number of subcellular locations including the plasma membrane, Golgi
Ptl\g
atus, coated vesicles, and CURL (Geuze et at., 1984a and b; Geuze et aI. , 1985). A
ipl distrbution is seen for the cation dependent mannose 6-phosphate receptor where
is Seen at the cell surface, 20% in endocytic vesicles, and the remainder in the Golgi
tus (Stein et at., 1987a). Neither of the receptors is found in lysosomes (Stein et at.,
.Q87a; Brown , Goodhouse, and Farquhar, 1986). Functional studies of the movement of
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gure 13: Possible Model for the Subcellular Distribution and Movement of the
,;
..Ulan 6-P Receptor. The IGF-II/an 6-P receptor resides primarly in the trans Golgi
, '~~~
fWork. From this comparment the receptor can move to the prelysosomal compartment
tf,"
';;/
ugh c1athn coated vesicles or escape the coated vesicles to reach the plasma membrane.
e that reach the plasma membrane are then endocytosed through clathn coated vesicles to
the same prelysosomal comparment. In the prelysosomal comparent the decreased pH
ses the dissociation of ligand from receptor, and the receptor is sorted back to the Golgi
, atus while the ligands go 'On to lysosomes.
receptors have shown that in I-cell fibroblasts (Brown and Farquhar, 1984b) or following
tUnicamycin treatment (Gonzalez-Noriega et al., 
1980; Brown, Constantinescu, and
Farquhar, 1984) receptors accumulate in Golgi coated vesicles, while chloroquine causes
accumulation in endosomes (Brown, Constantinescu, and Farquhar, 1984). Monensin and
anti-receptor antibodies also cause the accumulation of receptors intracellularly (Braulke 
aI., 1987; Nolan et al., 
1987). Although binding of ligand does cause a conformational
change in the receptor as measured by protease sensitivity (Westcott, Searles, and Rome,
1987), the ligand occupancy does not appear to affect receptor movement (Oka and Czech,
1986; Braulke et al., 1987). Both Man 6-P receptors cycle from the cell surace and return
to the trans Golgi (Duncan and Kornfeld, 1988) and copurify in intracellular vesicles which
contain the asialoglycoprotein receptOr (Messner, Griffiths, and Kornfeld, 1989). There
is, however, sortng of receptors such that 20-45 minutes following internalization the
IGF-II/an 6-P receptor is sorted from the transfemn and asialoglycoprotein receptors
(Geuze et al., 1983; Stoorvogel et al., 1989).
L. The Synthesis, Processing, and Degradation of the IGF -II/Man 6-
Receptor
The IGF-IT/Man 6-P receptor is synthesized as a 2491 amo acid preprotein , which
gives rise to a 2451 amino acid mature protein following removal of the presequence
(Morgan et at., 1987). FoJlowing synthesis, this protein undergoes a series of
modcations to give rise to mature receptor (Figue 14). The fIrst receptor form detectable
in H35 cells has an Mr=245 kDa, which is converted to an Mr=250 kDa form with a half
time of 2 hours (MacDonald and Czech , 1985). The 245 kDa form has 2-6 mannose side
chains, and about half of the total man noses appear in the mature form (MacDonald and
Czech, 1985). Neuraminidase treatment causes the conversion of the 250 kDa form into
the 245 kDa form (MacDonald and Czech , 1985). Endo H treatment causes the 245 kDa
form to be converted to a 232 kDa form, a form which accumulates in the presence of
icamycin (MacDonald and Czech , 1985). Monensin caused the accumulation of the 245
"I.
"""
1$a form (MacDonald and Czech, 1985). BW 5147 (Goldberg, Gabel, and Kornfeld,
83) and CHO (Sahagian and Neufeld, 1983) cells show similar processing following
translation. Both the 245 kDa or the 250 kDa forms are capable of binding IGF-II, while
the 232 kDa form wasn t functional in binding this ligand. No glycosylation is apparently
required for binding of mannose 6-phosphate (Sahagian and Neufeld, 1983). It has been
hyp0thesized that the lag time following synthesis of this, and other, receptors to bind
ligand is due to a requirement to form the correct disulfide bonds in the endoplasmic
reticulum (Olson and Lane, 1989). Like the IGF-llan 6-P receptor, the cation dependent
mannose 6-phosphate receptor is synthesized as a precursor, then glycosylated to a mature
form withn 2 hours (Stein et ai., 1987a).
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The degradation of the receptor occurs slowly, with a half life of 24 hours in human
fibroblasts (Creek and Sly, 1983). In I-cell disease the halflife is somewhat longer, being
32 hours, while P-glucuronidase and N:CI decreased the half life slightly (Creek and
Sly, 1983). The degradation is nonlysosomal (Creek and Sly, 1983; Sahagian, 1984), is
not inhbited by leupepti (Creek and Sly, 1983), and may involve an extracellular protease
(Sahagian, 1984). The degradation rate also appears to depend on the cultue conditions as
CHO cells showed a half life of receptor of 16 hours in monolayer but only 6 hours in
suspension culture (Sahagian and Neufeld, 1983). One cell line, MOPC 315, possess a
markedly decreased number of receptors because, although receptor is synthesized
normally, it is degraded very rapidly (Goldberg, Gabel, and Kornfeld, 1983).
ft .
M. The IGF-II/Man 6-P Receptor as a Signallng Protein
The biological role of the IGF-II/an 6-P receptor in signalling responses to the
IGFs has been under debate for a number of years. Two types of responses have been
proposed to be mediated by IGF-II though the IGF-II/an 6-P receptor: insulin-like and
proliferative responses. In this section the evidence accumulated supponing and refuting a
role for the IGF- lllMan 6 P receptor in mediating these responses wil be presented. In the
discussion section of this manuscript this data wil be combined with data from this thesis
project and both possibilities evaluated more critically and a conclusion reached.
The data supportng a role of the IGF-llan 6-P receptor in mediating some of the
i'esponses to IGF- II is supported by a number of types of evidence: 1. correlation of IGF
binding to the IGF-IIan 6-P receptor with responses; 2. the inability of these responses
to be blocked by antibodies to the insulin and IGF-I receptor; 3. the ability of some
responses to be blocked by antibodies which recognize the IGF-ll/Man 6-P receptor; and
4. the ability of ligands for the Man 6-P binding site of the IGF-II/an 6-P receptor to alter
these responses.
, ,
IGF- II has been implicated to cause an increase in thymidine and sulfate
incorporation into feta rat costa carlage though its own receptor based only on the abilty
of IGF-II to cause this response (Hil and Milner, 1984). On the basis of ligand
specificity, IGF-II stimulates 2-deoxyglucose and a-aminoisobutyrc acid uptake in L6
, myoblasts (Beguinot et at., 1985), increases the activity of the Na+JH+ exchanger in canine
, renal proximal tubular cells (Mellas, Gavin , and Hammerman, 1986), and promotes
, growth in the K562 human erythroblast cell line (Tally, Li, and Hall, 1987) and in fetal rat
adrenal cells (van Dijk , Tanswell , and Challs, 1988) though the IGF-IIIMan 6-P receptor.
Using antibodies which block ligand binding to the insulin receptor, the IGF-
lJan 6-P receptor has been implicated to induce increases in thymidine incorporation in
human fibroblasts (King et at., 
1980) and to phosphorylate the insulin receptor a-subunit
. ,in dog kidney basolateral membranes (Hammerman and Gavin, 1984). A combination of
(the dose dependence of the response, the inabilty of the response to be inhibited by
taotibodies to the insulin or IGF-I receptors, and by the ability of this response to be
mimicked by antibodies to the IGF-II/an 6-P receptor provide strong evidence that an
:icrease in glycogen synthesis is medated through the IGF-II/an 6-P receptor in human
::hepatoma cells (Har et ai., 1987). A role of the IGF-II/an 6-P receptor is indicated in
(induction of inositol trphosphate (IP3) production in renal proximal tubule basolateral
\inembranes by a 2-fold potentiation of the IGF-II effect by mannose 6-phosphate (Rogers
iandHamerman, 1989). .
The most studied IGF-II responsive system involves the increase in thymidine
incorporation observed in Balb/c 3T3 cells made competent with PDGF then primed with
IEOF (Nishimoto et ai., 1987a and b). Corresponding with this response was a 2-fold
IS-Ustained increase in Ca++ influx which was dependent upon extracellular Ca++ and
iinhibitable by lanthanum, cobalt, and tetramethlin but not nitrendipene (Nishimoto et ai.,
d987a and b). Much higher concentrations of IGF-I are required to induce this response.
BA YK864 induced Ca++ influx in primed competent cells resulted in a similar increase in
?H-thymidine incorporation (Nishimoto et ai., 1987a and b). IGF-ll appears to act through
a:c protein as it attenuated pertussis toxin induced ADP ribosylation of a 40 kDa G-protein
:inthese cells (Nishimoto et ai., 1989). Finally, an antibody to the IGF-llan 6-P receptor
!ihcreases thymidine uptae and Ca++ influx in this system (Kojima et ai., 1988).
There are a number of pieces of evidence which indicate that the IGF-II/an 6-
deptor plays no role in medating the responses of IGF-II. The IGF-I receptor has been
n to mediate the IGF-II induced increase in a-aminoisobutyric acid uptake in rat
us muscle (Yu and Czech , 1984a) and in DNA synthesis in human fibroblasts
ianetto, DiCarlo, and Wisehar, 1987) and rat granulosa cells (Adashi , Resnick, and
Rosenfeld, 1990). Using anti-IGF-II/Man 6-P receptor antibodies, it has been
""'
strated that the IGF-llan 6-P receptor plays no role in the IGF-ll induced increase
NA synthesis in H-35 Hepatoma cells (Mottola and Czech, 1984) and in a-
the.
aminoisobutyrc acid uptake, glucose transport, and protein synthesis by L6 myoblasts,
although the anti-receptor antibody was able to block IGF-II binding to its receptor and
h ..
decrease the rate of degradation of IGF-II (Kiess et al. 1987). These peices of evidence
\tV;,.,
have disproven the proposed role of the IGF-II/an 6-P receptor in mediating these
f .
parcular responses.
';on;' Other types of experiments also question the role of IGF-II/Man 6-P receptor in
sign.alling responses to IGF-II in general, but in more indirect ways. A disruption of the
IGF: U gene in mice results only in a decrease in growth (DeChiara, Efstratiadis, and
bertson, 1990). Such an effect argues against a critical role for the IGF-II binding
capabilty of the IGF-llan 6-P receptor. More evidence comes from chick myotubes,
which lack IGF-II/Man 6-P receptors, but show an increase in amino acid uptake, protein
synthesis , and decrease in protein degradation at 5 nM IGF-II (Janeczko and Edinger,
1984; Conover et al., 1986), similar to responses seen in cells possessing IGF-llan 6-
receptors. The presence of a second binding site on the IGF-I receptor which preferentially
binds IGF-ll and is not blocked by aIR-3, the anti-IGF-I receptor antibody used in the
studies discussed above (Cas lla et al., 1986) calls into question experiments implicating
':0
the IGF-llan 6-P receptor as the signaling receptor by blockig IGF-I receptor with this
antibody. IGF-II responses could also be mediated by a recently discovered receptor
which has been cloned and sequenced and which resembles the insulin and IGF-I receptors
f(Shier and Watt, 1989). This may be a new IGF-II receptor. Finally, some pieces of data
provide alternative explanations for some of the observed phenomenon. The ability of
insuln to inhibit pertussis toxin catayzed ADP-ribosylation of G-proteins through its own
irceptor (Rothenburg and Kah, 1988; Ciaraldi and Maisel, 1989) brings up the possibilty
;;thatthe effect in primed competent Balb/c 3T3 cells, discussed above, could be mediated by
the insulin or IGF-I receptor. There is also evidence that the normal secretory pathway of
the IGF-II/an 6-P receptor may involve G-proteins and Ca++ based on the abilty of
Jiterations of these components to alter lysosomal enzyme release (Goda and Pfeffer, 1988;
Waren, 1989) and affinity for ligand (Bryson and Baxter 1987). It would not be unusual
if ligands for the receptor altered its intracellular movement, and thereby these parameters.
The fact that IGF-II/an 6-P receptor phosphorylation is altered by binding of lysosomal
' '
enzymes or mannose 6-phosphate (Panneerselvam and Balasubramanian, 1989) further
suggests that receptor conformation may be altered upon ligand binding and transmitted
-"
across the membrane; however, there is no indication that this phosphorylation plays any
tr,i., 'fuer role in signallng.
11('"
N. Receptor Forms in Serum
The initial "soluble receptors" were generated by special treatments of lymphocytes
or liver membranes to induce the release of these proteins. Insulin receptors (Gavin, Buell,
and Roth, 1972) and growth hormone receptors (McGuffin et al., 1976; Herington, Elson,
and Ymer, 1981) were generated in this manner. Recently, however, tre serum receptors
have been identied. Recent publications have proposed the use of serum receptors in both
the diagnoses and treatment of certin diseases, as descrbed below..
1. The Transferrin Receptor
The transfern receptor has been demonstrated in human serum as -90 kDa band in
immunoblots. It is present at approximately 255 ng/ml in healthy adults. Alterations in the
levels of the serum transferrn receptor have been observed in a number of disease states:
acute leukemia (368 ng.ml), myeloma (422 ng/ml), and malignant lymphoma (478 ng/ml;
Kongo et ai., 1986). Recently an immunoassay has been devised to measure serum
transfemn receptor levels (Fowers et ai., 1989; Trowbridge, 1989). Using this assay, the
normal transfemn receptor level in serum is 5 mg/, while in aplastic anemia the level is
decreased to -2. 5 mg/ (Flowers et ai., 1989; Trowbridge, 1989). Iron deficiency anemia
or sickle cell anemia result in signifcant increases in serum transferrn receptor, to 18 mg/
and 33 mg/, respectively (Flowers et al., 1989; Trowbridge, 1989).
2. The Growth Hormone Receptor
The growth hormone receptor is the best characterized of the serum receptors. The
serum receptor is capable of binding growth hormone (Ymer and Herington, 1985;
Baumann et al., 1986), is immunologically similar to the membrae receptor (Barard and
Waters, 1986; Baumann and Shaw, 1988), and is similarly regulated by growth hormone
(Hick et al., 1990). The serum receptor is derived from a soluble cytosolic receptor found
in liver (Herigton, Elson, and Ymer, 1981; Ymer, Stevenson, and Herington, 1984; Ymer
and Herington , 1984; Herington, Ymer, and Stevenson , 1986; Barard and Waters, 1986;
Spencer et al., 1988) and is produced from an alternatively spliced message from the
membrane receptor (Leung et al., 1987; Baumbach , Horner, and Logan, 1989). While this
protein is normally present in human serum (Herington, Ymer, and Stevenson, 1986), it is
absent in patients with Laron dwarsm (Daughaday and Trivedi, 1987).
3. The Nerve Growth Factor Receptor
A trncated form of the nerve growth factor receptor having an Mr -50 kDa as
opposed to the cellular nerve growth factor receptor with an Mr -80 kDa has been detected
in the medium conditioned by schwann cells, schwannoma, PC12 cells, and superior
cervical ganglionic neurons (DiStefano and Johnson, 1988). This protein can also be
found in neonatal rat urne, amniotic fluid, and in the stomach of the fetal rat (DiStefano
and Johnson , 1988).
4. Neural Cell Adhesion Molecule (NCAM)
NCAM, a neural adhesion molecule, exists as transmembrane forms, in forms
lacking a transmembrane region but possessing a lipid membrane anchor, and as a soluble
fonn released from cells, all of which are generated by alternate splicing of a single gene
(Gower et al., 1988).
5. The Class I Antigens
Soluble forms of the class I, or major histocompatability, antigens have been
detected in serum complexed with microglobulin (Gussow and Ploegh, 1987). At
present there is evidence that such proteins could be generated from different genes,
different alternatively spliced messages, or be proteolytic products of the normal cell
associated class I antigens (Gussow and Ploegh, 1987).
6. The Interleukin Receptors
Unlike the serum receptors described above in which most of the information
relates to the strcture and synthesis of the receptor, the serum interleukin receptors have
been studied predominantly for their clinical importce. The serum interleukin 2 receptor
is released by cytotoxic T-cells upon activation, apparently by a proteolytic mechanism
(Bar, Korner, and Theze, 1988). The amount of receptor detected in serum vares by the
detection method used, but all results show significant increases with varous types 
malignancies: malignant lymphoma (Hamngton et aI., 1988), lung cancer (1.66 fold;
Marno et al., 1990), Kawasak disease (4. 2 fold, depending on disease activity; Lang
et al., 1990), and multiple sclerosis (2.3 fold; Greenberg et al., 1988; Capra et aI. , 1990;
Rudnick and Bara, 1990).
Recent experients have also suggested a possible clinical application for the serum
interleukin 1 receptor. Injection of mice with serum interleukn 1 receptor significantly
extended the surival of hear transplants and prevented lymph node hyperplasia in
response to injection of allogeneic cells (Fanslow et al., 1990). In either case, injection of
interleukn 1 reversed the effects of the serum interleukin 1 receptor (Fanslow et al., 1990).
This suggests that serum receptors can be used to bind and/or remove their ligands, a
process that could have clinical implications for a number of the serum receptors
discovered and could promote the synthesis of serum receptors not found in nature.
7. The IGF -WMan 6-P Receptor
The serum form of the IGF-II/Man 6-P receptor was initially discovered in rat
serum (Kess et al., 1987), and later in sheep (Gelato et al., 1989), monkeys (Gelato et al.,
1988), and man (Causin et a/., 1988). It is identical to the cellular receptor in its ability to
bind ligand, although it is -10 kDa smaller than the cellular receptor (Kiess et al., 1987;
Causin et al., 1988). This difference in molecular weight cannot be removed by
endoglycosidase treatment (Kiess, Gelato, and Nissley, 1989). The serum receptor is high
in fetal and neonatal 
serum and decreases with age (Kiess et al. 1987), similar to the
developemental regulation observed for the cellular receptor in various tissues
(Alexandrides, Moses, and Smith
, 1989; Sklar et al. 1989; Valentino, Ocrant, and
Rosenfeld, 1990). The serum IGF-ll/Man 6-P receptor is not likely to playa significant
role as it can account for only a smal percentage of the serum IGF binding proteins: 3-
in adult rats and sheep (Kiess 
et ai., 1987; Gelato et ai., 1989), 20% in monkey (Gelato 
ai., 1988), but up to 50% in fetal sheep (Gelato 
et ai., 1989). The apparent lack of effect
of an IGF-II deletion on development furer calls into question the importance of IGF-
binding by the IGF-II/an 6-P receptor (DeChiara, Efstratiadis, and Robertson , 1990).
The presence of both IGF-II/Man 6-P receptor (Causin et ai., 1988) and lysosomal
enzymes (Belfiore et ai., 1974) in urine suggests that the serum form of the IGF-II/an 6-
P receptor may playa role in binding lysosomal enzymes in serum and removing them
though the urne
The studies described in the enclosed manuscripts are designed to increase our
understanding of the strcture, regulation , and function of the IGF-llan 6-P receptor by
studying forms of this protein that have not been studied previously: non-mamalian
receptors and the serum form of the receptor. While only a few specific questions have
been addressed, a number of interesting implications are suggested by the results as are
C ,
veral new areas of research.
The fIrst question addressed is whether Man 6-P receptors from species other than
those previously studied (a number of mammals) possess the capacity to bind IGF-II. The
rationale for these experiments arses from two different pieces of evidence. The fIrst is
..:1 
that a number studies to address the presence of IGF receptors in chickens have identifIed
ac;""
only IGF-I type receptors (Kasuga et ai., 1982b; Bassas et ai. 1988). Second, given the
te!: , '
general and crtical role of the Man 6-P receptor in sorting lysosomal enzymes, it is unliely
h\' L"
tluit this protein would be absent in any species. The approach taken to answer this
. q
estion is to affinity purify Man 6-P receptors, then to use I25I-IGF-II in affinity
lfU?'
crosslinking and binding experiments. Receptors were isolated from rat (as a positive
control), chicken, and Xenopus (to address the general pattern of binding in evolution) and
ceo.Uuat and chicken I25I-IGF-II were used in the binding studies.
The remainder of the manuscripts involve a number of studies to address the
fe(:;
" , , q
stio of the relationship between the serum and cellular IGF-II/an 6-P receptors and
..,
to fUrher characterize the serum receptor. The fIrst studies addressed the 
strcture and
tif;,!
1)inding functions of the serum IGF-II/Man 6-P receptor. In order to compare the
strctures of the cellular and serum IGF-IIan 6-P receptors, antibodies were raised
against two peptides: one in the extracellular region of the receptor, and a second in the
cytoplasmic tail of the receptor. These antibodies were then used in imunoblots to detect
possible trncations of the serum receptor as compared to its cellular counterpar. In order
to assess the binding functions of the serum receptor, receptor immobilized on anti-IGF-
IIan 6-P receptor Affigel or PMP-Sepharose was affinity crosslined to I25I-IGF-II. In
this way its abilty to bind mannose 6-phosphate, as shown by its specific binding to PMP-
Sepharose, and to bind IGF- II, as assessed by crosslinkng to iodinated ligand, could be
demonstrated.
The next set of studies continued studies of the receptor in the whole animal to
furer elucidate the relationship between the cellular and serum receptors. As has been
discussed in an earlier section , the IGF-II/Man 6-P receptor in cells , most notably
adipocytes, is translocated from an intracellular comparment to the cell surface in response
to insulin. If the serum receptor is a proteolytic product of the cellular receptor produced
by proteolysis from the cell surace, we would expect the serum levels of the IGF-II/an
P receptor to increase in response to insulin. This effect has been monitored using the
imunoadsorption and imunoblottig technique described above.
Finally, the question of a possible precursor/product relationship between the
cellular and serum IGF- ll/Man 6-P receptor was addressed. A system was developed
where cultured cells were briefly labeled with 35S amino acids, then IGF-ll/Man 6-
receptor immunoadsorbed from cell membranes or the medium at several times thereafter.
Additionally, the effects of a number of agents, including insulin
, protease inhibitors, and
ligands for the receptor
, on the process of cellular receptor degradation/serum receptor
--r;'
production was studied. These experiments are discussed in the final manuscript in the
Materals, Methods and Results section.
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SUMMARY
The recent demonstration that a single mammalian receptor protein binds both
mannose- phosphate (Man- P) and insulin- like growth factor II (IGF-II) with high
affinity has suggested a multifunctional physiological role for this receptor, possibly
including signal transduction. In order to better understand the functions of this receptor
we have investigated the propertes of Man- P receptors from non-mammalian species.
Receptors were affinity purified from Triton X- 100 extracts of total membranes from
Xenopus and chicken liver as well as rat placenta using pentamannosyl- phosphate
(PMP)-Sepharose. The Man- P receptor was adsorbed to the PMP-Sepharose and
specifically eluted by Man- P in all three species, as evaluated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis followed by silver staining. When the purified
receptors from these three species were crosslinked to I25I-IGF-II with disuccinimidyl
suberate (DSS), only receptors isolated from rat membranes were affinity labelled. To
furer evaluate the properties of these Man- P receptors, binding of I25I-rat-IGF-II and
I25I-chicken YGTA-IGF-II to purified receptors from Xenopus, chicken, and rat was
evaluated by polyethylene glycol (PEG) precipitation. Only the rat Man-6 Preceptor
exhibited detectable binding of I25I-IGF-ll. These data suggest that the emergence of a
high affinity IGF-II binding site on the Man- P receptor occurred in evolution after the
divergence of mammals from other vertebrates. Thus, the biological actions of IGF- II in
chickens and frogs appears to be initiated by the tye I IGF receptor.
, -
The insulin-like growth factors I and II (IGF-I and II) are widespread among
animals, yet the physiologic roles and mechanisms of action of these hormones is
incompletely understoo. The synthesis and release of IGF-I into the circulation has been
demonstrated to be regulated by growth hormone (1), and IGF- I induces growth when
admnistered directly (1). Simarly, IGF-ll has been implicated in a number of physiologic
effects, including stimulation of thymidine incorporation (2-5), RNA and protein synthesis
(6), Ca2+ influx (2), glucose (6-7) and amno acid (6) uptake, glucose incorporation into
glycogen (8), glucose oxidation (4), protein phosphorylation (9), and cell proliferation (3)
and differentiation (10). IGF-II has also been reported to inhibit protein degradation (6)
, and change intracellular pH (11). Biological responses of IGF-I and IGF-II have been
shown to be mediated by a type I IGF receptor which is structurally very similar to the
insulin receptor, a heterotetrameric tyrosine kinase composed of two a and two subunits
(1). Another receptor for IGF- , the type II IGF receptor, bears no resemblance to these
signalling receptors. It consists of a single polypeptide chain with one transmembrane
segment, a short cytoplasmic domain, and no protein kinase activity (12- 18). Furthermore,
this IGF-II receptor has been shown to be identical to the cation independent Man-
receptor as demonstrated by sequence analysis (12- 16) and binding studies (12).
A number of experiments have been designed to elucidate through which receptor
or receptors the biological activities of IGF- II are mediated. Some of these studies indicate
that IGF-II effects are mediated through the insulin or IGF-I receptor, either by analysis of
dose response relationships or by the use of antibodies which block binding of peptide
ligands to insulin (4) and IGF-I (6) receptors. Other results have been interpreted to
suggest that some biological effects may be mediated through the IGF-II/an- P receptor
(7- 11). Some of these effects ofIGF-II are mimicked by anti-IGF-II/an- P receptor
antiserum (2, 8). However, two preparations of anti-receptor antibodies which block
ligand binding to the IGF-llan- P receptor did not block biological responses (19, 20).
The signalling potential of the IGF-llan-6-P receptor thus remains controversial.
The presence of IGFs has been reported in chickens (21), reptiles, amphibians,
and fish (22) where their presence has been assayed by radioimmunoassay or the ability to
compete with the mamalian peptide for binding to mamalian IGF-II/an- P receptor.
Furthermore, mammalian IGFs have been shown to stimulate DNA synthesis, nutrent
transport and cell multiplication in chick embryo fibroblasts (3 , 23) and in cultured chick
myotubes (6). These peptides also act to initiate differentiation in chick myoblasts (9).
Other processes affected by IGF's include DNA, RNA and protein synthesis in chick
chondrocyte cultures (24) and glycogen, RNA, and protein synthesis in chick liver cells
(25). These data strongly support the hypthesis that the avian and mamalian IGFs have
been highly conserved durg evolution in both function and strcture. The parial amno
acid sequences of the chicken IGF's further support this conclusion (21). However,
studies on binding and affinity crosslinking of I25I-IGF-II to cell membranes have
indicated that chickens possess an IGF receptor which resembles the mammalian IGF-
receptor and binds both ligands with near equal affinity (3, 26). No labellng of a type II
IGF receptor was detected in such experiments. In this study, we have addressed this
issue directly by assessing the abilty of affinity purified Man- P receptors from rat,
chicken, and Xenopus to bind with rat and chicken I25I-IGF-II.
EXPERIMENT AL PROCEDURES
Materials. Rat IGF-II was purfied from BRL-3A cell conditioned medium as descrbed
(27). Chicken YGTA varant form of IGF-II was a gift from Dr. F.J. Ballard, CSIRO,
Adelaide, South Australia. Purfied IGF-II was radioiodinated using Enzymobeads
(BioRad) to a specific activity of 40-250 Ci/g. Pentamannosyl- phosphate (PMP),
prepared from the native Y -2448 Q-phosphomannan from H. holstii was a gift of Dr.
E. Slodk, Midwest Area Northern Regional Research Center, Peoria, IL. PMP-
Sepharose was prepared as descrbed (28). Nitrocellulose filters with a 45 Ilm pore size
were obtained from the Millpore Corporation. All other chemicals were reagent grade or
better.
Preparation of Membranes from Rat Placenta, Chicken Liver, and
Frog Liver. A microsomal membrane fraction was isolated from rat placentas taken at
day 19 of gestation as described previously (29), and chicken and Xenopus liver
membranes were prepared by the same technique. Membrane extracts (5 mg protein/ml)
were prepared by incubation with 50 ro 4- (2-hydroxyethyl)- piperazineethanesulfonic
acid (Hepes), 0. 15 M NaCl, 1% Triton X- 100, 5 ro glycerophosphate, pH 7.4, plus
protease inhibitors by gentle mixing for 1 h at 3 C. The protease inhibitors were leupeptin
antipain and benzamdine at concentrations of 10 Ilg/ml each, 20 Ilg/ml aprotinin, 12.
Ilg/ml chymostatin, and 1 ro PMSF. The mixture was centrfuged for 10 min at 15000 x
g in a microcentrfuge and the supernatant fraction was used as the extract. Protein was
assayed by the Bradford method (30).
Purification of Man- P Receptors with PMP-Sepharose. Triton X- lOO
extracts of microsomal membranes containing 1 mg membrane protein from rat placenta
chicken liver, or Xenopus liver were adsorbed with PMP-Sepharose in 50 ro Hepes,
15 M NaCI, 0.05% Triton X- 100, 5 mM glycerophosphate, pH 7.4, with
antiproteases. After an overnight incubation at 4 C, the resin was loaded into a column
and, for the rat and chicken membranes, prewashed in 50mM Hepes, 0.5 M NaCI , 0. 1 %
Triton X- lOO, 5 ro glycerophosphate, pH 7.4. Material was then eluted sequentially in
buffer alone, buffer containing 5 ro Man- P, containing 5 mM glucose- phosphate,
and finally 5 ro Man-
Affinity Crosslinking of 12SI-IGF-II to Purified Receptors. Following
purfication with PMP-Sepharose, receptors from 100 Jlg membrane protein were
suspended to a volume of 0.2 ml with KR buffer containing 1% BSA plus 4 nM 1251-
IGF-ll with or without 400 nM unlabelled IGF-ll. These mixtures were then incubated for
4 hat 23 C. The samples were subjected to affinity cross-linking with DSS as descrbed
before (31).
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE). Electrophoresis was cared out under reducing conditions, samples were heated
to 100 C for 10 min in SDS sample buffer with dithiothreitol. Electrophoresis was
performed as descrbed (32) on 6% polyacrylamide gels. Silver staining was performed
using a BioRad silver stai kit as described (33).
Quantitation of Ligand Binding Using the Polyethylene Glycol (PEG)
Precipitation Method. The studies of ligand binding to receptor were performed as
previously described (29). Briefly, 0. 1 ml of a stock solution of 4 nM 125I-IGF-II and
unlabelled IGF-II at 0, 10, 40, 100, 400, and 1000 nM was combined with an equal
volume of a solution of purfied receptors at 4 Jlg of protein. Following incubation for 1 h
at 3 C, 0.5 ml of 0.9 mg/ml bovine "(-globulins in 0. 1 M sodium phosphate buffer, pH 7.4
and 0.5% PEG were added to each sample, the sample mixed, and incubated at OOC for 15
min. This mixture was then fitered through nitrocellulose fiters which were blocked 
incubation in KR containg 1 % bovine serum albumin, the filters washed 3 times with 8%
PEG, and the "(-radiation from the filters measured.
RESUL TS AND DISCUSSION
" '
In the fIrst experimental protocol (Fig. 15), PMP-Sepharose was used to affinity
rify Man- P receptors from membrane extracts of rat placenta (lanes 1 , 3), chicken
liver (lanes 4, 5, 6), and Xenopus laevis liver (lanes 7, 8, 9). A Triton X - 100 extract of
ole membranes was incubated with PMP-Sepharose overnight, then this material was
loaded onto a column and the fractions eluted by buffer alone (not shown), mannose-
pposphate (lanes 1, 4, and 7), glucose- phosphate (lanes 2, 5, and 8), and Man-
(lanes 3, 6, and 9). From each frction one aliquot was electrophoresed (SDS-PAGE) then
!l;yer stained (panel B). A duplicate sample was incubated with 125I-IGF-II and the
qpsslinkng agent DSS and subjected to SDS-PAGE, and the gel autoradiographed (panel
A). Although most of the protein fails to bind to the column and elutes in the fIrst washes
"(ith buffer, the Man- P receptor binds the column strongly and is mostly eluted by Man-
Pas demonstrated by a silver staned Mr-250K band (lanes 3, 9).
Affmity crosslinng of the purfied rat receptor preparations yielded a labelled band
at Mr-260K, corresponding to the ligand-receptor complex (lanes 1 , and 3). Very low
but significant amounts of labelled rat receptor were also visualized in the mannose-
phosphate and glucose- phosphate elutions (lanes 1A and 2A) even though silver stained
receptor was not evident. In contrast, no labelled receptor bands were detected when either
chicken or Xenopus receptor preparations were crosslinked with 125I-IGF-II (lanes 4-
9).Increasing the exposue ties of the autoradiogram of the chicken and frog preparations
fIve-fold also failed to reveal labelled bands (not shown). Using this technique, the
presence of receptors with up to a 10 fold lower affinity than mammalian IGF-II/an-
receptors should be easily detected.
The data in Figure 15 strongly support the idea that Man- P receptors from
Xenopus and chicken fail to bind IGF-II, yet it is possible that IGF-II and its receptor have
diverged in evolution such that ligand-receptor interactions are species specific. Direct
binding studies using both rat and chicken IGF-II using the purfied Man- P receptors
were performed to definitively test this hypothesis. In Figue 16 (panel A) is shown the
competition by excess un labelled rat IGF-II of 125I-rat IGF-II binding to Man-
receptors purified from the thee species described in Figure 15. While rat 125I-IGF-
binds significantly to rat receptor by a saturable process, no binding to the chicken or
XenopUS receptor by this ligand is observed. This experiment was repeated (Fig. 2, panel
B) using 125I-chicken IGF-ll as ligand with similar results: neither chicken nor Xenopus
Man- P receptors bind chicken 125I-IGF-II significantly, while the rat receptors bind this
ligand with high affinity.
The data presented above demonstrte that chicken and Xenopus liver cells contain
Man- P receptors, but that they lack the abilty to bind IGF-II with measurable affinity
under the experimental conditions described here. In these species, the presence of IGF's
has been demonstrated, and, in the chicken, IGF-ll has been shown to cause a number of
physiologic responses, many similar to those documented in mammals. Importantly, the
chicken Man- P receptor fails to bind chicken 125I-IGF-II with high affinity, while the rat
receptor binds this ligand with high affinity. It has previously been demonstrated that
chickens possess a type I IGF receptor tyosine kinase which binds IGF-I and II with near
equal affinity (3). It thus seems likely that both IGF-I and IGF-II mediate biological
actions by interactig with this type I IGF receptor in chickens.
FOOTNOTE
The abbreviations used are: IGF I and II, insulin like growth factor I and II; Man-
P, mannose- phosphate; PMP, pentamannosyl- phosphate; DSS, disuccinimidyl
suberate; KR, Krebs Ringer phosphate buffer; SDS-PAGE, sodium dodecylsulfate
), : 
polyacrylamide gel electrophoresis; PMSF, phenylmethylsulfonyl fluoride; Hepes, 4-(2-
i hydroxyethyl)- piperazineethanesulfonic acid; BSA , bovine serum albumin; PEG,
;,;
' polyethylene glycol.
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Note Added in Proof
While this manuscript was undergoing review, a paper was published (Canfield,
'Y. . and Kornfeld, S. (1989) The Journal of Biological Chemistry 264 , 7100-7103)
which also reported that the chicken Man 6-P receptor failed to bind IGF-II with high
affinity.
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Figure 15. Analysis of fractions eluted from a PMP-Sepharose column by
affnity crosslinking. Triton X - 100 extracts were prepared of 1 mg of protein from rat
placenta (lanes 1, 2 , 3), chicken liver (lanes 4, 5, 6), and frog liver (lanes 7, 8, 9). These
extracts were incubated in a total volume of 2 ml with 1 ml of PMP Sepharose overnght at
40C. Following the incubation, the rat and chicken membranes were prewashed in a high
!buffer as descrbed in the Experimenta Procedures. Fractions were eluted with 1 ml of
buffer alone (not shown), buffer containing 5 mM mannose- phosphate (lanes 1 , 4 , 7),
bJW contaiing 5 mM glucose- phosphate (lanes 2, 5, 8), or buffer containing 5 mM
'"1'
!" ,
Man P (lanes 3, 6, 9). One aliquot of each fraction (0. 1 ml) was then analysed by SDS-
f"b.
GE followed by silver staning (panel B), while another alquot (50 
l) was analysed by
ssiinng with DSS to 4 nM 125I-IGF-II, followed by SDS-PAGE and autoradiography
t'-
,.,
(panel A). The apparent Mr of the receptor band in the crosslinking study is increased to
260K due to the added molecular mass of the crosslined IGF-ll.
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Figure 16. Analysis of the binding of 125I-rat and chicken IGF-II to
purified Man- P receptors. Receptors purified on PMP- Sepharose (4 g protein)
were incubated in a total volume of 0.2 ml with 2 nM 125I-IGF-II from rat (panel A) or
chicken (panel B) containing 0, 5, 20, 50, 200, or 500 nM unlabelled rat IGF- II.
Following a 1 h incubation at 3 C, samples were PEG precipitated as described (29) and
the y-radation from the filters measured.
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Pucation of peptides 13D and 22C.
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Purfication of IGF-llan 6-P receptor for antibody generation and
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Performance of immunoblots used in the manuscrpt.
Preparation of the manuscrpt
Summary
The insulin-like growth factor (IGF)-Wmannose- phosphate (Man- P) receptor
present in mammalian tissues as an apparent Mr = 250 K glycoprotein has recently been
detected in fetal rat serum in a lower Mr form (240K). In the present studies the serum
-- 
receptor was affinity labelled with 125I-IGF-ll after its adsorption onto pentamannosyl-
phosphate-Sepharose, demonstrating that it can also bind both ligands simultaneously. The
:rec ptors in both serum and fresh plasma exhibited the lower Mr compared to tissue
receptors, indicating this form circulates 
in vivo. In order to probe the strctural basis of
Jhe serum receptor s lower Mr, we raised antipeptide antibodies against cytoplasmic and
extracellular domains of the tissue form of the rat receptor deduced from complementar
;PNA clones (MacDonald, R.G., et al Science 239, 1134- 1137, 1988). Peptide 22C,
EEETDENETEWLMEEIQVP APR, located in the cytoplasmic domain 32 residues C-
\terminal to the transmembrane region, and peptide 13D , YYLNVCRPLNPVPGCN,
.located 1476 residues N-termnal to the transmembrane domai were synthesized and used
ias.immunogens in rabbits. IGF-II/an- P receptors were fIrst immunoprecipitated from
ther rat serum or a Triton X- lOO extract of rat placental plasma membranes using a
,polyclonal antireceptor antibody. The immunoadsorbed receptors were then reduced,
lklated, electrophoresed on SDS-PAGE , blotted onto nitrocellulose, and probed with
lantipeptide antibodies. Anti-13D revealed the major receptor band in all the membrane and
rum samples tested as well as several minor species of lower apparent Mr in serum.
cFeta\ and neonatal rat sera contained 3-4 times as much of the receptor as adult serum. In
\contrast, anti-22C recognized the membrane IGF-II/an- P receptor, but failed to
;fecognize any of the serum receptor species. These results indicate that the serum IGF-
,WMan- P receptor is trncated or altered in its cytoplasmic domain, consistent with the
hypothesis that it is derived from cells by proteolytic cleavage.
The type II insulin-like growth factor (IGF)l receptor is one of a group of receptors
ithat bind the insulin-like growth factors (IGFs) with high affinity (1-3). It consists of a
single polypeptide chain of approximate Mr =250 K (4-8) which has no apparent tyrosine
Lkirt seactivity in vitro (9). These propertes contrast with the type I insulin and IGF-
receptors which share similar heterotetrameric strctures (1-3, 10, 11) containing intrnsic
tYosine kinase activities apparently required to produce biological effects in response to
: ligand binding (12-15). Although several recent studies have reported biological effects
potentially mediated through the IGF-II receptor (16- 18), there is no definitive evidence
qhat this receptor has a signalling function (19-22).
fJ , Recently, Morgan et ai. (23) and we (24) have reported isolation of complementar
,DNA clones for the type II IGF receptor from the human and rat, respectively. The
deduced amino acid sequences were found to be greater than 80 % identical to that of the
ib'ovine cation-independent mannose- phosphate (Man- P) receptor reported by Lobel 
ai. (25). Subsequent isolation of the full-length complementary DNA (cDNA) for the
bovine receptor (26) and the recent independent cloning of the human cation-independent
Man- P receptor cDNA (27) confirm this high sequence identity among these species.
Dirt biochemical and immunological experiments have demonstrated that a single receptor
protein does indeed contain distinct binding sites for both IGF-II and Man- P-containing
ligands (23, 24 , 28-30). The IGF-llan- P receptor from all three species contains a
single stretch of 22-23 hydrophobic amno acids comprising the transmembrane domain.
This region is bounded by a short (163- 167 residues) C-termal cytoplasmic domain and a
very large (::2000 residues) N-termnal extrcellular domain characterized by fifteen repeat
sequences of -150 residues in length (23-27). Binding of IGF-II and Man- P to either the
rat (24) or human (28), but not bovine (30), receptors exhibited positive cooperativity.
Kiess et ai. (31) have recently reported the existence of immunoreactive IGF-
IIan- P receptor in rat serum. Affnity cross-linng studies using 125I-IGF-ll revealed
a developmental pattern of expression of the circulating form of the receptor, with high
levels found during late gestation and early neonatal life (31). Moreover, the serum IGF-
IIan- P receptor species exhibits a slightly lower apparent Mr than the cellular receptor
upon sodium dodecyl sulfate-polyacrlamide gel electrophoresis (SDS-PAGE). In this
study, we report strctural analysis of the serum form of the rat IGF-IIan- P receptor
using antibodies directed against peptide sequences present in the cytoplasmic and
extrcellular domains of the receptor. The results demonstrate that the serum IGF-ll/Man-
P receptor binds both IGF-ll and Man- P-containing ligands but is incapable of binding
anti-cytoplasmic peptide antibodies. The data are consistent with the hypothesis that the
serum IGF-llan- P receptor is trncated at its C-termnal domain and is devoid of its
trsmembrane anchor.
Experimental Procedures
Materials. Rat IGF-II was purified from BRL-3A cell conditioned medium as
described (32). Purified IGF-II was radioiodinated using Enzymobeads (BioRad) to a
specific activity of 40-250 Ci/g. Pentamannosyl- phosphate (PMP), prepared from the
, native Y-2448 phosphomannan from H. holstii was a gift of Dr. M.E. Slodk , Midwest
Area Northern Regional Research Center, Peoria, IL. PMP-Sepharose was prepared as
descrbed (33). Dithiotheitol (DTT was 99% pure from Chemical Dynamics Corporation
and sodium iodoacetate (Fisher Biotech) was recrstallized twice from methanol. All other
chemicals were reagent grade or better.
Preparation of Serum and Plasma. Male Sprague-Dawley rats obtained from
Taconic Fars, Germantown, NY, were used at ages 14 d (-25 g), 35 d (-75 g), 70 d
200 g), and 200 d (300-350 g). Blood was obtained by decapitation. Serum was
prepared by clotting blood at 3 C for 20 h followed by centrfugation at 2000 x g for 10
min. Sera were then filtered through 0.45 11m sterile fiters and stored at - C until use.
For the preparation of plasma, blood was collected directly into 3 volumes of buffered
salne contaning 1 mM phenylmethylsulfonyl fluoride (PMSF), 3 mM EDTA , and 80 U/ml
heparn. Cells were removed from the diute plasma by centrfugation.
Preparation of Plasma Membranes from Rat Placenta. Plasma
membranes were isolated from rat placentas taen at day 19 of gestation as described
previously (4). Membrane extracts (5 mg protein/ml) were prepared by incubation with 50
mM 4-(2-hydroxyethy1)- piperazineethanesulfonic acid (Hepes), 1% Triton X- 100, pH
7.4, plus antiproteases by gentle mixing for 1 h at 3 C. The antiproteases were leupeptin
antipain and benzamdine at concentrations of 10 Ilg/ml each, 20 Ilg/ml aprotinin, 12.
Ilg/ml chymostatin , and 1 mM PMSF. The mixture was centrfuged for 10 min at 15000 
g in a microcentrfuge and the supernatant fraction was used as the extract. Protein was
assayed by the Bradford method (34).
, ,
Antisera Against the IGF- II/Man- Receptor. IGF-II/Man-
receptors were purified from rat placental plasma membranes by IGF-II-Sepharose
, chromatography as previously descrbed (4). The primar strcture of the rat IGF-ll/Man-
:6-P receptor deduced from cDNA clones (24) was the basis for design of synthetic
pep tides. Peptides were synthesized on an Applied Biosystems Model 430A solid phase
peptide synthesizer (University of Massachusetts Medical Center Peptide Synthesis
Facilty). Each of the peptides was then purified by reverse-phase high pressure liquid
'chromatography and analyzed for amino acid composition by the PICO- TAG method
(University of Massachusetts Medical Center Protein Chemistr Facility, supported by the
;Diabetes and Endocrinology Research Center). Peptides were coupled to keyhole limpet
:hemocyanin (KLH) as descrbed (35). Rabbits were immunized with 1 mg of peptide-
KLH emulsified in Freunds complete adjuvant, boosted 4 weeks later with 1 mg peptide-
KLH in Freunds incomplete adjuvant (East Acres Biologicals, Southbridge, MA). Sera
were assayed by enzyme-linked immunosorbent assay and dot immunoblot against either
peptide 13D or 1 mg: 5 mg peptide 22C-bovine serum albumin (BSA) conjugate (Figure
'17). The polyclonal antibody raised against the native pured receptor has been described
previously (19,36). Crude immunoglobulin frctions were obtained by ammonium sulfate
:precipitation (36), and were further purfied by chromatography on diethylaminoethyl-
(cellulose in 5 ro phosphate buffer, pH 6.
Immunoadsorption of the IGF-II/Man- P Receptor and Adsorption
:with Pentamannosyl- Phosphate-Sepharose. IGF-II/Man- P receptors were
immunoadsorbed from serum, plasma, or Triton X- 100 extracts of rat placental plasma
membranes as described before (6,37). For adsorption with PMP-Sepharose, serum (50
J.1) or membrane extrcts (0. 1 mg protein in 50 IJ ) were added to 25 J.1 of the resin in 0.
ml total volume of 50 mM Hepes, 0. 15 M NaCl, 0.05% Triton X- 100, 5 mM 
glycerophosphate, pH 7.4, with antiproteases. After incubation for 2 h at 4 C, the resin
was washed tWice with the same buffer.
Affinity Crosslinking of 12SI-IGF-II to Immobilzed Receptors.
Following immunoadsorptionor adsorption with PMP-Sepharose, the washed resin pellets
were resuspended to a volume of 0.2 ml with Krebs-Ringer phosphate buffer containing
1% BSA plus 4 nM 125I-IGF-II with or without 400 nM unlabelled IGF-II. These
mixtures were then incubated for 4 h at 23 C. The samples were subjected to affinity
cross-lining with disuccinimidyl suberate as descrbed before (1). Briefly, 50 J.1 of resin
(antibody Affigel or PMP-Sepharose) with material bound was incubated in KR + 1 %
BSA for 2-4 h at 23 C. To this was added 25 nanomoles of disuccinimidyl suberate, then
the sample was placed on ice for 1 h. The sample was then washed in 1 m1 of 100 mM
Tris-HCI, pH 7.4 before electrophoresis.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis. For the
antipeptide antibodies to recognize the IGF-II/Man- P receptor, the receptor had to be
reduced and alkylated under denaturing conditions (Figure 17). For reductive alylation,
washed resin or membrane pellets were heated for 15 mi at 100 C in 0. 1 m1 of 10% SDS,
25 M Tris, 10 mM DTT, pH 8.3. The samples were cooled, 5 III of 0.5 M sodium
iodoacetate was added, followed by incubation in the dark at 23 C for 30 min. For
electrophoresis under non-reducing conditions, samples were heated to 100 C for 10 min
in SDS sample buffer without DTT. Electrophoresis was performed as described (38) on
6% polyacrlamde gels.
Western Immunoblotting. IGF-ll/Man- P receptors were transferred from
polyacrylamde gels to nitrocellulose as described (37). The immunoblots were blocked for
30-60 min at 23 C in 0.22 Ilm-fitered 0.5% nonfat dry milk dissolved in 15 mM Tris,
15 M NaCI, pH 7.4. Incubations with the anti-receptor, anti- 13D, or anti-22C antibodies
were done at 3 C for 16-20 h using 1:800, 1:500, or 1:200 dilutions, respectively, of
puried immunoglobulin fractions in blocking buffer. The blots were then washed,
incubated with 125I-protein A, and washed again as described (37).
, '. '. ,
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Results
Characterization of antireceptor and 
anti peptide antisera. Peptides 13D
and 22C were synthesized on the basis of sequences in the extracellular and cytoplasmic
domains, respectively, of the deduced amino acid sequence of the rat IGF-II/Man-
receptor (24, Fig. 17 A). Antisera raised in rabbits against each of these peptides exhibited
immunoreactivity against the corresponding peptide in dot blots 
and enzyme- linked
immunoassays (data not shown). In order to test the strctural requirements for
immunoreactivity of each antiserum against the IGF-II/Man- P receptor, rat placental
plasma membrane proteins were electrophoresed under either non-reducing conditions,
after reduction or reductive alylation. Western immunoblots of these gels are shown in
Fig. 17B. The polyclonal antireceptor antiserum recognized the Mr -230 K receptor
species under non-reducing conditions, but did not react with either the reduced or
reductively alylated receptor (Fig. 17B). In contrast, anti- 13D immunoglobulin failed to
recognize the non-reduced receptor, but reacted strongly with the receptor after reductive
alklation under denaturing conditions. The receptor migrates at a higher apparent Mr
(-280 K) under these conditions. Anti-22C immunoglobulin specifically recognized the
high Mr IGF-llan- P receptOr under all three conditions, but the degree of reactivity
improved progressively as a function of increasing disruption of disulfide bonds in the
receptor (Fig. 17B). In addition, anti-22C cross reacted with an unkown low Mr species
derived from placental membranes which migrated just above the dye front in SDS-P AGE
on 6% gels (Fig. 17B , lanes 7-9). Unlike the receptor, optimal recognition of this low Mr
protein by anti-22C apparently does not depend on reductive alkylation. Based on these
results the antiserum against the native receptor was subsequently used to immunadsorb
IGF-II/Man- P receptors from sera or Triton X- 100 extracts of placental plasma
membraes, whereas the antipeptide antibodes have been employed as Western blot probes
following SDS-PAGE of the imunoadsorbed receptors.
Structural analysis of the cellular and serum forms of the receptor
using domain-specific antisera. 
Fig. 18A shows a Western immunoblot of IGF-
llan- P receptors immunoadsorbed from a Triton X- 100 extract of rat placental plasma
membranes and rat sera and probed with the polyclonal antieceptor antiserum. A single
high molecular weight receptor species of Mr -230 K is specifically immuno-adsorbed
from the plasma membrane extract, whereas serum samples from rats aged 14 d through
200 d contained a single immunoreactive species of slightly lower apparent Mr than the
cellular receptor. These results obtained by diect immunoadsorption of the IGF-II/an-
P receptor from serum samples agree with the findings of Kiess 
et ai. (31), who parially
purified the serum receptor using gel filtration chromatography. In addition, the
concentrtion of receptors in rat serum is developmentally regulated, with maximal levels
found in early neonatal life (31, Fig. 18A). Quantitative analysis of the data in Fig. 18A
demonstrated that neonatal rat serum contained approximately 3-4 times as much receptor
as found in serum from adult (200 d) rats. We observed that the concentration of receptors
in fetal rat serum was approximately the same as that found in serum from day 14 neonatal
rats (data not ilustrted).
Analysis of immunoblots containing reduced and alkylated IGF-II/Man-
receptors using the anti-peptide antibodies revealed strking differences between the
structures of the cellular and serum receptors (Fig. 18B and 18C). In addition to
recognizing a major 260 K species, the antiserum raised against the extracellular domain
peptide 13D reacted with at least three discrete species of lower apparent Mr, the smalest of
which had an Mr of -160 K (Fig. 18B). All forms of the serum IGF-II/an- P receptor
had reduced apparent Mr rela!ive to the 280 K cellular receptor under these conditions. We
, '
conclude from these data that, despite the apparent heterogeneity of the IGF-II/an-
x;eceptors in rat 
serum, the region in the extracellular domain of the receptor that is
recognized by the anti-13D antiseru is essentialy intact.
Immunoblots of IGF-llan- P receptors probed with the cytoplasmic domain-
specific anti-22C antiserum revealed another importnt strctural difference between the
seru and cellular receptors (Fig. 18C). Whereas the cellular receptor (Fig 18C, 
lane 1)
as recognized by this antiserum under identical conditions to those used in Fig 18B, none
()f the serum receptor species reacted significantly with anti- 22C (Fig 18C, lanes 3-10).
The autoradiogram in Fig 18C (lanes 5- 10) also reveals reaction of anti-22C with several
bands of Mr-130- 140K, the serum concentration of which appears to increase with the age
pf the rats. However, these species are not derived from the IGF-II/an- P receptor
because they react with both anti-receptor and control non-immune imunoglobulin affmity
resins. These data demonstrate that the cytoplasmic domain is either absent or altered in the
serum IGF-IIan- P receptor.
Comparison of IGF-II/Man- receptors present in rat serum and
plasma. One possible explanation for the observed heterogeneity of the serum IGF-
IIan- P receptor as depicted in Figue 18 is proteolytic cleavage durng the process of
clotting bloo to obtain serum. In order to address this hypothesis, we prepared plasma
from day 14 neonata rats and diectly compared the strctures of IGF-II/an- P receptors
in plasma and serum using the antipeptide antibodes described above (Figure 19). Neither
the receptors isolated from serum nor dilute plasma reacted with anti-22C, but both
exhibited an identical set of polypeptide bands which reacted with anti- 13D. These results
demonstrate that the structural propertes of the serum receptor are representative of the
IGF-IIan- P receptor that circulates in the animal.
. ,,'
Ligand binding characteristics of the serum IGF -ll/Man- P receptor.
The data in Fig. 20A demonstrate that 125I-IGF-ll may be specifically cross-linked to the
serum receptor immobilzed on antibody-Affigel. This experiment shows that a single
-230 K receptor band is observed under non-reducing conditions (Fig. 20A lane 7).
Reductive alkylation of the cross-linked serum receptor results in an increase in the
apparent Mr of the major affmity-labeled species to -260 K, plus the appearance of several
species of lower apparent Mr (Fig. 20A, lane 9). In contrast, cross-linkng of 125I-IGF-
to the plasma membrane receptor revealed only a single labeled species regardless of
treatment (Fig. 20A, lanes 5). These findings indicate that the serum form of the IGF-
IIan- P receptor specifically binds 125I-IGF-II. Furhermore, in conjunction with the
data ilustrted in Figue 18, these observations suggest that the receptor circulates in blood
as a miture of species having identical apparent Mr, some of which exist as proteolytically
cleaved complexes held together by intramolecular disulfide bonds.
It was not previously known whether the serum form of the IGF-II/Man-
receptor retains the capacity to bind Man- P-containing ligands. In order to address this
question, we developed a method for 125I-IGF-II affinity labeling ofreceptors adsorbed to
pentamannosyl- phosphate (PMP)-Sepharose (Fig. 20B). Both the plasma membrane
receptor (Fig. 20B, lane 1) and the receptor from day 14 neonatal rat serum (Fig. 20B, lane
5) were adsorbed by PMP-Sepharose. Washing the affinity resin with 5 mM Man-
readily eluted both receptor species (Fig. 20B, lanes and 7). These data demonstrate that
despite the apparent strctural diferences between the cellular and serum forms of the IGF-
llan- P receptor, each is capable of binding both IGF-ll and Man-6-P.
Discussion
The objective of the present studies was to begin a detailed structural
- --
characterization of the serum form of the rat IGF-IIan- P receptor. For this purpose,
we have acquied and charcterized thee different antisera specific for the rat IGF-IIan-
P receptor. A polyclonalantiserum raised against the native receptor was used to
immunoadsorb receptors from serum under mild and relatively rapid conditions. The
immunoadsorbed receptors were subsequently immunoblotted with two antisera raised
against peptides derived from deduced amno acid sequence within the extracellular versus
cytoplasmic domains of the rat IGF-II/Man- P receptor. These studies demonstrate that
the serum receptor fails to react with an antiserum specific for a peptide sequence located in
the cytoplasmic domain of the receptor, 32 residues C-terminal to the transmembrane
domain (Figs. 17 and 18). These data strongly suggest that the cytoplasmic domain is
either missing or substatially altered in the serum receptor.
Taken together, the present results and previous observations are consistent with
-the hypothesis that the serum form of the IGF-II/an- P receptor lacks both the C-
tennnal intracellular and transmembrane domains: 1) The rat IGF-llan- P receptor is
an intrnsic membrane glycoprotein which is normally anchored in the membrane by a
single 22-residue hydrophobic sequence (24 31). Thus, the presence of this receptor in
serum implies changes in the membrane-spanning region of the protein. 2) The 10- 15 K
reduction in apparent Mr of the serum receptor relative to the cellular receptor suggests the
removal of a small porton of the protein upon formation of the serum receptor (31 , this
study). Examination of the amino acid sequence of the rat IGF-II/Man- P receptor
predicted from cDNA clones (24) indicates that trncation of the receptor by deletion of
both the transmembrane and 5ytoplasmic domains would involve removal of 189 amino
acids producing a reduction in Mr of 21 134. Ths value is reasonably consistent with the
observed differences in electrophoretic migration of tissue versus serum forms of the
receptor upon SDS-PAGE analysis. 3) Failure of the serum receptor to react with the anti-
22C antiserum demonstrates that the peptide sequence constituting the epitope(s) for this
immunologic probe are significantly different or missing from the serum receptor. The
possibilty stil remains that the peptide sequence is merely altered rather than deleted from
the serum receptor. Further studies wil be required to determine the actual C-terminal
sequence of the serum receptor.
It appears that a minor fraction of circulating IGF-II/Man- P receptor is
proteolytic ally nicked. The antiserum specific for peptide 13D located in the extracellular
domain of the receptor recognized at least three distinct immunoreactive species lower than
Mr = 260 K in serum isolated from rats aged 14 d through 200 d (Figs. 18 and 19). This
discovery was an unexpected consequence of reductive alylation of the receptor under
denaturng conditions in order to permt reaction with the antiserum. The multiple receptor
species observed raged in apparent Mr between 160 K and 260 K, indicating that although
all circulating forms of the receptor had an altered cytoplasmic domain, several species
were severely trncated. Does the serum IGF-II/an- P receptor circulate as multiple,
independent species of different apparent Mr or as a mixtue of proteolytic ally nicked forms
of intact Mr = 220 K receptor? Our experiments favor the latter conclusion. Western blots
of non-reduced receptors using polyclonal anti-receptor antisera revealed only a single 220
K serum receptor (Fig. 18A). Results of affinity cross-linking experiments using 1251-
IGF- II also support this concept. In agreement with the data of Kiess et al. (31), we found
only a single IGF-II binding species in rat sera, which exhibited an apparent Mr of -230 K
under non-reducing conditions (Figure 20). However, when the affinity cross- linked
, '
receptors were subjected to reductive alylation , the receptor migrated as a famly of bands
dominated by a 260 K major species (Figure 20).
The strctural features of the serum receptor revealed in our studies suggest a
proteolytic process by which cells release IGF-IIan- P receptors into the circulation.
The pathways by which the IGF-II/an- P receptor recycles between intracellular and
ell-surace membrane comparents in order to transport lysosomal enzymes and IGF-
to the lysosomes are well known (39,40). An importnt stage in each of these processes is
the release of receptor-bound IGF-II or lysosomal enzymes upon acidification of
endosomes. Previous studies have demonstrated that, after releasing these ligands, the
IGF-II/an- P receptors return to the Golgi apparatus or the cell surface, thus escaping
gradation in lysosomes (39-42). However, a significant percentage of the receptors
within the endosomallumen may undergo parial proteolysis at discrete, susceptible sites
near the trnsmembrane domain. Liberated from its anchorage, the receptor extracellular
domai could subsequently be released. Alternatively, the receptor may be proteolytic ally
cleaved at the cell surface by unkown proteases. It is possible that the serum IGF-IIan-
P receptor is synthesized from an alternatively spliced mRNA to produce a trncated
protein which is subsequently secreted. However, this explanation is inconsistent with the
observation of a single -9 kb IGF-II/an- P receptor transcript in RNA isolated from
several species (23). The serum receptor is clearly not derived from cellular receptors by
proteolysis during the process of collecting or clotting the blood. Thus, the data in Figure
19 demonstrate that the receptor is present in plasma at levels comparable to those in serum,
aadthat the receptors in serum and plasma have simiar strctures. These data suggest that
receptor species we have studied is the normal circulating form of the receptor. 
addition, we have found that amiotic fluid taken at days 19-20 of gestation also contains
high levels of IGF-IIan- P receptors which are strcturally similar to those in serum
(data not ilustrated).
The existence of several other soluble receptors has also been documented. Among
these are the trsferrn receptor (43), the EGF receptor (44), the growth hormone receptor
,(45-47) and the insulin receptor (48). Of these, the soluble insulin and EGF receptors have
not been demonstrated in circulation (44, 48), and the precise strcture and physiologic
roles, if any, of the transfemn and growth hormone receptors in serum have not been
shown (43, 45-47). The source and function of IGF-llan- P receptors in blood is also
unknown. Kiess et al. (31) detected receptors in the blood of rats up to one year old.
. Indeed our studies indicate that the concentration of receptors in the circulation declines by
only a factor of 3- to 4-fold from day 19 of gestation to day 200 postparum (Figure 18).
During this period, levels of the receptor in many rat tissues, including brain, lung, liver
and intestie, decline dramatically near birh by factors of 5 to 10 (49).2 The relatively high
level of receptors in blood of adult rats suggests that receptors may be released into the
circulation as a normal consequence of receptor function rather than as a means of shedding
unneeded receptors from the tissues following completion of fetal development. Acting as
a carer of circulating IGF-II appears to be ruled out in view of the much higher levels of
carer proteins (31), but the receptor may serve to scavenge lysosomal enzymes which
have been released from cells. Our data (Fig. 20B) demonstrate that the serum receptor
retains the ability to bind Man- P containing ligands. In this way, the receptor may
inactivate the enzymes or transport them to an unknown destination for internalization or
degradation, in a manner similar to the action of a2-macroglobulin (50,51). This
hypothesis predicts the existence of cell-surace receptors which bind the IGF-II/an-
receptor and internalize the ligand receptor complex, a possibility that could be tested
diectly.
Footnotes
1 The abbreviations used are: IGF-I and - , insulin-like growth factor-I and II; Man-
p"mannose- phosphate; SDS-PAGE, sodum dodecyl sulfate-polyacrylamde gel
electrophoresis; PMP, pentamannosyl- phosphate; PMSF, phenylmethylsulfonyl fluoride;
DTT, dithiotheitol; Hepes, 4-(2-hydroxyethyl)- piperazineethanesulfonic acid; KLH
keyhole limpet hemocyann. ; BSA: bovine serum albumi.
2Tepper, M.A., MacDonald, R.G., Brockleban, C. , Ullrich , A. , and Czech
P., manuscript in preparation.
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Fig 17. Antipeptide antibodies specific for the cytoplasmic and
extracellular domains of the IGF-IVMan- P receptor. A. Schematic diagram
representing the coding region of the rat IGF-II/an- P receptor cDNA (24). The
transmembrane domain is indicated by the solid bar. Peptide 13D is a 16-amino acid
sequence located 1476 residues N-termnal to the trsmembrane domain. Peptide 22C is a
22-amio acid peptide located 32 residues C-termnal to the trnsmembrane domain. B.
Strctura requirements for recognition of the IGF-llan-6-P receptor by antieceptor and
antipeptide antibodies. Aliquots (0.4 mg protein) of rat placental plasma membranes were
electrophoresed under non-reducing conditions (Lanes 7), after reduction with 10 mM
DTT (2, 8), or following reductive alkylation (3, 9). Electrophoresed proteins were
transferred to nitrocellulose, and probed with antireceptor (1-3), anti- 13D (4-6), or anti-
22C (7-9) immunoglobulins as indicated. Values for molecular weights of pre-labelled
standard proteins are indicated.
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Fig. 18. Characterization of cellular and serum forms of the IGF-II/Man-
P receptor using anti peptide antibodies. Triton X- lOO extract of rat placental
plasma membranes (0.4 mg protein Lanes 2) or serum (1.0 ml) isolated from rats aged
14 d (3,4), 35 d (5,6), 70 d (7, 8) , or 200 d (9, 10) were immunoadsorbed with
antireceptor immunoglobulin- Affigel (odd numbered lanes) or nonimmune
immunoglobulin-Affigel (even numbered lanes). Pror to electrophoresis, washed resin
pellets were either heated for 15 min at 1000C in SDS sample buffer without DTI (Panel
A) or reduced and alkylated as descrbed (B and C). The parallel immunoblots were
probed with antireceptor (A), anti- 13D (B), or anti- 22C (C) antibodies as indicated.
Autoradiogrs of the imm,:noblots are shown.
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Fig. 19. The plasma IGF -II/Man- P receptor has the same structure as the
serum receptor. Neonatal rat serum (0.5 ml Lanes 1, 6) and dilute neonatal plasma
(2 ml, 3, 8) were immunoadsorbed with anti-receptor (odd) or nonimmune (even)
immunoglobulin-Affigel resins. The washed resins were reduced and alkylated,
electrophoresed on SDS-PAGE, and then the gel was immunoblotted with anti- 13D (1-4)
or anti-22C (5-8) antibodies s noted
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Fig 20. Affinity crosslin king of 12SI-IGF -II to serum and cellular IGF-
II/Man- receptors. A. Triton X- lOO extracts of plasma membranes (0. 1 mg
protein, Lanes 5) or neonatal serum (0. 1 ml, 10) were immunoadsorbed with anti-
receptor immunoglobulin-Affigel (2-5, 10) or nonimmune immunoglobulin-Affgel (1,
6). The washed resin pellets were then incubated with 4 nM 125I-IGF-ll in the absence (1,
6, 7, 9) or presence (3, 10) of 400 nM unlabelled IGF-II. After incubation for 4
h at 23 C, the samples were further incubated for 1 h at 3 C with 0. 125 mM
disuccinirdyl suberate, and electrophoresed on SDS-PAGE. B. Triton X- lOO extracts of
plasma membranes (0. 1 mg protein Lanes 4) or neonatal serum (0. 1 ml, 5 -8) were
adsorbed with 25 III of PMP-Sepharose. The resin pellets were washed in the absence
(1,2,5,6) or presence (3, 8) of 5 ro Man- P as indicated. The samples were then
incubated with 4 nM 125I-IGF-II with (even) or without (odd) 400 nM unlabelled IGF-
followed by cross-linking with disuccinimidyl suberate and electrophoresis on SDS-
PAGE. Autoradiograms of the dred gels are shown.
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STRUCTUR AN REGULATION OF THE SERUM INSULIN-LIKE GROWTH
FACTOR IIOSE- PHOSPHA TE RECEPTOR
KEVIN B. CLAIONT AND MICHAEL P. CZECH
University of Massachusetts Medical Center, Program of Molecular Medicine and
Depanent of Biochemistr, 55 Lake Avenue Nort, Worcester, MA 01655
INRODUCTION
A significant and rapid effect of insulin admiistration is the translocation of a
number of proteins from an intracellular comparment to the cell surface. Among these
proteins are glucose transporters (1-4) and receptors for IGF-IIan- P (5, 6), transferr
(7, 8), and el2 macroglobuli (9). Translocation of the glucose transporter appears to play
a role in increasing cellular uptake of glucose, while the receptors may increase the uptake
of nutrents and other factOrs required for cell growth. The increase in the number of cell
suace receptOrs correlates with an increased bindig of ligand with concommtat increase
in uptake of ligand, and a decrease in the number of intracellular receptors which fractionate
in low density microsomes (5-9). However, while the number of cell surface glucose
transporters is only increased approximately two- to five-fold, the amount of glucose
transpon may be increased by as much as 20-fold (1-4), indicating that intrsic activity of
transpon is also increased by insuli.
Of the proteins translocated to the cell surface in response to insuli , the IGF-
ITan- P receptor (10-12) and the transferr receptOr (13) have been detected as having
serum fonns. We have previously shown that the serum IGF-IIan- P receptor is C-
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termally trncated, and that its levels decrease over time beyond 14 days after bir (12
and Figure 22). We hypothesized that the serum receptor was most liely a proteolytic
product of the cellular receptor. The serum receptor could be a product of the action of
proteases on the cell surace. In this cas, it would be expected that insul could induce an
increase in the release of IGF-llan 6-P receptor into seru. In this paper we investigate
the acute reguaton of serum receptor levels by insuli.
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MATERI AN METHODS
Materials. IGF-II/an- P receptors were purified from rat placental plasma
membranes by IGF-ll-Sepharose chromatography as previously described (13). The
priar strctue of the rat IGF-IIan- P receptor deduced from cDNA clones (14) was
the basis for design of synthetic peptides. Dithiothreitol (DIT) was 99% pure from
Chemical Dynamics Corporation, and sodium iodoacetate (Fisher Biotech) was
recrstalze twice from methanol. Al other chemical were at least reagent grade.
Pre aration of Serum. Male Sprague-Dawley rats at 150 g, obtaied from Taconic
Far, Gennantown, NY, were injected subcutaneously with 0.2ml PBS alone or with 2U
insulin in 0.2 ml PBS. Thiry minutes following injection , blood was obtaied by
decapitation. Serum was prepared by clotting blood at 3 C for 6 h followed by
centrgation at 2000 x g for 10 mi. Sera were then fitered through 0.45 mm sterie
fiters and used immediately. Insuli treatment resulted in a decrease of serum glucose
levels from 110 to 30. Enzyme activities (creatine kiase and lactate dehydrogenase)
meased in serum were not signifcantly altered by ths treatment.
Pre aration of Plasma Membraes from Rat Placenta. A plasma membrane fraction
was isolated from rat placentas taken at day 19 of gestation as described previously (13).
Membrane extracts (5 mg proteinml) were prepared by incubation with 50 mM 4-(2-
hydroxyethyl)- piperazineethanesulfonic acid (Hepes), 1 % Triton X- lOO, pH 7.4, plus
antiproteases by gentle miing for 1 h at 3 C. The antiproteases were leupepti, antipain
and benzamidine at concentrations of 10 mg/ml each, 20 mg/ml aprotinin, 12.5 mg/ml
chymostatin , and 1 mM PMSF. The mixture was centrfuged for 10 mi at 15000 x g in a
microcentrge and the supernatant fraction was used as the extract. Protein was assayed
by the Bradford method (15).
1 -
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Antisera and Antibodies. . The anti-IGF-IIan- P receptor antisera used are as
described by MacDonald et al (12). Briefly, the antireceptOr antiserum was raised in
rabbits agaist intact pured rat cellular receptor. Anti-22C was raised agaist the peptide
EEETDENETEWLMEEIQVPAPR which is located 32 residues C terminal to the
transmembrane domain, and anti-13D was raised against the peptide
YYLNVCRPLNPVPGCD located 1476 residues N-terminal to the cytoplasmic domai
(Figue 21A). In the experiments described, the antieceptor antiserum was imobilzed
on affigel as described (12) to immunoadsorb the receptors from serum or membrane
extracts. The antipeptide antisera were used to immunoblot reduced and alylated
receptors. For the trasferr receptor experiments, a single monoclonal antibody obtaied
from Dr. Roger Davis was used for the imunoadorption and the immunoblotting (16).
Immunoadso tion of the IGF- an- P Rece tor and the Transferrn Rece tor.
IGF-II/an- P receptors were immunoadsorbed from TritOn X- lOa extracts of rat
placental plasma membranes as described before (17, 18). For immunoadsorption from
serum, serum was diluted 1: 1 with HBS containing protease inhibitors, then
immunoadsorbed in the same manner as a membrane extract. The same procedure was
used for immunoadsorption of the transferr receptor.
Sodium Dodec l Sulfate-Pol lamde Gel Electro horesis. For the antipeptide
antibodies to recognize the IGF-IIan- P receptor, the receptor had to be reduced and
alylated under denaturing conditions, as shown (12 and Figure 2 1B). For reductive
alylation , washed resin or membrane pellets were heated for 15 mi at 100 C in 0. 1 m1 of
10% SDS, 0.25 M Tris, 10 mM DIT, pH 8.3. The samples were cooled, 5 ml of 0.5 M
sodium iodoacetate was added, followed by incubation in the dark at 23 C for 30 min or
more. Reduction alone was adequate to immunoblot the transferr receptOr, so it was
simply heated to 100 C for 5 min in sample buffer containing 10 mM DTT.
Electrophoresis was perfonned as descrbed (19) on 6% polyacrlamide gels.
Western Immunoblottin . IGF-IIan- P receptors were transferred from
polyaclamde gels to nitrocellulose as descrbed (18). The imunoblots were blocked for
30 min at 23 C in 0.22 mm-f1tered 0.5% nonfat dr mi dissolved in 15 mM Tris, 0.
M NaCl, pH 7.4. Incubations with the anti-13D , anti-22C, or anti-transferr antibodies
were done at 3 C for 16-20 h using 1:500, 1:200, or 1:1000 dilutions, respectively, of
pured immunoglobuli fractions or ascites fluid in blocking buffer. The blots were then
washed, incubated with 125I-protein A (anti-13D and anti 22C) or 125I-goat anti-mouse
IgG (anti-transferr receptOr), and washed agai as described (18). The autoradiograms
are shown. Quantitation was perfonned by scanning the appropriate lanes on the
autoradiograph on a Beckman DU-8 Spectrophotometer, cutting out the appropriate peaks,
and weighing them. Thus, areas are measured in mg corresponding to the weight of the
paper contaig the peak.
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RESULTS AN DISCUSSION
While the presence of receptors in serum has been known for many years, little is
known about how the receptors are releasd into the serum or what regulates this process.
In a previous paper (12), we addressed the strcture and developmental regulation of the
serum IGF-IIan 6-P receptor. The three anti-IGF-IIan 6-P receptor antibodies used
differed greatly in their abilty to recognize receptor in immunoblots. The anti-receptor
antibody recognized receptor only under nonreduced conditions, anti-13D only following
reductive alylation, while anti-22C was able to recognize receptor under all conditions
tested although it, too, preferred reductive alylaton (Figure 21B). Using these antibodies
we showed that the serum receptor lacked a cytoplasmic domain (Figure 22). This
experiment furher demonstrates that the levels of IGF-llan- P receptor in serum is
developmentaly regulated (Figue 22). This regulation is similar to the developmental
regulaton of the cellular receptor which peaks near the time of bir, then fals in a number
of tissues (19).
To further investigate the relationship of the cellular and serum receptors, we have
looked at a more acute reguator of cell surace levels of IGF-IIan- P receptor. Insuli
addition to insuli sensitive cell causes a rapid redistribution of IGF-IIan- P receptors
from an intracellular comparment to the cell surface (6). If serum receptor is generated
from receptors at the cell surace by a proteolytic mechanism, this process might lead to an
increase in the levels of receptor in serum. To measure the levels of receptor in serum,
IGF-IIJan 6-P receptor was immunoadsorbed to antireceptor antibody affigel, washed
thoroughly as described in the methods, then immunoblotted with anti-22C, anti-13D , or
silver staied. As can be seen in the silver staied gel (Figure 23) a single band,
corresponding to the IGF-II/an- P receptor, is seen to be increased in the
immunoprecipitates. That this effect is not due to differences in the amount of antibody
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used in the immunoadsorption or to gross differences in blood proteins is demonstrated by
the amount of protein in the antibody and contamatig bands being very similar in both
the control and insuli treated animals. While, as previously demonstrated (Figue 22) 
anti-22C recognizs only cellular receptor (Figue 24), the anti-13D antibody recognizs a
protein in cell extracts as well as a protein of slightly lower molecular weight in serum
(Figue 24). The serum receptor from insulin treated animals is present at approximately
2.5 fold the level seen in control animal.
To detennine if this acute regulation of serum receptor levels was specific for the
IGF-IIan- P receptor, we used the same procedure to measure levels of transfeITin
receptor in seru from the same animal. Transfeni receptor levels in serum are regulated
similarly to the IGF-IIan- P receptor, being increased twofold following insulin
treatment (data not shown).
The acute regulation of serum receptor levels has several interesting implications.
First, such acute regulation argues agaist the possibilty of serum receptor arsing from a
message distinct from the cellular receptor: the time necessar to synthesize the IGF-
llan-6- Preceptor (17) is very much greater than the period of insuli treatment in these
animal. Second, the same process that generates the serum IGF-llan- P receptor may
generate the serum transfeni receptor. It has recently been shown that these two receptors
coexist in intracellular vesicles which also contai the HepG2 type glucose transponer, and
that these vesicles move to the surface in response to insulin (20). A liely explanation for
the results presented is that proteolysed receptors exist in these vesicles and that insulin
stulaton causes these vesicles to migrte to the cell surace, releasing the serum receptor
fragments. Another possibilty is that receptors ar cleaved from the cell surface dirctly.
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Figure. 21. Antibodies which recognize the IGF-II/Man 6- receptor. A.
A schematic of the IGF-IIan 6-P receptor indicatg the locations of the peptides agaist
which antibodies were raised. B. The strctural requirements for each antibody to
recognize receptor in an immunoblot differ. Aliquots (0.4 mg of protein) were
electophoresed under nonreducing conditions (lanes 1 , 4, and 7), following reduction with
10 mM DTT (lanes 2, 5, and 8), or afer reuctive alylation with 10 mM DTT followed by
5 JlM IA (lanes 3, 6, and 9). Gels were then transferred to nitrocellulose and
immunoblotted as described. The molecular weights of pre staied molecular weight
standards are indicated. Figure used with permission of the Journal of Biological
Chemistt .
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Figure. 22. Structure and developmental regulation of the serum IGF-
II/Man- P receptor. Triton X-100 extracts of rat placental plasma membrane (0.4 mg
protein, lanes 1 and 2), or 1 m1 of serum from rats aged 14 days (lanes 3 and 4), 35 days
(lanes 5 and6), 70 days (lanes 7 and 8), or 200 days (lanes 9 and 10) were
immunoadsorbed to anti-IGF-II/Man 6-P receptor antibody affigel (odd lanes) or a
preimmune antibody affigel (evenlanes). Samples were electro-phoresed under
nonreducing conditions (A) or following reductive alylation (B and C). Following
transfer the nitrocellulose fiters were immunoblotted with the indicated antibodies. An
autoradiogram of these immunoblots is shown. Figure used with permisssion of the
Joural of Biological Chemistr.
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Figure 23. Silver stain of immunoprecipitates of IGF -II/Man- P receptor
from serum. IGF-IIan- P receptors were immunoadsorbed from serum as described
in Figure 21 , then subjected to SDS-PAGE under reducing conditions on a 
polyacrylamide gel, followed by silver staiing. This silver stai demonstrates that the
levels of imunoglobulin used in the immunoadsorption and the amount of serum used for
the immunoadsorption are constant while the IGF-IIan- P receptor level is increased
approxiately twofold (band indicated by arow).
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Quantitation of IGF- II/Man 6-P Receptor Levels
D Anti- 13D
IE Anti-22C
Membrane
Extract
Control
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Figure 24. The regulation of receptor forms in serum by insulin. Receptors
were immunoadsorbed from an extract of 0.5 mg plasma membrane protein (E), or 5 ml
serum from rats injected with insuli (I) or carer (C) alone 30 miutes before sacrifice,
using polyc1onal antisera raised agaist IGF-IIan- P receptors. Immunoadsorbed
receptors were then reduced and alylated, then subjected to SDS-P AGE under reducing
conditions on 6% polyacrylamde gels, and trsfelTed to nitrocellulose. The nitrocellulose
fiters were then imunoblotted with anti-22C antierum or an anti-13D antiserum followed
by 125I-protein A. Each imunoblot was then quantitated as described in the methods.
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Insulin Injection Increases the Levels of Serum Receptors for Transferr and Insulin-lie
Growth Factor llannose 6-Phosphate in Intact Rats
Kevin B. Clairont and Michael P. Czech
Progr in Molecular Medicine and Deparent of Biochemistr, University of
Massachusetts Medical Center, 55 Lake Avenue North, Worcester, MA 01655
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Abstract
Previous work indicates a serum form of the insulin-like growth factor Illmannose
phosphate (IGF-II/an 6-P) receptor that circulates in mammals is a trncated form of
the cellular receptor which lacks its cytoplasmic domain (MacDonald, R.G. et al (1989) J.
BioI. Chem. 264, 3256-3261). In this study, the effects of insulin administration on the
levels of the serum forms of IGF-IIan 6-P and transfemn receptors were measured.
Following subcutaneous injection of insulin into rats fasted overnight, the amount of IGF-
IIan 6-P receptor in serum increases to approximately twice that observed in untreated
animals within 30 minutes, then decreases to a level lower than the initial level by 60
minutes before returning to control values by 90 minutes. The time course of the initial
increase in serum receptor levels in response to insulin is similar to that observed for the
decrease in blood glucose concentrations. Measurements of serum enzyme activities
(creatine kinase and lactate dehydrogenase) during this time show no significant increase in
response to insulin treatment. Furthermore, the increase in serum of IGF-II/an 6-
receptors is proportional to the amount of insulin injected over the range tested. In diabetic
rats the serum IGF-llan 6-P receptor concentration is decreased to approximately 80% as
much serum receptor as normal, age matched rats. The acute response of serum IGF-
IIan 6-P receptor levels to insulin administrtion is similar in both time course and extent
of change to the increase in isolated fat cells of cell surface receptor levels due to insulin
action. These results suggest the hypothesis that insulin stimulates the movement of
cellular IGF-ll/Man 6-P receptors to the cell surace where they are proteolytic ally cleaved
and released into serum.
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In trod uction
A significant and rapid effect of insulin administration is the translocation of a
number of proteins from an intracellular comparment to the cell surace. Among the
protein for which ths has been demonstrted in rat adipocytes are glucose trsporters (1-
4) and receptors for IGF-II/an- P (5, 6), transfemn (7, 8), and (X2 macroglobulin (9).
Translocation of the glucose trsporter appear to playa role in increasing cellular uptae
of glucose. The increase in the number of these cell surface receptors correlates with
, increased cellular binding of ligands with concomitant increases in uptake of ligands. This
phenomenon is associated with a concomitat decrease in the number of intracellular
receptors which fractionate in low density micro somes (5-9).
Of the proteins translocated to the cell surface in response to insulin, the IGF-
II/an- P receptor (10-12) and the transferrn receptor (13) have been detected as having
serum forms. We have previously shown that the serum IGF-II/an- P receptor is
trncated at the C-termnus, and that its levels in rats decrease over time beyond 14 days
,after birh (12). We hypothesized that the serum receptor is most likely a proteolytic
,product of the cellular receptor, produced by the action of proteases on the cell surface. In
'this case, it would be expected that insulin might induce an increase in the release of IGF-
, '
IIan 6-P receptor into serum, secondar to its effect to increase cell surface receptor
numbers.
In this paper we investigate the regulation of serum IGF-II/an 6-P and transferr
. receptor levels by insulin. Serum receptors assayed in rats 30 minutes following insulin
injection showed an approximately two-fold increase in the levels of both receptors in
serum as compared to untreated animals. , The increased amount of IGF-II/Man 6-
. receptor over time following insulin injection demonstrated simlarty to the effect on blood
glucose levels. Similarly, as has been shown for the decrease in blood glucose levels, the
increase in IGF-II/an 6-P receptor in circulation was dependent upon the amount of
insulin injected. Serum IGF-II/an 6-P receptors were also assayed in RT6 depleted
diabetic rats and found to be decreased compared to controls. The evidence presented
\iemonstrtes that the level of IGF-llan 6-P receptors in serum is regulated by insulin.
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Materials and Methods
erial IGF-llan- P receptors for antiboy generation were pured from rat
placenta plasma membranes by IGF-ll-Sepharose chromatography as previously described
(13). The priar strctue of the rat IGF-llan- P receptor deduced from cDNA clones
(14) was the basis for design of synthetic peptides used in the generation of anti-peptide
antibodes. Dithiotheitol (DTT was 99% pure from Chemical Dynamcs Corporation , and
Odum iodoacetate (Fisher Biotech) was recrystallzed twice from methanol. All other
chemicals were at least reagent grade.
e..ara rum. Male Sprague-Dawley rats at 100 to 150 g, obtained from
Taconic Fars, Germantown , NY, were injected subcutaneously with 0.2 ml phosphate
buffered saline (0.01 M sodium phosphate, 0. 15M NaCI, pH 7.4) alone or with 0.
insulin (or the indicated dosage) in 0.2 ml phosphate buffered saline. Thirty minutes
following injection (or at the times indicated) blood was obtained by decapitation. Serum
was prepared by clotting blood at 4 C for 6 h followed by centrfugation at 2000 x g for 10
min. Sera were then used immediately. Insulin treatment resulted in a decrease of serum
glucose levels (measured in the clinical chemistr facility at the University of Massachusetts
Medical Center) from 110 to 30 mg/dl (Fig. 25C and 26). Enzyme activities (creatine
Iqase and lactate dehydrogenase) measured in seru were not significantly altered by this
tteatment (2708:t628 to 2950:91 and 607:t183 to 853:!125, respectively).
Diabetic rats, generously provided by Dr. Aldo Rossini, were of the BB-DRlor
strain and were either spontaneous diabetics (1 animal) or RT6 depleted (3 animals).
Diabetes was confirmed by glycosurea and a blood glucose ::250 mg/dl on the day of
sacrfice and animals were never treated with insulin. These animals and nondiabetic
littermates, or age matched rats of the same strain , were sacrificed at approximately two
weeks of age and blood obtained by heart puncture. Blood glucose levels were 317:t172
for the diabetic rats and 15O:15 for the matched controls.
aration of Plasma Membranes from Rat Placenta. A plasma membrane fraction
was isolated from rat placentas taken at day 19 of gestation as described previously (13).
Membrane extracts (5 mg protein/ml) were prepared by incubation with 50 mM 4- (2-
hydroxyethyl)- piperazineethanesulfonic acid (Hepes), 1 % Triton X- 100, pH 7.4, plus
antiproteases by gentle mixing for 1 h at 3 C. The antiproteases were leupeptin , antipain
and benzamidine at concentrations of 10 mg/ml each, 20 mg/ml aprotinin , 12.5 mg/ml
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chymostati, and 1 mM PMSF. The mixtue was centruged for 10 min at 15000 x g in a
microcentrfuge and the supernatant fraction was used as the extract. Protein was assayed
by the Bradford method (15). The cellular form of the IGF-II/Man 6-P receptor was
isolated from this preparation.
.. -
ImmunoadsOI:ption of the IGF-IIlMan- P Receptor and the Transfemn Receptor
IGF-II/an- P receptors were immunoadsorbed from Triton X- 100 extracts of rat
placental plasma membranes as descrbed before (16, 17). For immunoadsorption from
serum, serum was diluted 1:1 with Hepes bufferred saline (50 mM Hepes, 0. 15M NaCl,
pH 7.4) containing protease inhibitors, then immunoadsorbed in the same manner as a
membrae extrct The same procedure was used for imunoadsorption of the transferr
receptor.
dium Do ulfate-Pol crylamide Gel Elec hore is. For the antipeptide
antibodies to recognize the IGF-II/Man- P receptor in western immunoblotting, the
receptor had to be reduced and alkylated under denaturing conditions, as previously
described (12). For reductive alkylation, washed anti-receptor antibody affigel or
membrane pellets were heated for 15 min at 100 C in 0. 1 ml of 10% SDS, 0.25 M Tris, 10
\nM DTI, pH 8.3. The samples were cooled, 5 ml of 0.5 M sodium iodoacetate was
added, followed by incubation in the dark at 23 C for 30 min or more. Reduction alone
was adequate to immunoblot the transferrn receptor, so it was simply heated to 100 C for
5 min in sample buffer containing 10 mM DTI. Electrophoresis was performed as
descrbed (18) on 6% polyacrlamde gels.
Antisera and Antibodies.. The anti-IGF-II/an- P receptor antisera used were
those descrbed by MacDonald et al (12). Briefly, the antireceptor antiserum was raised in
rabbits against intact purfied rat cellular receptor. Anti-22C was raised agaist the peptide
EEETDENETEWLMEEIQVP APR which is located 32 residues C terminal to the
transmembrane domain , and anti- 13D was raised against the peptide
YYLNVCRPLNPVPGCD located 1476 residues N-termnal to the cytoplasmic domain
(12). In the experients described, the antieceptor antiserum was immobilzed on affigel
as described (12) to immunoadsorb the receptors from serum or membrane extracts. The
antipeptide antisera were used to immunoblot reduced and alkylated receptors, or a
polyc1onal anti-receptor antibody to immunoblot nonreduced receptors. For the detection
of trsferrn receptors a monoclonal antibody obtaned from Dr. Roger Davis was used for
the imunoadsorption and the immunoblotting (19).
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estern Imm ott . IGF-II/an- P receptors were transferred from
polyacrlamde gels to nitrocellulose as descrbe (17). The immunoblots were blocked for
30 min at 23 C in 0.22 j.m-fitered 0.5% nonfat dr milk dissolved in 15 ro Tris, 0.15 M
NaCl, pH 7.4. Incubations with the anti- 13D, anti-22C, or anti-trnsferr antibodies were
done at 3 C for 16-20 h using 1:500, 1:200, or 1:1000 dilutions, respectively, of purified
imunoglobulin fractions or ascites fluid in blockig buffer. The blots were then washed,
incubated with 125I-protein A (anti- 13D and anti 22C) or 125I-goat anti-mouse IgG (anti-
trnsfemn receptor), and washed again as descrbed (17). The autoradiograms are shown.
Quantitation was performed by scanning of autoradiograms on an LKB Ultroscan XL
densitometer and integrating peak areas; or by cuttg out the bands of interest and counting
them directly. Thus, amounts of receptors are expressed in areas determined by the
densitometer or in counts per minute.
Results
In order to measure the effect of insulin on levels of receptors in serum, rats were
injected with 0.5 U of insulin in phosphate buffered saline or with saline alone. At varous
ties following this injection, the animals were sacriced and serum obtaied as described
in Material and Methods. From this serum, IGF-II/an 6-P receptors were isolated by
ynunoadsorption , electrophoresed on SDS-P AGE, and transferred to nitrocellulose. As
shown in Figure 25, serum receptor levels increase rapidly to reach approximately twice the
ontrollevel 20 minutes following insulin injection. Following this peak at 20 minutes,
levels decrease rapidly in the next 40 minutes to a level approximately 50% of control
levels, before returing to the initial concentration at 90 miutes. The serum glucose levels
'Nere also measured at these times (Fig. 25C). In general, the initial increase in serum
receptor levels correlated with the decrease in glucose levels (Fig. 25B and 25C), although
the degree of change differed. After this initial change, however, the glucose levels
r,emained low while the serum receptor concentrations rapidly decreased below the initial
:vel by 60 miutes, then retued to resting levels by 90 minutes.
We next studied the sensitivity of serum IGF-IIIan 6-P receptor levels to insulin
by injecting the rats with different amounts of insulin. The levels of receptor in serum
increased with increasing doses of insulin injected (Fig. 26) up to very high levels (10
Units/rat). The gradual increase in serum receptor levels over the range of 0.0001 Unit to
10 Units in response to increasing amounts of insulin injected contrasts sharly with the
acute dose dependence of glueose levels in which no effect is seen below 0.01 Unit and a
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maximal effect is obtained by 1 Unit. It is of interest that a significant change in serum
receptor levels is observed at 0.01 Units while no change in blood glucose is seen at this
dosage.
If insulin induces an increase in the levels of IGF-II/Man 6-P receptor in
circulation, it might be expected that decreases in circulating insulin should result in a
decrease in serum receptor levels. In order to test this hypothesis, rats were injected with
an anti-RT6 antibody to induce diabetes (20) and their serum IGF-II/an 6-P receptor
levels measured as descrbed above, and compared to matched controls as described in the
method. Diabetic rats had circulating IGF-IIan 6-P receptor levels that were slightly but
signifantly decreased (83. I:: 1. 1 %; mean:: S.D. 3 matched sets) as compared to
nondiabetic controls. Furthermore, the rats of this genetic strain are prone to diabetes, and
the nondiabetic littermates had blood glucose levels that were markedly elevated as
compared to the Sprague-Dawley control rats used for the other experiments (150 as
compared to 110 mg/dl). A comparson of these diabetic rats to the Sprague-Dawley
control animals showed a 50% decrease in serum receptor levels in the diabetics (not
ilustrated).
In order to verify the identity of the protein studied as the serum IGF-II/an 6-
receptor and to determne if other serum receptor proteins might be similarly regulated,
additional antibodes were used. Animals were injected with 0.5 U insulin, then sacrficed
30 minutes later. IGF-IIan 6-P receptors were immunoadsorbed from placental plasma
membranes or the serum samples descrbed above, electrophoresed on SDS-PAGE , and
transferred to nitrocellulose as descrbed in Materials and Methods. These fiters were then
probed with an antipeptide antibody as descrbed in the legend of Figure 27. While, as
previously demonstrated (12), anti-22C recognizes only cellular receptor, the anti- 13D
antibody recognizes a protein in cell extracts as well as a protein of slightly lower molecular
weight in serum (Fig. 27). The serum IGF-IIIan 6-P receptor from insulin treated
animals is present at approximately 2.5 fold the level seen in control animals. The lower
Mr forms of the serum form of the IGF-II/an 6-P receptor previously described by
MacDonald et ai. (12) are present in much lower amounts than the major form thus not
contrbuting greatly to the total amount of serum IGF-IIan 6-P receptor. They do,
nevertheless, appear to be regulated in a manner similar to the major species shown.
Analysis of similar preparations of immunoadsorbed receptor by silver staining showed
that a single band, corresponding to the known migration of the IGF-llan- P receptor
is increased in the immunoprecipitates. Similarly, an approximately two-fold increase in
,;,
128
trsferr receptor levels in serum are observed following insulin treatment (from 525Z291
to 11OO:91 cpm, mean :!.D. N=3; Fig. 27). The measurement of other enzyme levels in
seru, as descrbe in Materials and Methods, demonstrtes that these changes are not due
to a general increase in serum protein levels.
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Discussion
The results presented support a model whereby the serum IGF-II/an 6-P and
trsferr receptors are degradation products of their cellular counterpars, produced either
by proteolysis from the cell surace or by intracellular proteolysis within vesicles followed
by release of vesicle contents. In these models, the initial increase in serum receptor levels
would reflect the insulin induced increase in receptors at the cell surface. The decrease in
serum receptor at 60 minutes would then reflect the recovery of the cells from the insulin
induced increase causing a decrease in the exocytosis rate and the number of cell surace
receptors. Finally, by 90 minutes the level of exocytosis would retur to control levels as
would the number of receptors available at the cell surace. The determnation of which of
these models (or others) correctly descrbes the release of receptors from cells wil require
the development of a tissue culture system which produces serum receptor forms.
A third possible explanation for the insulin induced increase in serum receptor
levels is that the hormone causes a decrease in the rate at which receptors are cleared from
circulation. It seems unlikely that insulin would induce a specific decrease in the clearance
rate of these proteins, as circulating enzyme levels were not appreciably changed by this
treatment. Furhermore, the time course of this response would require a decrease in the
clearance rate initially, followed by an increased rate by 60 minutes, then another decrease
to the control values by 90 minutes. However, such a possibilty cannot be ruled out at this
tie. Such a hypothesis could be tested by injecting rats with radiolabelled serum receptor
and measurng the rate of clearance in insulin treated and untreated animals. However, the
low concentration of receptors in serum and their apparent occupancy state make this
trncated protein diffcult to purfy.
The acute regulation of serum receptor levels has several interesting implications.
First, such acute regulation argues against the possibility of serum receptor arsing from
RNA messages distinct from the cellular receptors: the time necessar to synthesize the
IGF-II/an- P receptor (16) is much greater than the period of insulin treatment in these
animals. Second, the same process that generates the serum IGF-II/an- P receptor may
generate the serum transfern receptor. It has recently been shown that these two receptors
coexist in intracellular vesicles which also contain the HepG2 type glucose transporter, and
that these vesicles move to the surace in response to insulin (21). It is possible, if not
likely, that other proteins regulated by insulin, such as the a2-macroglobulin receptor, may
also share this degrdative pathway.
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Fig. 25. Serum IGF-II/an 6-P receptor levels at several times following insulin
treatment. Male Sprague Dawley rats at 100-125 g were injected with 0.5U of insulin, then
sacrificed at 0, 2, 5, 10, 20, 30, 45, 60, 90, or 120 minutes following injection and their
blood colected. Serum was obtained, and IGF-IIan 6-P receptors immunoadsorbed as
described in materials and methods. A. Following immunoadsorption, serum receptors
were e1cetrophoresed following reductive alkylation on SDS-PAGE, transferred to
nitrocellulose, and immunoblotted using anti- 13D antibody followed by 1251 protein A.
Each point corresponds to serum pooled from two animals. The IGF-ll/Man 6-P receptor
bands excised from autoraiogrs from two independent time courses are shown. B. The
receptor levels from the immunoblots were quantitated by densitometr as descrbed in the
methods and averaged. Results are measured as means.: D. (N=3), normalized by mean
peak area over each time course. C. Serum glucose levels obtained over the same time
course. Levels were determned as described and the results are shown as means .: 
(N=3) normalzed by the averages for each of the thee time coures.
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Fig. 26. The serum IGF-II/an 6-P receptor levels following treatment with varous
amounts of insulin. Male Sprague Dawley rats at 1oo- 125g were injected with 0.0001
001, 0.01, 0. 1, 1.0, or 10.0 Units of insulin per rat. Animals were sacrificed 20
minutes following injection and serum obtained. Blood glucose and serum receptor levels
were determned as described except that a polyclonal anti-IGF-IIjMan 6-P receptor
antibody was used to probe immunoblots in place of the anti-peptide antibody. Each data
point represents the pooled serum from 2 animals. Blood glucose levels shown are
means:.D. (N=3) and receptor levels are means:.D. (N=2).
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Fig. 27. The levels of transferrn and IGF-II/an 6-P receptors in serum of control and
insulin treated rats. Receptors were immunoadsorbed from an extract of 0.5 mg plasma
membrane protein (E), or 5 ml serum from pooled from 4 rats injected with insulin (I) or
carer (C) alone 30 minutes before sacrifice, using polyc1onal antisera raised against IGF-
II/Man- receptors or a monoclonal specific for the transferrin receptor.
Immunoadsorbed receptors were then subjected to SDS-PAGE as described in materials
and methods and transferred to nitrocellulose. The nitrocellulose fiters were then
imunoblotted with anti-22C antiseru or anti- 13D antiserum followed by 125I-protein A
or anti-transfemn receptor antibody followed by 125I-goat anti-mouse Ig. A. The bands
of interest excised from an autoradiogram are shown. B. The autoradiographs depicted in
A were quantitated by densitometr and the areas under the receptor peaks plotted.
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Summary
The IGF-II/an 6-P receptor directs lysosomal proteins to a prelysosomal
comparent from which they go on to form lysosomes while the receptor returns to the
Golgi apparatus. The degradation of the IGF-II/Man 6-P receptor thus must be
extralysosomal. By pulse-chase labellng of cultured BRL-3A cells, we directly
demonstrate that the loss of cellular IGF-llan 6-P receptor correlates with the appearance
of a trncated form of the IGF-llan 6-P receptor which is found in the medium. The
ability of serum and conditioned medium to increase the rate of appearance of receptor in
the medium in a phosphate dependent manner suggests that the degradation of the cellular
IGF-llan 6-P receptor occurs by lysosomal enzyme mediated proteolysis of the receptor
from the cell surface to produce a trcated receptor form.
-Y'--
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A number of published reports describe experients using pulse-chase protocols to
address the synthesis, processing, and degradation of the IGF-IIjan 6-P receptor
(Goldberg, Gabel, and Kornfeld, 1983; Creek and Sly, 1983; Sahagian and Neufeld,
1983; Sahagian, 1984; MacDonald and Czech, 1985). These reports demonstrated that the
receptor required a significant length of time to reach maturity (4-8 h), that it was
glycosylated, that some processing was necessar for ligand binding, and that the receptor
had a long half life (24-48 h). Through the use of a number of agents which disrupt
lysosomes, these reports also demonstrated that the degradation of the receptor was not
lysosomal (Creek and Sly, 1983; Sahagian, 1984). The mechanism of receptor
degradation has remained an open question.
In 1987, the first report of a serum form of the IGF-II/an 6-P receptor in
circulation was reported (Kiess et ai., 1987). Subsequent reports demonstrated that the
serum receptor could bind IGF-II and Man 6-P containing ligands simultaneously, that it
was cytoplasmically altered or trncated as compared to the cellular receptor, and that in
circulation the receptor was proteolysed into smaller fragments (MacDonald et ai., 1989).
It has also been shown that the IGF-II/Man 6-P receptor can be found in urine (Causin 
ai., 1988). This suggested that the serum IGF-II/Man 6-P receptor might be an
intermediate form in the degradation of the protein.
In order to address the degradative pathway of the IGF- IIan 6- P receptor and the
possible role of the serum IGF-II/an 6-P receptor in this process, we have performed
pulse-chase protocols on cultured cells and isloated IGF-IIan 6-P receptor forms from
cell membraes and medium. In all cells studied the appearance of receptor in the medium
correlates with the disappearance of receptor from the cells. In BRL-3A cells quantitation
of cellular receptor loss and the appearance of receptor in the medium demonstrates that this
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pathway accounts for essentially al receptor degradation. In studies in which diferentiated
3T3-L1 adipocytes were fractionated, receptor appearance in the medium followed
appearance at the cell surace. Cyc1ohexamde, a protein synthesis inhibitor, showed litte
or no effect on the production of the serum IGF-II/an 6-P receptor when added after a 1
hour pulse. Results from all cell lines studied are consistent with the model that the serum
IGF-II/an 6-P receptor is the major, if not sole, degradative product of the cellular
receptor generated by proteolysis of the cellular receptor at the cell surace.
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Results
an P Rece tors A ear in th Medium f Cultured C lls
In order to develop a system in which to study the synthesis of the serum IGF-
IIan 6-P receptor and its relationship to the cellular receptor, cellular and medium
receptors were isolated following a pulse-chase protocol on a number of different cell lines:
BRL-3A (rat liver), L6 (rat myoblast), CHO-K1 (Chinese hamster ovar), and SL-
, (chick embryo fibroblasts). In each cell line, the cells were labelled with Tran35S label for
1 hour, then incubated in unlabelled medium for the times indicated (Figure 28). In each
case receptor accumulated in the cells at 0 and about 3.5 hours following a 1 hour pulse
label, then decreased to lower levels by about 20 hours. Simultaneously, serum receptor
was absent from the medum at the star of the chase, then accumulated slightly by about
5 hours, with similar levels seen by about 20 hours. This is consistent with the loss of
, IGF-llan 6-P receptor from the cells being accounted for by the appearance of receptor
in the medum and previous information on the specifcity of the antibody used (MacDonald
and Czech, 1985). The primar translation product (232 kDa) is not recognized by the
antibody until it has been glycosylated to -245 kDa. This post-translational modification
accounts for the additional receptor appearng between 0 and about 3.5 hours following the
pulse. During this time, receptor is also appearng in the medium and, as wil be discussed
furer in the following section, serum receptor in the medium is gradually lost, possibly
, by further degradation or reuptake. Taking these factors into account, it appears that a
significant portion of the receptor lost from the cells appears in the medium. This is the
case with all cell lines studied regardless of the tissue or species from which receptor is
obtaned.
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The Appearance of Receptors in the Medium Ouantitatively Accounts for the Loss of
Radiolabelled IGF-II/an 6-P Receptors from Cell Membranes
As descrbed above, the quantitation of the amount of receptor lost from cells and
appearng in the medum is dificult due to the dynamcs of this system: cellular receptor is
synthesized and processed slowly makg the 0 time point following the 1 hour pulse label
an inappropriate starng value to determne the total amount of labelled receptor in the
experient On a simlar scale of time, cellular receptor is degraded in to medium receptor
, then, after some lag, serum receptor is further degraded to a form not identified in our
assays. In order to address this issue better a representative cell line, BRL-3A cells, were
labelled for 1 hour with EXPRE35S35S label then incubated with unlabelled medium for the
times indicated (Figure 29). At the star of the experiment, there is no receptor in the
medum, and only the -245 kDa precuror is seen in cells. Over the next several hours the
-245 kDa precursor is converted into the -250 kDa mature receptor and a trncated receptor
is fit seen in the medum. At later times, cellular receptor is gradually converted into the
trncated form of the receptor found in the medium. Quantitation of the results shows that
109 :! 39% of the receptor lost from the cells appears in the medium. Protein synthesis is
not necessar for the synthesis of the serum receptor as it occurs in the presence of the
protein synthesis inhibitor cyclohexamide (Figure 30, lanes 11 and 12). Furthermore,
neither form of the IGF-llan 6-P receptor was detected in the supernatant following the
pelleting of total membranes (data not shown), demonstrting that no detectable amount of
the serum receptor is stored in the cytoplasm or in the lumens of disrupted vesicles prior to
appearce in the medium. These data further support the idea of proteolysis from the cell
surace, and rule out any possibilty that the serum receptor is translated from a message
distict from that of the cellul receptor.
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fect of Li ds. Seru . a d Co iti he Produc f IGF- ll
P Receptor in the
It would be expected that agents which cause a redistrbution of IGF-II/an 6-
receptors or bind to it might alter the rate at which the cellular IGF-II/Man 6-P receptor is
proteolysed into a trcated form of the receptor. In order to test this hypothesis, BRL-
cells were pulse-labelled for 1 hour, then chased in serum free medium with or without
insulin, fetal bovine serum, conditioned medium, or ligand. Insulin (Figure 30, lane 2),
IGF-II (Figure 30, lane 3), and Man 6-P (Figure 30, lane 5) cause little or no significant
change in the rate at which serum receptor is released into the medium as compared to cells
grown in control medium (Figure 30, lane 1). The lysosomal enzyme j3-galactosidase
(Figure 30, lanes 6-8) likewise causes no significant change in the rate at which this
process occurs. Addition of fetal bovine serum (Figure 30, lane 9) or conditioned medium
(Figure 30, lane 11) increases the rate at which serum receptor is produced, with the effect
being reduced or negated by alkaline phosphatase treatment (Figure 30, lanes 10 and 12).
The results suggest that serum and conditioned medium may contain a Man 6-P contaning
protease which binds to the receptor and causes the indicated cleavage. The ineffectiveness
of other ligands in negating this process, however, is unclear. Another possibility is that
the dephosphorylation inactivates the protease which is involved in this process.
fect of Protease Inhi s on the Production of um Rece tor
The predicted proteolytic release of IGF-llan 6-P receptors from the cell surface
would be expected to be hindered by the addition of protease inhibitors to the chase
medium of pulse labelled BRL-3A cells. Addition of a combination of the protease
inhibitors leupeptin, antipaiI!, aprotinin , and benzamdine (Figure 31) or chymostatin and
144
PMSF inhibit the proteolytic cleavage which produces the serum receptor. Individually,
the protease inhibitors aprotiin, chymostatin, or PMSF completely inhibit the production
of the receptor in medium from the cellular receptor, while benzamdine inhibits the process
to a lesser extent. Leupeptin and antipain have no effect on the production of serum
receptor in the medum as compared to cells incubated in the absence of protease inhibitors
for the chase period. Taken together the data are suggestive of a chymostatin-lie protease
which are present in serum or released from cells into the medium, and can then bind and
cleave the IGF-II/an 6-P receptor at any of a number of sites in the juxtamembrane
region. The results do not, however, the inhibition of this process by protease inhibitors
through another mechanism.
Subce ar Fraction tion of L1 Adipocytes
In order to address the site from which the serum IGF-II/an 6-P receptor is
released into the medium, a cell line for which membranes can easily be fractionated, the
3T3-L1 adipocyte, was used. The adipocytes were labelled with 35S-cysteine for 1 hour,
then the medium replaced with nonradioactive medium. At several times thereafter cells
were placed on ice, medium removed, and cells homogenized. Over the time course
studied the receptor was lost from the total membranes and quantitatively appeared in the
medium (Figure 32). Next, in order to address the site of proteolysis of the cellular
receptor to produce the serum receptor, cells were labelled for 30 minutes, then placed in
unlabelled medium for 0, 10, 20, 30, 40, and 50 minutes (Figure 33). The homogenates
from each of these times was then fractionated into plasma membranes and low density
microsomes (panel A). A precuror form (-245 kDa) is seen at the very short ties only 
the low denstity microsomes, and is converted over time into the mature form of the
receptor (-250 kDa). Follo ing maturation , the mature form of the receptor is found at the
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plasma membrane (panel B). At yet later times, serum receptor is detected in the medium
(panel C). This time course suggests that plasma membrane receptors are a prerequisite to
generating serum receptors. Taken together this evidence suppons proteolysis of the
cellular IGF-II/an 6-P receptor from the plasma membrane to produce the serum form of
the receptor.
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Discussion
The Synthesis of Medium Receptors
While proteolysis from the cell surace would seem to be the most straightforward
way to produce a serum form of a receptor when a cellular form already exists, this
mechanism has not previously been identified as a significant route whereby serum
receptors are produced. The most studied serum receptor, the serum growth hormone
receptor, has been definitively demonstrated to arse from an independently produced
protein product from the cellular receptor which is always in a soluble form (Herington
Ymer, and Stevenson, 1986; Leung et ai., 1987). Additionally, there is evidence of
multiple messages including some lacking transmembrane domains for the neural cell
adhesion molecule (Gower et ai., 
1988) and the class I antigens (Gussow and Pleogh
1987). In those cases in which the serum receptor forms are independently produced, a
serum receptor function independent of the cellular receptor is indicated. Most likely, these
functions are similar to those indicated for the serum IGF-binding proteins: inactivation and
removal of ligand and/or an increase in the half-life of ligand in circulation.
The demonstration that the serum form of the IGF-II/an 6-P receptor is a product
of the cellular receptor brigs up an additional possibilty: perhaps the serum IGF-llan 
P receptor is simply a degradative intermediate in the breakdown of the cellular receptor.
This idea will be discussed further below. It is also worth considering again at this time
that evidence regarding serum binding proteins has indicated that the serum receptor is not a
major binding protein of IGF's in circulation (Kiess 
et ai., 1987). The other type of ligand
for this receptOr, mannose 6-phosphate containing lysosomal enzymes, have also been
demonstrated in serum (Belftore et ai., 
1974; Lombardo et ai., 1980). However, there is
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little evidence addressing the role of the serum form of the IGF-II/an 6-P receptor in
binding these proteins in serum. The low concentration of serum IGF-II/an 6-P receptor
in serum argues against an important role in this function.
e Sy s a atio an P R pto
The IGF-IIan 6-P receptor is synthesized as a 2491 amino acid preprotein, from
which 50 amino acids are removed to give rise to the mature receptor (Morgan et al.,
1987). The mature peptide has an Mr-232 kDa in the absence of glycosylation
(MacDonald and Czech, 1985; Figure 34). A parially processed protein containing some
glycosylation is produced faily rapidly which migrates with an Mr-245 kDa and is the
earliest receptor form recognized by the antibody used in these studies. Upon funher
processing this protein is converted into a mature form of Mr- 250 kDa. The conversion of
the 245 kDa form to the 250 kDa form occurs with a halftime of approximately 2 hours in
H35 cells. Data presented in this manuscrpt (Figure 33) demonstrates that maturation
precedes the arval ofIGF-II/an 6-P receptor at the plasma membrane. Such processing
is not necessar, however, for the acquisition of the ability to bind mannose 6-phosphate
contaning ligands (Sahagian and Neufeld, 1983). The observed very long processing time
is consistent with experiments which have suggested that the IGF-II/an 6-P receptor may
bind lysosomal enzymes in the cis Golgi, and car them from there to the lysosomes
(Brown and Farquhar, 1984; Brown, Goodhouse, and Farquhar, 1986). The IGF-llan
P receptor may cycle from the cis region of the Golgi apparatus to the prelysosomal
comparent, then back to the same region of the Golgi apparatus. During each cycle, a
small percentage of the receptors escape this pathway, traverse the remainder of the Golgi
apparatus where they may be furher glycosylated, then arve at the plasma membrane.
Thus, the receptor could unc!ergo a number of cycles of delivery of lysosomal enzymes to
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the prelysosomal comparment while stil at the immature Mr of 245 kDa. A small
percentage of receptors would escape this pathway durng each cycle, get processed to the
250 kDa matue fonn, and reach the plasma membrane.
Those receptors that reach the plasma membrane would also be available to be
proteolytic ally released and degraded. Data presented in this manuscript suggests that such
a protease may be released from cells and accumulate in the medium or in serum. The
protease would then bind to the receptor at a Man 6-P binding site and cause the proteolysis
which produces the serum receptor form. This process is generally unaffected by the
binding of mannose 6-phosphate, IGF-II, or (3-galactosidase. The proteolysis appears to
be dependent on Man 6-P as pretreatment with alaline phoshatase eliminates this activity,
although effects of alaline phosphatase on proteolytic activity cannot be ruled out. The
lack of an effect of insulin on this process may be due to a lack of sensitivity of the BRL-
3A cells to insulin or a lack of receptor redistrbution in these cells caused by insulin. In
other experients (not shown) insulin did increase the initial rate at which serum receptor
was produced in 3T3-L1 cells, a cell line in which IGF-II/Man 6-P receptors are
redistrbuted in response to insulin. Taken together the data suggest proteolysis from the
cell surace by a previously released lysosomal protease (Figure 34). The released receptor
fragment would then appear in the medium, arving in serum in vivo where it may be
furer degraded or removed though endocytosis.
Conclusion
For no other protein has proteolytic cleavage from the cell been demonstrated as a
significant mechanism of protein degradation, although a proteolytic mechanism may be
involved in the transcytosis of IgA. The IGF-llan 6-P receptor, however, appears to
use this route as the major if not sole, mechanism of degradation. This process is
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dependent upon the presence ofIGF-llan 6-P receptors at the cell surace which can then
be proteolytc ally cleaved by a lysosomal protease which was previously released from the
cell. Such a degradative mechanism may have evolved as a necessar par of the sorting of
lysosomal enzymes by this receptor. The effeciency with which receptor is sorted from
lysosomal enzymes in the prelysosomal comparent has been demonstrated by the faiure
of numerous ultrastrctual studies to find this protein in lysosomes. However, the other
sortng steps, lysosomal enzyme binding to the receptor in the Golgi apparatus and sorting
of receptor (and receptor lysosomal enzyme complexes) in coated vesicles destined for the
prelysosomal comparment, are not as efficient. Lysosomal enzymes fail to bind to
receptor, they then arve at the cell surface. Receptors also escape sortng to reach the cell
surace, where they can capture the released lysosomal enzymes. One model is that 
lysosomal protease which has escaped the normal sorting pathway can cleave the cellular
receptor from the cell surface to release the serum form of the IGF-II/Man 6-P receptor.
This degradative mechanism may, therefore, be required in order for a protein to be
effciently sorted away from the lysosome, the major degradative comparment of the cell.
31-
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Experimental Procedures
Materials. IGF-llan- P receptors for antibody generation were puried from rat
placenta plasma membranes by IGF-ll-Sepharose chromatography as previously described
(Oppenheimer and Czech, 1983). The anti-IGF-II/Man- P receptor antisera used were
those previously descrbed (MacDonald et al , 1989). Cell lines were purchased from the
American Type Culture Collection. Cell cultured reagents are from Gibco.. Sodium
iodoacetate (Fisher Biotech) was recrystallized twice from methanol. All other chemicals
were at least reagent grade.
activ elln of ell . Pror to labellng, cells were grown to 90%
confluence (all cell lines other than 3T3-L1) or grown to confluence and differentiated as
descrbed (for 3T3-L1; Frost and Lane, 1985). Medium was then removed and replaced
by serum free modified Eagles medium buffered with 15 mM Hepes and lacking the
labelled amino acid(s). To this was added 0. 15- 1.0 mCi of 35S-cysteine, Tran35S-label
(ICN, Costa Mesa, CA), or EXPRE35S35S Label (New England Nucleur, Boston , MA)
and cells were incubated for 30-60 minutes at 37 C. Following this labellng period, this
medium was removed and replaced by serum free Dulbeccos modified Eagles medium.
Incubation was continued for the indicated times in serum free DME or DME supplemented
as indicated prior to homogenization.
eparatio f M ed Cell Lin . Cells were scraped into a
buffer consisting of 20 mM 4-(2-hydroxyethyl)- piperazineethanesulfonic acid (Hepes),
25 M sucrose, and 1 mM (ethylenedinitro)tetracetic acid (EDTA) pH 7.4, plus protease
inhibitors at OOC. The protease inhibitors were leupeptin, antipain and benzamidine at
concentrtions of 10 mg/ml ch, 20 mg/ml aprotinin, 12.5 mg/ml chymostatin , and 1 
l .
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PMSF. Following homogenization, total membranes were obtained by a single
centrfugation at 200, 000 x g.
Fractionation of 3T3 L1 adipocytes into plasma membranes and low density
micro somes was caned out by differential centrfugation as described (Simpson et ai.,
1983). Briefly, cells homogenized as descrbed above were centrfuged at 16000 x g for
20 minutes. The pellet from this spin was then resuspended in 20 ro Hepes, 1 mM
EDT A pH 7.4 and layered atop a sucrose cushion of this buffer containing 1. 12 M sucrose.
This was centrfuged at 100,000 x g for one hour and the material that remained above the
sucrose cushion diluted 10 fold in 20 ro Hepes, 1 mM EDT A , pH 7.4 and centrfuged at
30,000 x g. This final pellet is plasma membranes. The supernatant from the 16000 x g
spin was centrfuged at 30 000 x g for 30 minutes. The pellet from this centrfugation is
high density microsomes. A low density microsome pellet was obtained by a 200,000 x g
centrfugation of the supernatant from the previous step. Results from our laboratory
(Clancy and Czech, 1990) show an 8-fold enrchment in 5' nucleotidase in the plasma
membranes and no enrchment of activity in micro somes as compared to a cellular extract.
Furthermore, the lack of a doublet at short time points in the plasma membranes (Figure
33) argues against gross contamination of the plasma membranes by microsomes. All
membranes were resuspended in 20 mM Hepes, 1 mM EDT A , pH 7.4 and frozen at -
until use. Membrane protein was determined by the BCA method (Pierce, Rockford, IL;
Smith et ai., 1985).
To obtain a membrane extract the membranes obtained as described above were
solubilzed as follows. A volume of the membrane suspension obtain above equivalent to
2 mg of protein or the total membrane protein from one well was pelleted by
centrfugation for 5 minutes t 15,000 x g in a microfuge. The supernatant was removed
-;.:J.
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and the pellet resuspended in 50 III of 15 ro Tris, . 15 M NaCI, pH 7.4 containing 1 %
Triton X- lOO, 1% deoxycholate, and 0. 1 % sodium dodecylsulfate with the protease
inhibitors descrbed above. Following a 1 hour incubation at 4 C on and end-over-end
mixer, the mixture was centrfuged for 10 min at 1500 x g in a microcentrfuge and the
supernatant fraction was used as the extract. The cellular form of the IGF-II/an 6-
receptor was isolated from this preparation.
Pre aration of Medium for Immunoadsorption. Pror to homogenization of the
cells, medium was removed into centrfuge tubes and protease inhibitors added as
described above. The medium was then centrfuged at 35,000 x g or 200,000 x g to
remove cellular or membrane contaminants. Both techniques produced identical results
(data not shown). Medium was frozen at - C until needed. Pror to immunoadsorption
a frction of the medium corresponding to 0.2 mg membranes or the tota medium from one
well was concentrated using a Centrcon 30 (Amicon , Danvers, MA) or a Centrfugal
UltraFree with a 30,000 N. L. (Millpore, Bedford, MA.) to a volume of 0. 5 ml.
Imm ds01:p f the I an- P R r. IGF-II/an- P receptors
were immunoadsorbed essentially as described (MacDonald et ai., 1989). For
immunoadsorption from a membrane extrct the 50 III of extract was diluted to 0.9 ml with
50 ro Hepes, pH 7.4 and to a final concentrtion of 0. 15 M NaCI and 5 ro man nose 6-
phosphate. For medium, 50 III of extraction buffer was added to the medium and it was
diuted in the same manner as the membrane extrcts. Finally, to each was added 0. 1 ml of
a 50% slur of Anti-receptor antibody Affigel (BioRad, Richmond, CA) in 50 ro Hepes,
pH 7.4 containing 0. 1 % Triton X- 100. These mixtures were incubated overnight at 4
on an end-over-end mixer. Unbound material was removed by withdrawing the
supernatat following a rnute centrfugation in a microfuge at 15,000 x g. Ths material
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was then washed in this manner four times in 50 mM Hepes, 0.5 M N aCI, pH 7.4
containing 0. 1% Triton X- lOa, then once in each 50 mM Hepes, 0. 15 M NaCI, pH 7.4
with 0.05% Triton X- lOO and 50 mM Hepes, pH 7.4.
Sod m Dodecy ulfat l Electr . Samples labelled
with 35S were reduced by incubation in electrophoresis sample buffer contain 100 mM
dithiothreitol. Electrophoresis was performed as described (Laemmli, 1970) on 6%
polyacrylamde gels.
Aut adiogr,p d Gels and Ouanti ation f R sult . Gels contaiing
35S labelled material were staied with Coomassie brillant blue and destaed. They were
then treated with EN3HACE (New England Nucleur, Boston , MA) according to the
manufacturers instrctions. The gels were then dred and subjected to autoradiography.
Quantitation was performed using an LKB Ultroscan XL densitometer (LKB , Rockvile,
MD) to scan the autoradiographs or by cuttng out the bands and countig them in 
scintillation counter. Quantitated results shown are means z stadad deviations for three
repeats of each experient except for Figure 5B where the results are the quantitation of a
single experiment.
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Fil:ure The Medium Receptor Form Appears as Cellular Receptor is
Lost in BRL-3A, CHO-Kl, L6, and SL-29 Cells. Cells were grown to 90%
confluence, then labelled with 0.3 mCi Tran35S Label per 100 mm plate for one hour
followed by the indicated period in serum free medium. Cells were then placed on ice,
medum removed, cells homogenized and total membranes obtained. These samples were
then electrophoresed on SDS-PAGE , stained, destained, and EN3HANCEd. A. BRL-
rat liver cells (0, 3.5, and 20 hours). B. CHO-K1 chinese hamster ovar cells (0, 3.
and 20 hours). C. L6 rat myoblasts (0, 3.5, and 21 hours). D. SL-29 chick embryo
fibroblasts (0, 4, and 22 hours).
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ure 29: In BRL-3A Cells the Serum IGF-II/Man 6. Receptor
Quantitatively Accounts for the Loss of Cellular Receptor. BRL-3A rat liver
cells were grown to 90% conflunce in 35 mm plates, then labelled with 0.4 mCi
EXPRE35S35S Label for one hour. Radioactive medium was then replaced with serum
free DME with or without 0.2 mM cyc10hexamide for the indicated times. Cells and
medum were then separated and receptors purified as descrbed in the methods. A. Total
membrane samples from 0.2 mg membrane protein were electrophoresed on SDS-PAGE
stained, destained, and EN3HANCEd. . A representative autoradiogram is shown. 
Medum receptor from one plate was electrophoresed on SDS-PAGE, stained, de stained,
and EN3HANCEd. A representative autoradiogram is shown. C. Quantitation of the
results depicted in panels A and B by cuttng of receptor regions from gels and measuring
radioactivity in a scintilation counter.
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Contrl Insuli IGF-II 1+ M Man 6- Gal AP- FBS AP-FBS CM AP-
Condition
re Certain Agents Can Alter the Rate of Serum Receptor
Production. Cells grown in 6 well multiwell plates were labelled with 150 Ci of
EXPRE35S35S Label per well for one hour, after which this medium was removed and
replaced with serum free DME (1) or DME contaning 1 M insulin (2), 5 nM IGF-ll (3), 5
ro Man 6-P and 5 nM IGF-II (4), 5 ro Man 6-P (5), 10 galactosidase (6), alaline
phosphatase treated galactosidase (7), mock treated galactosidase (8), 10% fetal bovine
serum (9), alkaline phosphatase treated fetal bovine serum (10), medium conditioned by
BRL-3A cells for 24 hours (11), or alaline phosphatase treated conditioned medium (12).
A. Following a 42 hr incubation, cells were placed on ice and medium and membranes
obtained. Receptors were adsorbed to anti- IGF- II/Man 6-P receptor antibody,
electrophoresed on SDS-PAGE, stained, destained and EN3HANCEd. B. The receptor
bands were cut out from the gels and -emission measured in a scintilation counter. The
bars represent the averages of three experiments with those conditions which are
consistently different than the control indicated by an asterisk.
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Protease Inhibitor Ap An Lu Bz Ch Ph CA CB
I' Antibody 
Fi2u e 31: The Effect of Protease Inhibitors on the Production of the Serum
IGF-WMan 6-P Receptor. Cells were labelled with 0.5 mCi EXPRE35S35S Label for
1 hour followed by incubation in serum free DME (C) or DME containing the following:
Ap-aprotinin, An-antipain, Lu-leupeptin, Bz-benzamidine, Ch-chymostatin , Ph-PMSF
CA-leupeptin, antipain, aprotinin, and benzamidine, CB-PMSF and chymostatin at the
concentrations indicated in the methods for 20 h each following labellng period. The
control samples were then immunadsorbed to immune or preimmune Affigel 10 while all
other samples were imunoadorbed only to the immune AffgellO.
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Fi2ure The Serum Form of the IGF-II/Man 6-P Receptor Appears in
the Medium from 3T3-Ll Cells as it is Lost from the Total Membranes.
Differentiated 3T3-L1 adipocytes were labelled with 1 mCi 35S cysteine/150 mm plate for 1
hour. Labellng medum was then removed and the cells grown in serum free DME for the
indicated ties. Cells were then placed on ice, the medum removed, and the cells
homogenized and total membranes obtained. Receptors were isolated from membranes or
medum as indicated in the experiental procedures. A. Imunoadsorbed receptors were
electrophoresed on SDS-PAGE , stained with Coomassie Brillant Blue, and treated with
EN3HANCE. B. The receptor regions indicated were cut out of the gel and counted in a
scintillation counter. 
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e 33: The Appearance of the Receptor in the Medium Follows its
Appearance at the Cell Surface. Differentiated 3T3-L1 adipocytes were labelled with
0.3 mCi 35S-cysteine for 30 miutes, then placed in unlabelled medium for the tie
indicated. Cells were then placed on ice, medium removed, and the cells homogenized and
fractionated into plasma membrane and low density microsomes as descrbed in the
methods. The receptors were immunoadsorbed, electrophoresed, and EN3HANCEd as
descrbed in experimental procedures.
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e 3 The Life Cycle of the IGF-II/Man 6-P Receptor. The IGF-II/an
P receptor is synthesized as a 2491 amno acid pre-receptor from which a 50 amino acid
signal sequence is removed to give the matue peptide. The matue deglycosylated peptide
migrates with an Mr-232 kDa. Glycosylation of the peptide produces a receptor with an
Mr-245 kDa which is fully capable of binding ligand (MacDonald and Czech, 1985) and
which is further glycosylated to the mature 250 kDa receptor form with a half time of
severa hours. The immature 250 kDa receptor may actively transport lysosomal enzymes
from the cis Golgi to the prelysosomal comparent (Brown and Farquhar, 1984; Brown
Goohouse, and Farquhar, 1986) or may be retained in the endoplasmic reticulum or Golgi
appartus until fully glycosylated. The fully glycosylated form may then escape from the
Golgi apparatus and reach the cell surface. At the cell surface some of the receptor is
proteolytic aly cleaved to release the serum form of the IGF-II/an 6-P receptor while the
majority is re-internalized intact where it may direct more rounds of lysosomal enzyme
sortng. The serum receptor that is released may be furer degraded in seru, taken up by
cells, or cared in the serum tQ the kidneys and released in urine (Causin et ai., 1988).
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A. Non-mammalian Man 6-P Receptors Fail to Bind IGF-
The identification in chicken and Xenopus of a protein of the same molecular
weight as the mammalian IGF-II/an 6-P receptor which has high affinity for PMP-
Sepharose and can be specifically eluted by mannose 6-phosphate has a number of
interesting implications. These wil be discussed in the following order: 1. Implications
Relatig to the Function of the IGF-IIan 6-P Receptor; 2. Possible Applications of This
Finding to Futue Research; and 3. An Evolutionar Perspective.
1. Implications Relating to the Function of the IGF-II/Man 6-P Receptor
The presence of a 250 kDa Man 6-P receptor in non-mamalian species provides a
new aspect to the ongoing debate as to whether IGF-ll signals through the IGF-ll/Man 6-
receptor. This problem was initially discussed as Background (I. L.), and wil now 
discussed and a conclusion reached (Table 2). That data which relies simply on the ability
of IGF-II to cause a response (Hil and Milner, 1984) or upon dose response data
(Beguinot et ai., 1985; Mellas, Gavin , and Hammerman, 1986; Tally, Li, and Hall , 1987;
van Dijk, Tanswell, and Challs, 1988) as proof of signaling through the IGF-II/an 6-
receptor provide essentially no evidence as this relationship can be explained by the
modulation of effects through the insulin and IGF-I receptor by IGF binding proteins or
signalling though the second site on the IGF-I receptor which preferentially binds IGF-ll.
The presence of such an IGF- II preferrng site on the IGF- I receptor also explains the lack
of inhibition of effects by the antibody aIR- 3 (Har et ai., 1987), which blocks only
binding to the first, IGF-I yrefemng, site (Casella et ai., 1986). Biological effects
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mimicked by antibodies to the IGF-llan 6-P receptor (Har et at., 1987; Kojima et at.,
1988) may be caused by contamating antibodes to the IGF-I receptor, as both receptors
can co-pury on IGF-II Sepharose.
The responses observed in Balb/c 3T3 cells have used the types of evidence refuted
above to show that the effect is medated by the IGF-IIan 6-P receptor. This evidence is
inconclusive. The responses themselves also have several possible alternative
explanations. The fIrst, most obvious explanation is that the responses are occurrng
through the insulin or IGF-I receptor. Such an explanation is suggested by the recent
observation that insulin, like IGF- , can inhibit the penussis toxin catalyzed ADP-
ribosylation of G-proteins (Rothenburg and Kahn, 1988; Ciaraldi and Maisel, 1989).
Additionally, ligands which bind to the IGF-II/an 6-P receptor have been shown to alter
the intracellular movement of this protein (Braulke et at., 1989). It is possible that such
alterations could effect other receptors or the machinery involved in receptor cycling. 
proteins and calcium have been suggested to playa role in this process (Bryson and Baxter
1987; Waren, 1989); thus an alteration in the process may also alter these parameters.
Therefore, there is no conclusive evidence that IGF-II signals through the IGF-
II/an 6-P receptor. There is considerable evidence that the IGF-II receptor isn
responsible for signallng the effects of IGF-II. First, as discussed above (I. L.) a
number of responses have been diectly demonstrated not to be mediated by the IGF-
II/an 6-P receptor (Mottola and Czech, 1984; Yu and Czech, 1984; Furlanetto, DiCarlo,
and Wisehar, 1987; Kiess et at., 1987). Second, IGF-ll exists in birds and signals certain
responses, although birds lack an IGF-II/an 6-P receptor (Kasuga et at., 1982b;
Janeczko and Etlinger, 1984; Conover et at., 1986; Bassas et at., 1988). We (Claiont
and Czech, 1989a) and others (Canfield and Kornfeld, 1989) have recently demonstrated
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that chickens possess a Man 6-P receptor incapable of binding IGF-II. This demonstrates
that the receptor did not evolve primarly to bind IGF-II or to signal, and is not likely to
serve such a purose even in species with IGF-II/an 6-P receptors. IGF-II most likely
signals though the insulin, IGF-I, or the new , recently discovered member of the insulin
receptor famly (Shier and Watt, 1989). The IGF-IIan 6-P receptor primarly serves to
sort lysosomal enzymes to the lysosomes. At the cell surface it serves to scavenge
lysosomal enzymes, thereby removing them from circulation and the IGF-II binding site
may serve to allow the removal of IGF-ll from circulation and lead to its degradation.
2. Possible Applications of This Finding to Future Research
An interesting line of research is suggested as a direct extension of the
demonstration that mammalian Man 6-P receptors possess a binding site for IGF-II, while
non-mammalian receptors do not. The cloning and sequencing of the cDNA of a
nonmammalian Man 6-P receptor may suggest that a domain lacking from the
nonmamalian receptor but present in the mamalan receptor as the bindig site for IGF-
II. Such a putative binding domain could be tested directly by mutagenesis in this
interesting region of the receptor. Whether or not such an obvious sequence difference
exists, a non-mamalian receptor wil be a useful tool as chimeras can be made between
mammalian and non-mammalian Man 6-P receptors to confer IGF-II binding to a non-
mammalian Man 6-P receptor. Such a system wil allow the identification of the IGF-
binding site. A similar system has recently been used to localize the epidermal growth
factor binding site on its receptor (Lax et ai., 1988; Lax et ai., 1989).
Subsequent cloning and sequencing of the gene for the mammalian and non-
mammalian Man 6-P receptor in the region of the binding site can give insight into the
evolution of function. Specifically, a popular theory holds that exons contain the
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information to code for strctural or functional regions, and that these may be moved and
copied among genes for proteins to confer such a strctural or functional domain on a new
protein. Introns ar simply regions of noncoding information which separate exons and
faciltate such movement by allowing exons to move freely without interrpting other
codng regions. There has been, however, no diect proof for this theory. If the Man 6- 
receptor gained the ability to bind IGF-II by gaining an exon from an IGF-II binding
protein, this would provide the fIrst diect evidence for such an occurrence (Figure 35).
3. An Evolutionary Perspective.
According to Darin s theory of evolution (Darin, 1859), natural selection wil
serve to reta favorable traits and elimate unfavorable ones. For this reason we generally
assume that a conserved function or sequence is important to the organism. By this
consideration, we would expect the IGF-II binding capacity to play an important role in
maals. What could this fuction be?
One possibilty, mentioned above, is that the primar purpose of the binding of
IGF-II by the IGF-llan 6-P receptor is to degrade IGF-II. Under what circumstance
would this be so important of a function that it would be retained in all mammals? In
vertebrates, there is considerable varation in the IGFs observed and the receptors that exist
for them. Specifically, fish and amphibians possess only IGF-I, higher vertebrates both
IGF-I and IGF-II (Daughaday et ai., 1985; Engstrom, Bell, and Schofield, 1987; Dawe 
ai., 1988). Mamals possess both IGF-I and IGF-llan 6-P receptors, while all lower
vertebrates possess only IGF-I receptors (Canfield and Kornfeld, 1989; Clairmont and
Czech, 1989). This leaves us with two phyla, reptiles and birds, which possess IGF-ll but
no specifc receptor for this molecule (Figure 36).
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Diverged from
Mammalian Lineage
(Millions of Years)
Class IGFs
MAMMALS I, II
Receptors
I, II
REPTILES I, II
200*
320
AMPIDBIANS
350
I, II
FISH
400
* Divergence between reptiles and birds.
+ IGF -I Receptor not directly demonstrated
Figure 36: The Evolution ofIGFs and IGF Receptors. lOF-l has been found in all vertebrate
species examied, while lOF-IT exists only in repties, birds, and mamals (Daughaday et aI.,
1985; Engstrom, Bell, and Schofield, 1987; Dawe et aI., 1988). The lOF-l receptor, liewise, is
present in al vertebrates which have been tested (Janeczco and Etlger, 1984; Conover et aI.,
1986), while the lOF-TIan 6-P receptor exists only in mammals (Canfield and Korneld,
1989; Claiont and Czech, 1989). Th inonnation suggests a duplication of the lOF gene
upon the divergence of repties from amphibians, and the acquisition of IOF-ll bindig capacity
by the Man 6-P receptor upon the divergence of mamals from reptiles and birds.
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This restrcts the role of the IGF-ll binding capacity of the Man 6-P receptor to a
secondar role: not only was this function added to a functional Man 6-P receptor, but it
evolved after IGF-II. The question remains as to why the possession of an IGF-
molecule and its receptor which serves only as a degradative route has been conserved.
One possibilty is suggested by the recent disruption of the IGF-ll gene in mice (DeChiara,
Efstratiadis, and Robertson, 1990) which induces reduced size. Perhaps when IGF-
initially evolved it caused a significant increase in the size of the animals possessing it
most likely early reptiles. Perhaps after some time, there was a niche formed for small,
highly evolved animals. Such a selective pressure would be expected to give rise to
mechanisms to remove IGFs from circulation. One solution would be the evolution of a
receptor to degrade these growth factors. While such an idea would explain the pattern of
IGFs and receptors we see in animals today, there is no strong evidence in suport of this
idea, and a number of other hypthesis could be imagined.
1 .
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B. The Serum Form of the IGF -II/Man 6-P Receptor
The majority of the studies discussed in this manuscrpt have dealt with the serum
form of the IGF-II/an 6-P receptor. These studies have directly addressed its origin in
cultue, and its strcture, regulation, and functionality in circulation. These studies have
demonstrted that the serum receptor is a product of the cellular receptor in a number of
diverse cultured cell lines. This protein released from cultured cells, lie the serum receptor
in circulation, is trncated as compared to the cellular receptor as determed by binding of
an antibody diected against a cytoplasmic peptide to these proteins. The serum receptor
also retains the abilty to bind both types of ligand: IGF-II and lysosomal enzymes
possessing the manose 6-phosphate recognition marker. Finaly, insulin is able to acutely
increase the levels of receptor in serum and to increase the rate of release of receptor from
cultued cells. In cultured cells this increase in release cOITelates with an increase in the cell
surace concentrtion of receptors.
A possible problem with the data demonstrating that the serum form of the IGF-
llan 6-P receptor is regulated by insulin involves a lack of knowledge of the occupancy
state of the receptors in serum before and after insulin treatment. In the cultured cell
system, immunoadsorption showed some dependence upon the occupancy state as
mannose 6-phosphate increased the proportion of IGF-II/Man 6- receptors
immunoadsorbed. However, while in the presence of Man 6-P the imunoadsorption was
essentially quantitative, approximately 90% of receptors were immunoadsorbed even in its
absence. It is therefore unlikely that changes in ligand occupancy of the IGF-llan 6-
receptor could account for the significantly larger changes observed in the amount of
receptors imunoadsorbed from the serum of diabetic, control , and insulin treated rats.
174
Receptor Cleared
\ L.
- f
IGF-IIan 6-P Receptor Seru Receptor
ROUte taen by receptor IGF-
Route taen by ligands Lysosoma Enymes
Figure 37: The Serum IGF-II/Man 6- Receptor. The serum receptor is
generated by proteolytic cleavage from the cellular receptor at the plasma membrae and
leaves behid an -10 kDa cyplasmic frgment. The receptor in seru can then bind IGF-
IT and lysosoma enzymes in serum and remove them. The cell surace IGF-llan 6-
receptor may al playa ro -in the clearce of these ligands from circulation.
, -
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From this data, a model can be proposed to explain the generation of the serum
receptor from the cellular IGF-IIjMan 6-P receptor (Figure 37). The IGF-IIjMan 6-
receptor is located primary in intrcellular locations. At any tie, however, approximately
10% of receptor is at the cell surace. Ths population is avaiable to a plasma membrane
protease which cleaves the receptor to release the extrellular domai of the receptor as the
serum receptor. The sortng of the remaining cytoplasmic piece is then altered such that it
is sorted to lysosomes for degradation. Such sorting of this isolated cytoplasmic domain
would be consistent with the observation that the IGF-II/an 6-P receptor cytoplasmic
domain is not capable of directing the proper sortng of an EGF receptor extracellular
domai in a chimera of these proteins (Dintzs and Pfeffer, 1990).
The cleavage of the receptor from the cell surface is consistent with all of the
available data: the degrdation rate is increased by insulin which increases the cell surface
concentration of receptors and by smaliligands for the receptor which would be expected to
alter the conformation of the receptor. Larger ligands, however, inhibit the degradative
process as do certain protease inhibitors. Finally, in the shorter pulse chase studies it is
possible to follow receptor from inside the cell, to the plasma membrane, and then into the
medum. This lag is consistent with the proposed model, but not with serum and plasma
membrane receptors travellng in the same vesicles to the cell surface. It is possible that the
serum receptor reaches the cell surace through an alternate route, but, given that it is a
soluble protein, it would be expected to move by bulk flow. If this is the case, the
membrae bound receptor could reach the cell surace no sooner than the medium receptor.
Once released, the serum receptor circulates as a functional binding protein capable
of binding both IGF-II and mannose 6-phosphate containing ligands. The role of the
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receptor in binding IGF-ll in circulation has been assessed to be minimal in most species,
being signifcant only in sheep fetus (Gelato et aI., 1989) or monkey (Gelato 
et al., 1988).
On the other hand, the role of the serum receptor in binding lysosomal enzymes has
not been well evaluated. Lysosomal enzymes have been shown to exist in circulation
(Belfiore et a/., 1974; Lombardo et al., 1980). It is of interest that their levels are
signifcantly increased in diabetes (Belfiore et al., 1974; Poon et al., 1979; Kohler, Sheth
and Good, 1981; Mialles et al., 1982; Perdichizzi et al., 1983) and that their levels have
been correlated with complications of this disease (Pitkanen et al., 1980; Goi et al., 1986;
Goi et al., 1987)). It is certainly possible, if not likely, that circulating lysosomal enzymes
could playa significant role in causing such complications as retinopathy and other types of
vascular and kidney degeneration. From this information and data presented in this thesis it
is possible to propose a hypothesis to explain the elevated lysosomal enzyme levels in
diabetes. The sorting of lysosomal enzymes by the IGF-II/Man 6-P receptor is an
imperfect process. Some lysosomal enzymes fail to bind to the IGF-IIJan 6-P receptor
and escape from the cell. The sortng of the IGF-II/an 6-P receptor is also imperfect and
some receptors reach the cell surface. Receptors at the cell surface can then serve to bind
and re-intemalize escaped lysosomal enzymes.
Insulin increases the concentration of IGF-IIan 6-P receptors at the cell surface
and in circulation, and wil therefore be expected to increase the rate of clearance of
lysosomal enzymes. In diabetes, the serum receptor level, and likely the cell surface
concentration as well, is decreased. This would be expected to result in a decrease in the
rate of clearance of lysosomal enzymes and an increase in their circulating level, as has
been observed. Such a model could be tested by measuring the effects of mannose 6-
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phosphate and anti-IGF-II/Man 6-P receptor antibodies on the levels of circulating
lysosomal enzymes in control and insulin treated animals.
The lysosomal enzyme level has been proposed as an acute measure of insulin in
diabetics to be used in measurng metabolic control (Goi et ai., 1986; Goi et ai., 1987).
The serum IGF-IIan 6-P receptor levels are much more acutely regulated than blood
glucose or lysosomal enzymes. This provides a possible explanation for the lysosomal
enzyme levels and could provide a more sensitive and more mechanistically understood
measure of metabolic control in diabetics. Another serum receptor, the serum form of the
transfemn receptor, has recently proven very useful in the diagnosis of anemias. Such a
role could develop for serum IGF-II/an 6-P receptor levels in diabetes, especially as an
extremely acute measurement to fie tune the insulin treatment in diabetics.
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Conclusions
The Man 6-P receptor evolved priary as a protein to sort lysosomal enzymes to a
prelysosomal comparent and to repeat this cycle many times without reaching the
lysosome where it, too, would be degraded. As a consequence of such an efficient sortng
away from the lysosome, this receptor cannot be degraded by that pathway. Instead some
of the receptor is improperly sorted in the Golgi apparatus and reaches the cell surface
instead of the prelysosomal comparment. IGF-ll/Man 6-P receptor at the cell surface can
then be proteolysed to release the serum receptor. The cell surface IGF-II/an 6-
receptors also serve to remove lysosomal enzymes from circulation. This serves both to
protect the body from these proteins and to scavenge lysosomal enzymes needed by the
cell. This scavenging has been demostrated in female carers of Hunter disease, an X-
linked loss of iduronate sulfatase. Those cells unable to produce this enzyme scavenge
enzyme released from producing cells into circulation.
The released serum receptor is eventually cleared from circulation and has been
observed in urne. While in circulation the receptor binds lysosomal enzymes. The serum
and cell surace receptors may also playa role in removing IGF- II from circulation in
mammals, as has been discussed in a previously. The mammalian IGF-II/Man 6-
receptor is unlikely to signal responses to IGF-II, but may modulate responses to IGF-
though the alteration of circulatig levels by binding and removing ligand from the blood.
In conclusion, the IGF-II/an 6-P receptor serves primarly to sort and scavenge
lysosomal enzymes. The receptor s ability to bind IGF-II serves only in a clearance and
degradative route for this protein. The IGF-II/an 6-P receptor binding of IGF-ll may,
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however, modulate signallng responses mediated by the insulin, IGF- , or other
unidentied IGF receptor.
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